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Abstract	
Pituitary	 tumor	 transforming	 gene	 1	 (PTTG1)	 -	 binding	 factor	 (PBF)	 is	 a	ubiquitously	 expressed	 transmembrane	 glycoprotein	 that	 is	 significantly	upregulated	 in	 a	 variety	 of	 human	 tumours,	 including	 those	 of	 the	 thyroid,	 breast	and	colon.	 In	thyroid	cancer,	PBF	is	 implicated	in	early	tumour	recurrence,	distant	metastasis	and	poor	oncological	outcome.	 Indeed,	PBF	 induces	cell	 transformation	
in	 vitro	 and	 tumourigenesis	 in	 vivo.	 PBF	 interacts	 with	 multiple	 protein-binding	partners	 and	modulates	 their	 activities	 and	 functions,	 including	 cortactin	 (CTTN),	the	 tyrosine	kinase	Src,	 the	 sodium	 iodide	 symporter	 (NIS)	 and	p53.	According	 to	the	 COSMIC	 (Catalogue	 of	 Somatic	 Mutations	 in	 Cancer)	 and	 TCGA	 (The	 Cancer	Genome	 Atlas)	 databases,	 27	 PBF	 mutations	 have	 now	 been	 reported	 in	 human	cancer.	 The	 studies	 in	 this	 thesis	 aimed	 to	 establish	 the	 basic	 biochemical	characteristics	 of	 the	 first	 10	 reported	missense	 PBF	mutations,	 including	 protein	glycosylation,	 dimerisation	 and	 stability.	 Following	 initial	 functional	 studies,	 the	impact	of	two	specific	mutations	discovered	in	vivo,	C51R	and	R140W,	upon	WT	PBF	function	 in	 modulating	 cellular	 proliferation,	 cell	 invasion,	 cell	 migration,	radioiodine	uptake	and	 transforming	ability	were	 investigated	 in	more	depth.	The	data	 in	 this	 thesis	 demonstrate	 that	 although	 the	 reported	mutations	 identified	 in	
vivo	 preserve	 some	 critical	 functions	 of	 PBF	 such	 as	 cellular	 proliferation	 and	radioiodine	 uptake,	 it	 is	 unlikely	 that	 PBF	 mutations	 represent	 distinct	 driver	events,	 and	 that	 upregulation	 of	 PBF	 expression	 in	 human	 cancer	 may	 be	 more	important	in	terms	of	driving	tumourigenesis	than	sequence	changes.	
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1.1	Pituitary	Tumor	Transforming	Gene	1	-	Binding	
Factor	(PBF)	1.1.1	Overall	
Pituitary	tumor	transforming	gene	1	(PTTG1)	-	binding	factor	(PBF),	also	known	as	 PTTG1IP,	 was	 first	 identified	 through	 investigations	 into	 PTTG	 (pituitary	 tumor	transforming	gene)	 functions	via	yeast	 two-hybrid	assays,	where	 it	was	 found	 to	be	a	binding	 partner	 of	 PTTG	 (Chien,	 Pei	 2000).	 PTTG	 functions	 as	 the	 human	 securin,	suppressing	 separase	 activity	 and	 prohibiting	 the	 premature	 separation	 of	 sister	chromatids	during	mitotic	anaphase	(Zou	et	al.	1999).	Although	initial	DNA	sequencing	errors	 in	 the	 publication	 of	 Chien	 and	 Pei	 (2000)	 suggested	 it	 to	 be	 a	 new	 and	unreported	gene,	PBF	was	later	found	to	be	a	formerly	cloned	gene,	c21orf3	(Yaspo	et	al.	1998).	
	PBF	remains	a	poorly	characterised	proto-oncogene	located	on	the	long	arm	of	chromosome	21	at	21q22.3	(Yaspo	et	al.	1998).	It	shares	no	significant	homology	with	other	human	proteins,	suggesting	potentially	unique	function,	but	it	is	highly	conserved	across	a	range	of	animal	species	(Figure	1.1)	(Smith,	Franklyn	&	McCabe	2011).		
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Figure	 1.1:	 PBF	 is	 highly	 conserved	 across	 different	 species.	 Representative	 amino	
acid	 sequences	 of	 PBF	 among	 various	 animal	 species	 compared	 to	 human	 PBF.	 PBF	
schematic	 illustrates	 an	 N-terminal	 signal	 peptide	 (blue	 colour),	 a	 plexin	 semaphorin	
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integrin	 (PSI)	 domain	 (yellow),	 a	 transmembrane	 region	 (pink),	 a	 bipartite	 nuclear	
localization	signal	(NLS,	green)	and	a	sorting	signal	(purple).	The	colours	of	amino	acid	
residues	were	classified	according	to	their	physicochemical	properties;	Red	-hydrophobic	
group,	Blue	-	acidic	group,	Magenta	-	basic	group,	Green	–	hydroxyl,	sulfhydryl,	amine	and	
glycine	(G)	amino	acids,	Grey	-	unusual	amino	acids.	An	asterisk	(*)	denotes	an	amino	acid	
which	is	fully	conserved.	A	colon	(:)	indicates	a	conservation	site	with	amino	acids	havingf	
strongly	similar	properties,	while	a	period	(.)	indicates	conservation	between	amino	acids	
with	weakly	similar	properties.	Adapted	from	https://ebi.ac.uk/Tools/msa/clustalo/.			
PBF	 is	 ubiquitously	 expressed	 as	 determined	 through	 Northern	 blotting	 in	multiple	human	tissues,	including	thyroid,	adrenal	gland,	stomach,	lymph	node,	trachea	and	bone	marrow	(Chien,	Pei	2000,	Yaspo	et	al.	1998).	PBF	is	predicted	to	be	a	type	1a	transmembrane	glycoprotein	(Yaspo	et	al.	1998)	consisting	of	6	exons	which	give	rise	to	180	amino	acids,	 and	spanning	24.23	kb	with	a	protein	molecular	mass	of	 around	22	kDa	(Chien,	Pei	2000).	PBF	contains	several	functional	domains,	with	a	putative	cleaved	N-terminal	 signal	 peptide	 (1-32),	 a	 plexin	 semaphorin	 integrin	 (PSI)	 domain	 (39-92)	comprised	 of	 8	 cysteine	 residues	 and	 implicated	 in	 cellular	 signaling	 and	 protein-protein	interactions	(Kozlov	et	al.	2004,	Bork	et	al.	1999),	a	transmembrane	region	(95-122)	and	a	C-terminal	30	amino	acids	containing	a	bipartite	nuclear	localisation	signal	(NLS)	situated	between	amino	acid	residues	149	and	166,	and	a	putative	motif	for	rapid	protein	 internalisation	 through	 coated-pit-mediated	 endocytosis	 (Yaspo	 et	 al.	 1998)	(Figure	1.2).	PBF	also	has	 two	putative	N-glycosylation	sites	at	asparagine	 residue	45	and	54	(Figure	1.2)	(Yaspo	et	al.	1998).	
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Figure	1.2:	Schematic	diagram	of	the	PBF.	Representative	PBF	structure	illustrating	an	
N-terminal	 signal	 peptide	 (residue	 1-32,	 blue	 colour),	 a	 PSI	 domain	 (residue	 39-92,	
yellow),	a	transmembrane	region	(residue	95-122,	pink),	a	bipartite	NLS	(residue	149-166,	
green),	a	putative	sorting	signal	(residue	174,	purple)	and	two	putative	sites	of	N-linked	
glycosylation	at	asparagine	residues	45	and	54	(N45	and	N54).		
In	 terms	of	 subcellular	 localisation,	 PBF	 is	 located	 in	both	 the	nucleus	 and	 the	cytoplasm	 (Chien,	 Pei	 2000);	 deletion	 of	 the	 NLS	 of	 PBF	 interrupts	 nuclear	translocation,	 resulting	 in	 shifting	 of	 PBF	 to	 the	 perinuclear	 and	 cytoplasmic	compartments	 (Chien,	 Pei	 2000).	 In	 immunofluorescence	 microscopy,	 PBF	 is	predominantly	 observed	 in	 specific	 vesicles	 within	 cells,	 and	 co-localises	 with	 the	marker	 for	 late	endosomes,	 tetraspanin	CD63	(Smith	et	al.	2009).	 In	keeping	with	 the	presence	 of	 a	 putative	 endocytosis	motif,	 a	mutant	 with	 a	 truncated	 C-terminus	was	mainly	apparent	at	the	plasma	membrane	(Smith	et	al.	2009).		
	 PBF	 also	 has	 amino	 acid	 sequences	 that	 are	 predicted	 to	 be	 sites	 of	 post-translational	 modification	 such	 as	 glycosylation	 and	 phosphorylation.	 Indeed,	asparagine	(N)	amino	acids	situated	at	residue	45	(N45)	and	54	(N54)	are	likely	to	be	potential	 sites	 of	 N-linked	 glycosylation.	 Furthermore,	 putative	 phosphorylation	residues,	 including	 serine,	 threonine	 and	 tyrosine,	 are	 predicted	 via	 the	 NetPhos	 2.0	Server	(http;//www.cbs.dtu.dk/services/NetPhos/).	Putative	phosphoserine	sites	were	determined	 at	 S85,	 S126	 and	 S132,	 while	 T10	 and	 Y174	 were	 predicted	 for	phosphothreonine	and	phosphotyrosine,	respectively	(Figure	1.3).			
N45	 		N54	
	              
1																																						32				39																																																															92	95																											122																										149														166			174				180															
								Signal	Pep5de																																								PSI	domain																							Transmembrane	region																																				NLS					Sor5ng	Signal	
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Figure	 1.3:	 Putative	 phosphorylation	 sites	 of	 PBF.	 Potential	 sites	 of	 PBF	
phosphorylation.	Red	line	indicates	threshold	=	0.500.	Scores	above	the	threshold	set	at	0.5	
indicate	predicted	phosphorylation	sites	for	threonine	(blue),	serine	(green)	and	tyrosine	
(pink).	Adapted	from	the	NetPhos	2.0	Server.	
PhosphoSitePlus®	 is	 another	 available	 website	 (http://www.phosphosite.org/)	supplying	 biological	 data	 related	 to	 post-translational	 modifications,	 especially	phosphorylation	(Hornbeck	et	al.	2015).	In	human	PBF,	tyrosine	residue	174	(Y174)	is	the	 most	 common	 phospho-protein	 site	 of	 PBF	 studied	 in	 approximately	 2,000	publications	(Table	1.1)	(Hornbeck	et	al.	2015),	and	is	the	same	residue	as	predicted	to	be	 a	 putative	 phosphorylated	 site	 through	 the	 NetPhos	 2.0	 Server	 (Figure	 1.3),	suggesting	that	Y174	is	a	critical	residue	for	PBF	phosphorylation.	
	
	
	
Table	1.1:	Phospho-protein	sites	of	PBF	determined	via	PhosphoSitePlus®.	Putative	
phosphorylated	sites	of	human	PBF.	HTP	=	number	of	hits	that	each	modification	site	was	
T10	
S85	
S126	 S132	
Y174	
HTP	 Amino	Acid	Residue		 Human	
1984	 Y174	 LFKEENPyARFENN_		
144	 Y165	 HDEIRKKyGLFKEEN		
1	 T156	 ERRAEMKtRHDEIRK		
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identified	through	mass	spectrometry.	Human	=	amino	acid	sequences	in	human	PBF.	Y	=	
Tyrosine	 residue;	 T	 =	 Threonine	 residue.	 The	 red	 lower	 case	 characteristics	 denote	
phospho-protein	sites	of	PBF.	Adapted	from	PhosphoSitePlus®.	
PBF	is	both	transforming	in	vitro	and	tumourigenic	in	vivo	(Stratford	et	al.	2005).	It	 is	 significantly	 upregulated	 in	 a	 variety	 of	 human	 cancer	 types	 such	 as	 pituitary,	thyroid,	colon	and	breast	(McCabe	et	al.	2003,	Stratford	et	al.	2005,	Watkins	et	al.	2010,	Read	et	al.	2016),	and	 independently	associated	with	poorer	oncological	outcome.	For	instance,	 patients	 diagnosed	 with	 papillary	 thyroid	 cancer	 who	 have	 high	 PBF	expression	 are	 more	 likely	 to	 develop	 early	 loco-regional	 recurrence	 and	 distant	metastasis,	and	have	decreased	disease	specific	survival	compared	to	those	who	carry	low	thyroidal	PBF	expression	levels	(Hsueh	et	al.	2013,	Stratford	et	al.	2005).	Moreover,	high	PBF	expression	 in	 colorectal	 samples	 correlates	with	 the	presence	of	 extramural	vascular	 invasion	 (EMVI)	 (Read	 et	 al.	 2016).	 Patients	 who	 have	 high	 PBF	 promoter	activity	 also	have	 increased	breast	 cancer	 risk	 (Xiang	 et	 al.	 2012).	 PBF	 interacts	with	and	 modifies	 the	 subcellular	 localisation	 of	 various	 important	 proteins	 such	 as	 NIS	(sodium	iodide	symporter),	regulating	radioiodine	uptake	in	thyroid	cancer	(Smith	et	al.	2013,	Smith,	Franklyn	&	McCabe	2011,	Smith	et	al.	2010)	and	MCT8,	controlling	thyroid	hormone	secretion	(Smith	et	al.	2012,	Smith	et	al.	2010).		
As	 PBF	 action	 has	mainly	 been	 characterised	 in	 3	 human	neoplasias	 -	 thyroid,	colon	and	breast	-	PBF	expression	and	function	is	now	described	in	these	settings:	
	 1.1.2	PBF	in	Thyroid	Cancer	
Chapter	1	 	 		
8		
1.1.2.1	Overview	of	Thyroid	Cancer		 Thyroid	 cancer	 comprises	 around	 1%	 of	 all	 new	 cancer	 cases,	 approximately	3,200	 patients,	 diagnosed	 each	 year	 in	 the	 United	 Kingdom,	 making	 it	 the	 18th	 most	common	 cancer	 in	 females	 and	 20th	 most	 common	 cancer	 in	 males	 in	 2011	(http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/thyroid/incidence/uk-thyroid-cancer-incidence-statistic)	 (most	 recent	 UK	 data	 available),	 and	approximately	 3.8%	 in	 the	 United	 States,	 where	 it	 is	 estimated	 to	 be	 the	 8th	 most	common	 cancer	 in	 the	 United	 States	 in	 2016	(http://seer.cancer.gov/statfacts/html/thyro.html).	 The	 incidence	 of	 new	 thyroid	cancer	cases	in	females	is	higher	than	that	of	males,	with	a	ratio	of	2.5:1,	and	in	the	UK	the	 crude	 incidence	 rate	 was	 6	 for	 every	 100,000	 women	 in	 2011	 (Figure	 1.4).	 The	proportion	of	new	cases	in	the	UK	is	significantly	lower	than	that	of	the	United	States	in	2011	 (most	 recent	UK	data	available	 in	2011),	which	demonstrated	an	 incidence	of	4	and	13.5	per	100,000,	respectively.	In	addition,	based	on	2010-2012	data	from	the	SEER	(Surveillance,	 Epidemiology,	 and	 End	 Results)	 database,	 1.1%	 of	 the	 American	population	may	be	diagnosed	with	 thyroid	cancer	at	some	stage	during	 their	 lifespan.	Although	 there	 has	 been	 a	 notable	 increase	 in	 thyroid	 cancer	 incidence	 due	 to	 a	significant	 increase	 in	 use	 of	 ultrasound	 scanning	worldwide,	 the	 death	 rate	 remains	stable,	 which	 is	 approximately	 0.5	 per	 100,000	 men	 and	 women	 per	 year	 (SEER	 18	2009-2013,	http://seer.cancer.gov/statfacts/html/thyro.html),	and	 the	5-year	survival	rate	 is	 around	 98.1%	 (SEER	 18	 2006-2012,	http://seer.cancer.gov/statfacts/html/thyro.html),	 depending	 on	 the	 staging	 and	subtypes	of	the	cancer.		
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Figure	 1.4:	 Incidence	 of	 thyroid	 cancer.	 European	 age-standardised	 incidence	 rates,	
1975-2011.	Taken	from	http://www.cancerresearchuk.org/.		
Thyroid	cancers	are	classified	into	four	categories	depending	on	histopathology,	which	 consists	 of	 papillary	 (including	 follicular	 variant	 of	 papillary	 carcinoma),	follicular	 (including	Hürthle	 cell	 carcinoma),	medullary	and	anaplastic	 thyroid	 cancer.	Papillary	 thyroid	 cancer	 is	 the	 most	 common,	 and	 accounts	 for	 around	 80%	 of	 all	thyroid	 cancer	 cases,	while	 follicular	 cancer	 are	 found	 in	10%	of	 all	 cases.	Anaplastic	cancer	is	the	least	common	tumour	type	(1%	of	thyroid	cancers),	but	carries	the	poorest	prognosis,	 with	 a	 5-year	 survival	 rate	 of	 around	 7%,	(http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-survival-rates)	 compared	 with	 98.1%	 overall	 in	 patients	 having	 any	 type	 of	 thyroid	 cancer	(http://	seer.cancer.gov/statfacts/html/thyro.html).	However,	the	precise	prognosis	of	papillary	thyroid	cancer	depends	on	post-operative	tumour	staging	(Table	1.2).		
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Staging	 TNM	staging	
5-year	
relative	
survival	rate	
I	
Tumour	≤	2	cm,	no	nodal	nor	distant	metastases		(T1	N0	M0)	 Near	100%	
II	
Tumour	>	2	cm	but	≤	4	cm,	no	nodal	nor	distant	metastases	(T2	N0	M0)	 Near	100%	
III	
Tumour	>	4	cm,	no	nodal	nor	distant	metastases		(T3	N0	M0)	or	Tumour	of	any	size	but	limited	to	thyroid	with	level	6	lymph	node	metastases	but	no	distant	metastases		(T1-3	N1a	M0)	
93%	
IV	
Tumour	of	any	size	extending	beyond	the	thyroid	capsules	to	invade	subcutaneous	tissue,	larynx,	trachea,	oesophagus	or	recurrent	laryngeal	nerve	with/without	regional	lymph	node	metastases	but	no	distant	metastases	(T4a	N0-1a	M0)	or	Tumour	of	any	size	extending	beyond	the	thyroid	capsules	to	invade	subcutaneous	tissue,	larynx,	trachea,	oesophagus	or	recurrent	laryngeal	nerve	with	lateral	cervical	lymph	node	metastases	but	no	distant	metastases	(T1-4	N1b	M0)	or	Tumour	of	any	size	invading	prevertebral	fascia	or	encasing	carotid	artery	or	mediastinal	vessel	with/without	lymph	node	metastases	but	no	distant	metastases	(T4b	AnyN	M0)	or	Tumour	of	any	size	with/without	lymph	node	metastases	but	having	distant	metastases	(AnyT	AnyN	M1)		
51%	
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Table	1.2:	5-year	relative	survival	rate	of	patients	diagnosed	with	papillary	thyroid	
cancer,	classified	by	7th	edition	of	American	Joint	Committee	on	Cancer	(AJCC)	TNM	
staging	for	thyroid	cancer.	Adapted	from	http://www.cancer.org/cancer/.	
Treatment	 of	 thyroid	 cancer	 consists	 of	 two	 major	 modalities:	 surgery	 and	radioiodine	 ablation	 (RAI).	 Nevertheless,	 the	minority	 of	 cases	which	 have	 refractory	disease	with	 poor	 radioiodine	 uptake	may	 gain	 some	 benefit	 from	obtaining	 external	beam	radiation	or	targeted	therapy,	but	still	carry	a	significantly	worse	prognosis.	Even	though	RAI	 is	 one	 of	 the	main	 treatments	 and	 68-80%	of	 thyroid	 cancers	 have	 some	sodium	iodide	symporter	(NIS)	activity	and	are	capable	of	accumulating	iodine	(Castro	et	 al.	 2001),	 thyroid	 cancer	 cells	 can	 uptake	 only	 20%	 iodine	 compared	with	 normal	cells	 and	 the	 uptake	 is	 significantly	 lower	 in	 poorly	 differentiated	 papillary	 thyroid	cancers	 and	 anaplastic	 thyroid	 cancers.	 Additionally,	 although	 thyroid	 cancer	 has	 a	relatively	good	prognosis,	up	to	30%	of	patients	still	develop	loco-regional	recurrence	(Jonklaas	et	al.	2006,	Desforges,	Mazzaferri	1993).	These	findings	may	be	explained	by	multiple	 biological	 mechanisms.	 For	 instance,	 expression	 levels	 of	 some	 microRNAs	(miR)	 such	 as	 human	 miR-27b	 and	 miR-96	 were	 significantly	 increased	 in	 human	papillary	thyroid	tumours	compared	to	normal	thyroid	(Lakshmanan	et	al.	2015).	The	same	was	also	observed	in	breast	cancer	compared	to	normal	breast	tissue	(Wang	et	al.	2009,	 Lin	 et	 al.	 2010).	 Indeed,	 exogenous	 expression	 of	 miR-27b	 also	 promoted	 cell	proliferation,	cell	invasion	and	cell	migration	in	breast	cancer	cells	in	vitro	(Wang	et	al.	2009).	 Moreover,	 overexpressed	 miR-96	 in	 breast	 cancer	 cell	 lines	 downregulated	tumour	suppressor	FOXO3a	(forkhead	box	O3)	expression	by	directly	 interacting	with	3’-untranslated	 region	 of	 FOXO3a	 mRNA,	 resulting	 in	 significantly	 increased	 cellular	proliferation	and	anchorage	independent	cell	growth	(Lin	et	al.	2010).	Therefore,	both	miR-27b	and	miR-96	may	play	a	vital	role	in	tumourigenesis	of	breast	cancer	(Wang	et	
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al.	2009,	Lin	et	al.	2010).	In	addition,	Lakshmanan	et	al.	reported	that	miR-339-5p	was	able	 to	 directly	 interact	 with	 the	 3’UTR	 of	 the	 human	 NIS	 (hNIS)	 mRNA,	 and	overexpression	of	this	miR	noticeably	reduced	NIS	mRNA	levels	and	radioiodine	uptake	in	both	HEK293	human	embryonic	kidney	cells	 transfected	with	NIS	and	MCF7	breast	cancer	 cells	 treated	 with	 transretinoic	 acid	 and	 hydrocortisone	 (Lakshmanan	 et	 al.	2015).	TGFβ1	 (transforming	growth	 factor	beta	1)	 also	decreased	TSH-stimulated	NIS	mRNA	 and	 protein	 expression,	 resulting	 in	 abolished	 radioiodine	 uptake	 ability	 in	FRTL-5	 thyroid	 cells	 (Kawaguchi	 et	 al.	 1997).	 Moreover,	 PBF	 expression,	 which	 is	upregulated	in	thyroid	cancer	compared	to	normal	tissue	(Stratford	et	al.	2005),	has	a	negative	 correlation	 with	 NIS	 mRNA	 expression	 levels	 (Read	 et	 al.	 2011),	 leading	 to	poor	radioiodine	uptake	 in	 thyroid	cancer.	Overexpression	of	PBF	reduces	 the	human	NIS	 upstream	 enhancer	 element	 (hNUE)	 activity	 in	 the	 NIS	 promoter	 (Boelaert	 et	 al.	2007),	and	also	alters	subcellular	localisation	of	NIS	from	the	plasma	membrane	to	late	endosomes	 (Smith	 et	 al.	 2009),	 resulting	 in	 decreased	 functional	 NIS	 activity	 that	 is	associated	with	tumour	recurrence	and	distant	metastasis	in	thyroid	cancer	(Boelaert	et	al.	2007).	Overall	then,	a	reduction	in	the	capability	to	uptake	radioiodine	into	thyroid	cells	 leads	 to	 a	 decreased	 ability	 to	 destroy	 residual	 microscopic	 thyroid	 disease,	potentially	causing	thyroid	cancer	recurrence,	a	process	PBF	is	intimately	involved	in.		
	
1.1.2.2	Clinical	Importance	of	PBF	Expression	in	Thyroid	Cancer	With	respect	to	PBF	in	thyroid	cancer,	there	is	wide-ranging	evidence	supporting	the	 importance	 of	 PBF	 in	 tumour	 development,	 progression	 and	 prognosis	 of	 this	tumour	 type.	Hsueh	et	al.	 recently	 reported	 that	61.4%	of	DTC	(differentiated	 thyroid	carcinoma)	patients	had	high	PBF	expression,	which	was	associated	with	significantly	
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increased	loco-regional	recurrence	and	distant	metastasis	at	the	time	of	diagnosis,	and	independently	reduced	disease	specific	survival	(Hsueh	et	al.	2013).	These	findings	also	supported	the	initial	finding	of	Stratford	et	al.	that	PBF	was	upregulated	in	human	well-differentiated	 thyroid	 cancer	 (DTC)	 compared	 to	 normal	 thyroid	 tissue	 (Figure	 1.5A)	(Stratford	 et	 al.	 2005),	 and	 that	 higher	 PBF	 mRNA	 expression	 was	 an	 independent	prognostic	marker	 for	 early	 recurrence	 in	DTC	patients	 (Figure	1.5B)	 (Stratford	et	 al.	2005).		
Figure	 1.5:	 PBF	 expression	 is	 significantly	 higher	 in	 DTC,	 especially	 in	 recurrent	
samples.	A,	PBF	mRNA	expression	in	thyroid	cancer	compared	to	normal	samples.	B,	PBF	
mRNA	expression	comparing	between	recurrent	and	non-recurrent	thyroid	tumours.	ΔCT	
=	cycle	threshold	(Ct)	of	PBF	subtracted	from	the	Ct	of	the	internal	reference	gene.	SEM	=	
standard	error	of	mean.	***P<0.001.	Taken	from	Stratford	et	al.	2005.	
	 Stable	 overexpression	 of	 PBF	 in	 murine	 NIH	 3T3	 fibroblast	 cells	 significantly	induced	 colony	 formation	 in	 soft	 agar	 assays	 compared	 to	 VO	 (vector	 only)	 controls,	demonstrating	the	ability	of	PBF	to	transform	cells	in	vitro	(Stratford	et	al.	2005).	When	injected	 into	 the	 subcutaneous	 tissue	 of	 nude	 mice,	 these	 NIH	 3T3	 cells	 stably	
	 	
A	 B	
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overexpressing	 PBF	 induced	 aggressive	 high-grade	 carcinomas	 (Figure	 1.6),	 while	control	cells	stably	expressing	empty	vector	did	not	(Figure	1.6),	implying	tumourigenic	capability	of	PBF	in	vivo	(Stratford	et	al.	2005).	
	
	
	
	
Figure	1.6:	PBF	is	tumourigenic	in	vitro.	Tumour	development	(black	arrows)	in	nude	
mice	injected	with	NIH	3T3	cells	stably	overexpressing	PBF	(PBF♯1	and	PBF♯2)	compared	
to	VO	control	(VO♯1).	Taken	from	Stratford	et	al.	2005.	
	 To	 investigate	 this	 potential	 effect	 in	 a	 more	 physiological	 setting,	 Read	 et	 al.	generated	a	transgenic	mouse	model	carrying	thyroid	specific	PBF	overexpression	using	the	 Tg	 (thyroglobulin)	 promoter	 (PBF-Tg)	 (Read	 et	 al.	 2011).	 PBF-Tg	 mice	 had	significantly	increased	sizes	and	weights	of	thyroid	glands	compared	to	litter-matched	WT	 mice	 (Figure	 1.7A	 and	 1.7B)	 (Read	 et	 al.	 2011).	 Interestingly,	 the	 histology	 of	thyroid	glands	in	PBF-Tg	mice	exhibited	hyperplasia	and	macrofollicular	lesions	(Figure	1.7C	 and	1.7D),	 and	had	 significantly	 increased	pAKT	 (phosphorylated	protein	 kinase	B),	 TSHR	 (thyroid	 stimulating	 hormone	 receptor)	 and	 cyclin	 D1	 expression	 levels	compared	to	WT	controls,	whilst	demonstrating	relatively	unchanged	thyroid	hormone	levels	compared	to	WT	mice	(Read	et	al.	2011).	
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Figure	1.7:	Overexpressed	PBF	induces	thyroid	gland	enlargement	in	PBF-Tg	mice.	
A,	thyroid	weight	of	PBF-Tg	mice	compared	with	age-matched	WT	mice.	Numbers	of	mice	
analysed	 are	 illustrated.	 B,	 representative	 images	 of	 thyroid	 glands	 of	 PBF-Tg	 and	WT	
litter	 mates	 at	 52-weeks	 old.	 Dashed	 lines	 illustrate	 the	 outline	 of	 thyroid	 glands.	 C,	
representative	 H&E	 microscopic	 figures	 of	 thyroid	 glands	 comparing	 WT	 and	 PBF-Tg	
mice.	Scale	bars,	100	mm.	D,	Quantification	of	follicular	diameter	in	thyroid	glands	of	PBF-
Tg	(N=5)	and	WT	litter	mates	(N=7)	at	age	26	weeks.	Scale	bars	=	100	μm.	Data	showed	as	
mean	±	SEM.	SEM	=	standard	error	of	mean.	**P<0.01;	***P<0.001.	Taken	from	Read	et	al.	
2011.	
However,	 even	 though	 thyroid	 glands	 were	 enlarged,	 no	 obvious	 cancer	induction	 was	 found	 in	 this	 study	 (Read	 et	 al.	 2011).	 Furthermore,	 in	 human	
C	 D	
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multinodular	 goitres	 (MNG),	 PBF	 mRNA	 and	 protein	 expression	 were	 significantly	induced	compared	to	normal	samples,	by	approximately	2.2-2.3	fold	(Read	et	al.	2011),	and	 TSHR	 protein	 expression	 was	 also	 increased	 (Read	 et	 al.	 2011).	 Thus	 although	overexpression	of	PBF	causes	thyroid	cell	proliferation	and	thyroid	gland	enlargement	through	an	increase	of	TSHR	expression	and	stimulation	of	the	AKT	pathway	in	PBF-Tg	mice	and	human	MNG,	this	situation	does	not	affect	circulating	thyroid	hormone	levels	(Read	et	al.	2011).		
	
1.1.2.3	PBF	and	Sodium	Iodide	Symporter	(NIS)	As	 PBF	 is	 up-regulated	 in	 human	 thyroid	 cancer	 and	 PBF	 overexpression	correlates	 with	 poorer	 oncological	 consequences	 (Hsueh	 et	 al.	 2013,	 Stratford	 et	 al.	2005),	several	studies	have	investigated	the	relationship	between	PBF	and	the	efficacy	of	 radioiodine	 (RAI)	 treatment	 in	 thyroid	 cancer.	 In	 human	 primary	 thyrocytes,	overexpressed	 PBF	 significantly	 decreased	 NIS	 mRNA	 expression,	 leading	 to	 a	significant	reduction	in	radioiodine	uptake	by	68%	compared	to	VO	transfected	cell	 in	
vitro	(Boelaert	et	al.	2007).	NIS	mRNA	expression	was	also	decreased	in	thyroid	cancer,	especially	 in	cancers	exhibiting	recurrence,	nodal	positive	status	or	distant	metastatic	disease	 (Boelaert	 et	 al.	 2007).	 Boelaert	 et	 al.	 also	 defined	 a	 mechanism	 of	 how	 PBF	reduced	 NIS	 expression	 and	 they	 found	 that	 overexpression	 of	 PBF	 significantly	reduced	 specific	 activity	 of	 the	 NIS	 promoter,	 including	 the	 human	 NIS	 upstream	enhancer	 (hNUE)	 through	PAX8/USF1	 (pair-box8/upstream	stimulatory	 factor1)	 sites	(Boelaert	et	al.	2007).	Although	there	is	evidence	that	PBF	represses	the	NIS	enhancer	(hNUE)	via	the	PAX8/USF1	binding	site,	the	actual	mechanism	is	unknown.	
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In	 addition,	 co-immunoprecipitation	 and	 GST	 (glutathione-S-transferase)	 pull-down	assays	confirmed	a	specific	interaction	between	PBF	and	NIS	(Smith	et	al.	2009).	Immunofluorescence	 (IF)	 microscopy	 revealed	 that	 overexpressed	 PBF	 modified	 the	subcellular	localisation	of	NIS,	from	the	plasma	membrane	(PM)	where	NIS	functions	to	late	endosomes	 (Figure	1.8A	and	1.8B)	 (Smith	et	al.	2009).	Thus	high	PBF	expression	was	associated	with	low	NIS	function	due	to	internalisation	of	NIS	by	PBF	(Figure	1.8)	as	well	as	secondary	to	transcriptional	repression.			
	
	
	
	
	
	
	
	
	
	
	
Figure	 1.8:	 PBF	 modulates	 subcellular	 localisation	 of	 NIS	 and	 co-localises	 within	
intracellular	 vesicles.	 A,	 representative	 immunofluorescent	 microscopy	 showing	
A	
B	
C	 D	
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endogenous	PBF	(red)	and	NIS	(green)	 in	COS7	cells	transfected	with	VO	and	HA-tagged	
NIS	 (NIS-HA).	 B,	 representative	 immunofluorescent	 figures	 demonstrating	 exogenously	
transfected	PBF	(red)	and	NIS	(green)	in	COS7	cells	co-transfected	with	PBF	and	NIS-HA.	
Magnification	=	100X.	Scale	bars	=	20	μm.	C	and	D,	representative	Western	blots	showing	
cell	 surface	 NIS	 (C)	 compared	 to	 total	 NIS	 (D)	 from	 cell	 surface	 biotinylation	 assays	 in	
COS7	cells	transfected	with	VO	or	PBF-HA.	Graphs	illustrate	mean	of	cell-surface	and	total	
NIS	 protein	 expression	 levels	 relative	 to	 the	 cell	 surface	 marker	 protein	 Flotillin-1.	
*P<0.05;	ns	=	not	significant.	Taken	from	Smith	et	al.	2009.	
Furthermore,	PBF	expression,	which	was	significantly	increased	in	human	MNG,	was	associated	with	a	significant	decrease	in	NIS	mRNA	expression	compared	to	normal	thyroid	 tissue	 (Figure	 1.9)	 (Read	 et	 al.	 2011).	 In	 PBF-Tg	 mice,	 NIS	 staining	demonstrated	 through	 immunohistochemistry	 showed	 a	 distinct	 reduction	 in	 PBF-Tg	mice	 compared	 to	 control	 WT	 mice	 (Figure	 1.10),	 and	 there	 was	 also	 a	 significant	decrease	in	thyroidal	NIS	mRNA	expression	apparent	in	the	PBF-Tg	model	(Read	et	al.	2011).	
	
																																						
	
	
	
Figure	 1.9:	 Reverse	 correlation	 between	PBF	 and	NIS	mRNA	 expression	 in	 human	
multinodular	 goitres.	 Representative	 scatterplot	 demonstrating	 correlation	 between	
PBF	and	NIS	mRNA	expression	in	human	MNG.	Data	were	analysed	using	Spearman’s	rank	
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correlation.	 ΔCT	 =	 cycle	 threshold	 (Ct)	 of	 PBF	 subtracted	 from	 the	 Ct	 of	 the	 internal	
reference	 gene.	 rs	 =	 rho	 score,	 indicating	 relationship	 between	 2	 genes	 via	 Spearman's	
rank	correlation	coefficient.	P=0.05.	Taken	from	Read	et	al.	2011.	
	
	
	
	
	
Figure	 1.10:	 NIS	 protein	 expression	 is	 reduced	 in	 PBF-Tg	 mice	 compared	 to	 WT	
littermates.	 Representative	 detected	 NIS	 staining	 through	 immunohistochemistry	
comparing	 thyroid	 glands	 of	WT	 and	 PBF-Tg	mice.	 The	 10%	 goat	 serum	was	 used	 for	
negative	control	(data	not	shown	in	the	original	publication).	Scale	bars	=	100	μm.	Taken	
from	Read	et	al.	2011.	
	 Importantly,	 knocking	 down	 PBF	 using	 specific	 siRNAs	 (small	 interfering	ribonucleic	 acids)	 in	 primary	 thyroid	 cells	 from	 PBF-Tg	 mice	 significantly	 rescued	radioiodine	uptake,	while	scrambled	siRNA	transfected	cells	did	not	(Read	et	al.	2011).	Moreover,	 de-phosphorylation	 of	 PBF	 using	 PP1	 administration	 (Src	 family-selective	tyrosine	 kinase	 inhibitor,	 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine)	 or	 artificial	 mutation	 of	 tyrosine	 174	 residue	 of	 PBF	 (Y174A)	 caused	 a	significant	increase	in	plasma	membrane	retention	of	PBF,	and	ameliorated	binding	to	NIS,	 leading	 to	 a	 significant	 increase	 in	 iodine	 uptake	 (Smith	 et	 al.	 2013).	 Taken	together,	 PBF	 overexpression	 significantly	 represses	 radioiodine	 uptake	 through	 NIS	functional	modulation,	a	characteristic	that	can	be	reversed	by	downregulation	of	PBF.	
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1.1.2.4	PBF	and	Monocarboxylate	8	(MCT8)	in	Thyroid	Cells		 Monocarboxylate	 transporter	8	 (MCT8)	 is	 encoded	 in	humans	by	 the	 SLC16A2	gene	 and	 functions	 as	 an	 active	 transporter	 for	 thyroid	 hormone	 secretion	 from	 the	thyroid	 gland	 (Friesema	 et	 al.	 2003).	 Co-IP	 and	 GST	 pull-down	 assays	 demonstrated	that	 PBF	 and	MCT8	 specifically	 bound	 in	 vitro	 (Smith	 et	 al.	 2012).	 In	 IF	microscopy,	when	 COS7	 cells	 were	 transfected	 with	 MCT8-HA,	 MCT8	 was	 mainly	 located	 at	 the	plasma	membrane	as	previously	shown	in	our	group	(James	et	al.	2009)	(Figure	1.11A).	However,	when	co-overexpressed	with	PBF,	MCT8	noticeably	shifted	to	the	intracellular	compartment,	 and	 co-localised	 with	 PBF	 within	 intracellular	 vesicles,	 resulting	 in	decreased	 PM	 staining	 (Figure	 1.11B	 and	 1.11C)	 (Smith	 et	 al.	 2012).	 Cell	 surface	biotinylation	assays	also	affirmed	a	significant	decrease	in	MCT8	expression	at	the	PM	when	cells	transfected	with	PBF	compared	to	VO	controls	(Smith	et	al.	2012).	
	
	
	
	
	
	
	
Figure	 1.11:	 PBF	 modifies	 the	 subcellular	 localisation	 of	 MCT8	 from	 the	 plasma	
membrane	 to	 cytoplasmic	 vesicles.	 A,	 representative	 confocal	 images	 in	 COS7	 cells	
A	
B	
C	
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transfected	with	VO	and	MCT8-HA.	B	and	C,	representative	epifluorescent	(B)	and	confocal	
(C)	microscopy	 in	COS7	cells	 co-transfected	with	PBF	and	MCT8-HA.	All	 images	 showing	
PBF	(red),	MCT8-HA	(green)	and	co-localisation	(yellow).	Scale	bars	=	20	μm.	Taken	from	
Smith	et	al.	2012.	
	 In	 the	 in	 vivo	 setting,	 thyroidal	MCT8	mRNA	 and	 protein	 expression	were	 not	changed	between	PBF-Tg	mice	and	controls	(Smith	et	al.	2012).	However,	there	was	a	significant	 increase	 in	 the	 accumulation	 of	 intrathyroidal	 thyroid	 hormone	 content,	including	 non-Tg	 and	 Tg	 bound	 T3	 and	 T4,	 in	 the	 thyroid	 glands	 of	 PBF-Tg	 mice	compared	 to	 WT	 litter	 mates,	 while	 serum	 thyroid	 hormones	 were	 similar	 in	 both	groups	 (Smith	 et	 al.	 2012).	 Taken	 together,	 PBF	 acts	 as	 a	 protein-binding	 partner	 of	MCT8,	 in	 common	 with	 its	 role	 for	 NIS,	 resulting	 in	 significant	 induction	 of	 thyroid	hormone	 accumulation	 in	 the	 thyroid	 gland	 through	 alteration	 in	 the	 subcellular	localisation	of	the	specific	thyroid	hormone	transporter	MCT8.		
	
1.1.2.5	PBF	and	p53	in	Thyroid	Cancer		 The	 tumour	 suppressor	 p53	 is	 a	 critical	 protein	 in	mediating	 genetic	 stability.	GST	 pull-down	 assays	 illustrated	 that	 p53	 specifically	 bound	 to	 PBF,	 with	 potential	binding	sites	at	residues	100-160	and	318-393	of	p53	(Figure	1.12)	(Read	et	al.	2014).	Co-IPs	and	proximity	ligation	assays	(PLA)	in	TPC1	and	K1	papillary	thyroid	cancer	cells	also	 validated	 the	 interaction	 between	 two	 proteins	 in	 the	 presence	 and	 absence	 of	ionising	radiation	(Figure	1.13)	(Read	et	al.	2014).		
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Figure	 1.12:	 PBF	 binds	 p53	 via	 GST	 pull-down	 assays.	Representative	Western	 blot	
showing	 binding	 between	 L-α-(35S)	 methionine	 labelled	 PBF	 and	 GST	 tagged	 p53,	
including	WT	 and	 its	mutants	 as	 demonstrated	 in	 schematic	 diagram	 of	 p53	 structure.	
TAD	=	transcriptional	activation	domain;	PRO	=	proline	rich	domain;	DBD	=	DNA-	binding	
domain;	TET	=	tetramerisation	domain	and	C-TERM	=	C-terminal.	Taken	from	Read	et	al.	
2014.		
	
	
	
	
	
	
	
Figure	 1.13:	 PBF	 specifically	 binds	 p53	 through	 co-IP	 and	 PLA	 assays.	 A	 and	 B,	
representative	co-IP	assays	of	PBF	and	p53	in	TPC1	(A)	and	K1	(B)	cells	with	either	non-
irradiated	 (–IR)	 or	 irradiated	 (+IR)	 conditions.	 Nab	 =	 no	 antibody	 control	 samples.	 C,	
	 	A	 B	
C	
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representative	 PLA	 images	 of	 PBF	 and	 p53	 in	 TPC1	 cells.	 Red	 dots	 indicate	 a	 specific	
interaction	between	2	proteins.	Scale	bars	=	10	μm.	Taken	from	Read	et	al.	2014.	
	 PBF	overexpression	reduced	p53	stability	through	two	mechanisms.	Firstly,	half-life	 studies	 in	 both	 TPC1	 and	 K1	 cells	 revealed	 that	 overexpressed	 PBF	 significantly	enhanced	 p53	 turnover	 compared	 to	 controls	 after	 120	minutes	 as	 demonstrated	 in	Figure	 1.14	 (Read	 et	 al.	 2014).	 Secondly,	 overexpression	 of	 PBF	 also	 significantly	induced	p53	ubiquitination	compared	to	VO	(Read	et	al.	2014).		
Figure	1.14:	Overexpression	of	PBF	induces	turnover	of	p53	in	vitro.	Representative	
Western	blots	of	p53	protein	relative	to	β-actin	 in	TPC1	(A)	and	K1	(B)	cells	 transfected	
with	VO	or	PBF,	and	treated	with	100	μM	Anisomycin	before	being	harvested	at	0,	60,	90	
and	120	minutes.	*P<0.05;	**P<0.01.	Taken	from	Read	et	al.	2014.	
	 In	 contrast,	 depletion	 of	 PBF	 using	 specific	 siRNAs	 in	 both	 TPC1	 and	 K1	 cells	significantly	increased	p53	stability	compared	to	scrambled	controls	after	120	minutes,	supporting	the	capability	of	PBF	to	regulate	p53	stability	in	thyroid	cancer	cells	in	vitro	(Read	 et	 al.	 2014).	 Moreover,	 PBF-Tg	 mice	 suggested	 impaired	 p53	 function	 via	significantly	 increased	 genetic	 instability	 compared	 to	 WT	 control	 mice	 as	demonstrated	via	fluorescent	inter	simple	sequence	repeat	(FISSR)	PCR	analysis	(Read	et	al.	2014).	In	primary	thyroid	cultures	from	transgenic	mice,	12	out	of	27	(40%)	DNA	repair	 genes	 such	 as	Mgmt	 (O(6)-methylguanine-DNA	methyltransferase	 gene),	 Xrcc3	
	A	 B	TPC1	 K1	
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(X-ray	repair	complementing	defective	repair	in	Chinese	hamster	cells	3)	and	Rad51	(a	member	of	the	RecA-like	gene),	were	significantly	reduced	(Read	et	al.	2014).		
In	terms	of	apoptosis,	an	absence	of	PBF	using	specific	siRNAs	(short	interfering	ribonucleic	 acids)	 treatment	 in	 thyroid	 cancer	 cells	 enhanced	 their	 response	 to	irradiation	with	 a	marked	 rise	 in	 caspase-3/7	 level	 and	 a	 significant	 reduction	 in	 cell	survival	 (Read	 et	 al.	 2014).	 However,	 when	 SW1736	 anaplastic	 thyroid	 cancer	 cells,	having	 no	 p53	 expression,	were	 transfected	with	 PBF,	 there	was	 no	 alteration	 in	 cell	viability,	 suggesting	 that	 any	 cell	 survival	 mechanism	 of	 PBF	 is	 likely	 to	 be	 p53	dependent	 (Read	et	al.	2014).	Taken	 together,	PBF	 functions	as	a	dysregulator	of	p53	activity	in	thyroid	cells.		
	1.1.3	PBF	in	Colon	Cancer		
1.1.3.1	Epidemiology	of	Colon	Cancer		Colorectal	cancer	is	the	4th	most	common	cancer	in	both	men	and	women,	and	is	estimated	to	comprise	approximately	8%	of	all	new	cancer	cases	in	the	United	States	in	2016	 (http://seer.cancer.gov/statfacts/html/colorect.html).	 Based	 on	 2009-2013	data	from	the	SEER	(Surveillance,	Epidemiology,	and	End	Results)	database,	the	incidence	of	new	colorectal	cancer	cases	in	males	has	been	slightly	higher	than	that	of	females,	with	a	ratio	of	1.3:1,	and	a	crude	incidence	rate	of	47.1	for	every	100,000	American	men	in	all	races	 (http://seer.cancer.gov/statfacts/html/colorect.html).	 Additionally,	 around	 4.5	percent	 of	 the	 population	may	 develop	 colorectal	 cancer	 at	 some	period	 during	 their	lifespan,	based	on	SEER	2010-2012	data.	
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The	death	rate	remains	quite	stable,	which	is	approximately	20-30	per	100,000	persons	per	year	 in	 the	 last	4	decades	(SEER	9	 Incidence	&	U.S.	Mortality	1975-2013,	http://seer.cancer.gov/statfacts/html/colorect.html).	 The	 5-year	 survival	 rate	 is	around	 65.1%,	 varying	 between	 60-68%	 in	 the	 last	 30	 years	 (SEER	 18	 2006-2012,	http://seer.cancer.gov/statfacts/html/colorect.html),	and	it	is	significantly	decreased	to	13.5%	in	patients	who	have	distant	metastasis.		
	 The	understanding	of	genetic	alterations	involved	in	colorectal	tumour	initiation	such	 as	 APC	 (adenomatous	 polyposis	 coli)	 and	 BRAF	 (V-Raf	 Murine	 Sarcoma	 Viral	Oncogene	Homolog	B)	is	well-characterised	(Davies	et	al.	2002),	whereas	the	potential	effects	of	genes	related	to	the	progression	of	 tumours	 in	 late	stages	such	as	TP53	and	KRAS	(V-Ki-ras2	Kirsten	rat	sarcoma	viral	oncogene	homolog)	remain	less	well	defined	(Fearon	2011).	
	 	
1.1.3.2	PBF	and	p53	in	Colon	Cancer		Functional	 inactivation	 of	 p53	 due	 to	 genetic	 mutation	 is	 identified	 in	approximately	 35-45%	 of	 colorectal	 cancers,	 and	 correlates	 with	 lymphatic	 invasion	and	overall	survival	(Russo	et	al.	2005).	The	frequency	of	mutations	also	escalates	with	more	advanced	tumour	stage	(Russo	et	al.	2005).	Additionally,	PTTG	is	upregulated	in	all	colon	cancers	compared	with	normal	tissues	(N=48),	and	higher	PTTG	expression	is	also	 associated	with	 invasion	 of	 surrounding	 lymph	nodes	 presumably	 being	 another	marker	 for	 invasive	 colorectal	 cancer	 (Heaney	 et	 al.	 2000).	 Moreover,	 a	 specific	interaction	 between	 PTTG	 and	 p53	 was	 determined	 in	 transformed	 cells	 (Kim	 et	 al.	2007);	 however,	 the	 precise	 mechanism	 of	 how	 PTTG	 regulates	 p53	 function	 is	 not	
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known.		
As	PBF	is	a	binding	partner	of	PTTG,	and	PBF	also	acts	as	a	negative	regulator	of	p53	 function	 in	 thyroid	 cancer,	Read	 et	 al.	 investigated	 the	 relationship	between	PBF	and	 p53	 in	 colon	 cancer	 (Read	 et	 al.	 2016).	 There	 was	 a	 significant	 increase	 in	 PBF	expression	 in	 colorectal	 cancers	 compared	 to	 matched	 normal	 samples	 (Read	 et	 al.	2016).	 The	 TCGA	 data	 suggest	 that	 this	 is	 unlikely	 to	 be	 due	 to	 an	 increase	 in	 copy	number	 and	 in	 fact	 revealed	 a	 deletion	 of	 PBF	 in	 around	 3%	 of	 colorectal	 tumours	(http://www.cbioportal.org).	GST	pull-down	and	co-IP	assays	 in	HCT116	colon	cancer	cells	 also	 confirmed	 the	 interaction	 between	 PBF	 and	 p53.	 Indeed,	 GST	 pull-down	assays	revealed	that	GST	tagged	WT-PBF	and	a	c-terminal	deletion	PBF	mutant	(Δ149-180)	still	bound	with	L-α-(35S)	methionine	labelled	p53,	but	that	deletion	of	amino	acids	94-149	(Δ94-149)	abrogated	the	ability	of	PBF	to	interact	with	p53	(Figure	1.15)	(Read	et	al.	2016).		
	
	
	 	
	
Figure	1.15:	PBF	binds	p53	via	a	specific	region	of	PBF.	Representative	Western	blot	
demonstrating	 binding	 between	 L-α-(35S)	methionine	 labelled	 p53	 and	GST	 tagged	PBF,	
including	WT	and	two	mutants	as	indicated.	Taken	from	Read	et	al.	2016.	
	 In	keeping	with	the	data	described	above	for	thyroid	cells,	upregulation	of	PBF	significantly	 induced	 p53	 turnover	 in	 HCT116	 colon	 cancer	 cells	 as	 demonstrated	 in	half-life	assays	 (Figure	1.16A),	and	also	 increased	p53	ubiquitination	compared	 to	VO	
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cells	as	shown	in	Figure	1.16B	(Read	et	al.	2016).	Both	mechanisms	lead	to	reduction	in	p53	 stability	 of	HCT116	 cells	 transfected	with	 PBF	 compared	 to	 controls	 (Read	 et	 al.	2016).	
Figure	 1.16:	 PBF	 overexpression	 decreases	 p53	 stability	 and	 induces	 p53	
ubiquitination	in	colon	cancer	cells.	A,	representative	Western	blotting	of	p53	relative	
to	 β-actin	 in	HCT116	 cells	 transfected	with	 either	 VO	 or	 PBF,	 and	 treated	with	 100	 μM	
Anisomycin	 before	 being	 harvested	 at	 0,	 60,	 90	 and	 120	 minutes.	 N=4	 individual	
experiments.	 Data	 presented	 as	 mean	 ±	 SEM.	 SEM	 =	 standard	 error	 of	 mean.	 B,	
representative	 Western	 blot	 showing	 high	 molecular	 weight	 of	 p53	 conjugates	 which	
represent	 ubiquitinated	 p53	 (Ubq-p53)	 in	 HCT116	 cells	 transfected	 with	 the	 same	
conditions	 as	 in	 Fig.	 16A	 and	 treated	 with	 the	 proteasomal	 inhibitor	MG132.	 **P<0.01.	
Taken	from	Read	et	al.	2016.	
	 		
1.1.3.3	PBF	and	Cell	Migration	in	Colon	Cancer		 In	 tumours	 harbouring	WT	 TP53,	 high	 expression	 of	 PBF	was	 also	 associated	with	the	presence	of	extramural	vascular	invasion	(EMVI)	in	tissue	samples	(Read	et	al.	2016),	 which	 is	 independent	 prognostic	 marker	 for	 local	 recurrence	 and	 decreased	overall	survival	(Smith	et	al.	2008),	compared	to	those	having	no	invasion	(Read	et	al.	2016).	In	vitro,	overexpressed	PBF	in	HCT116	colon	cancer	cells	significantly	promoted	cell	migration	by	60%	compared	to	VO	control	cells	(Figure	1.17).	
	 A	 B	
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Figure	1.17:	PBF	has	a	pro-migratory	characteristic	in	colon	cancer	cells	in	vitro.	A,	
graph	demonstrating	relative	proportion	of	migrating	HCT116	cells	 transfected	with	VO	
or	PBF	at	24	hours.	N=8.	Data	presented	as	mean	±	SEM.	SEM	=	standard	error	of	mean.	B,	
representative	microscopic	 images	of	migrating	regions,	with	magnified	 images	 in	 lower	
panel.	 Dashed	 lines	 of	 same	 diameter	 are	 labeled	 to	 highlight	 and	 compare	 the	 area	 of	
migration.	***P<0.001.	Taken	from	Read	et	al.	2016.	
	 Taken	 together,	PBF	 is	over-expressed	 in	 colorectal	 cancer	and	correlates	with	extramural	 vascular	 invasion.	 In	 vitro,	 and	 in	 common	with	 thyroid	 cell	 findings,	 PBF	binds	 p53	 and	 inhibits	 its	 functions.	 Furthermore,	 over-expression	 of	 PBF	 induces	increased	cell	migration.	Additional	insights	into	PBF’s	precise	roles	in	colorectal	cancer	are	required	to	fully	understand	its	mechanisms	of	action.	
	 1.1.4	PBF	in	Breast	Cancer		
	A	 B	
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1.1.4.1	Epidemiology	of	Breast	Cancer	Breast	 cancer	 is	 the	 most	 common	 cancer	 in	 females,	 and	 is	 estimated	 to	represent	 around	 14.6%	 of	 all	 new	 cancer	 cases	 in	 the	 United	 States	 in	 2016	(http://seer.cancer.gov/statfacts/html/breast.html).	 Based	 on	 SEER	 2010-2012	 data,	around	12.3	percent	of	the	female	population	may	be	diagnosed	with	breast	cancer	at	some	 time	 during	 their	 lifespan.	 Indeed,	 the	 number	 of	 new	 breast	 cancer	 cases	 in	women	was	125	for	every	100,000	in	the	USA	across	all	races,	based	on	SEER	18	2009-2013	data	(http://seer.cancer.gov/statfacts/html/breast.html).		
As	 for	 thyroid	and	colorectal	 cancer,	 the	death	rate	 remains	quite	stable,	being	approximately	 20-30	 per	 100,000	 persons	 per	 year	 over	 the	 last	 4	 decades	(http://seer.cancer.gov/statfacts/html/breast.html,	 SEER	 9	 Incidence	 &	 U.S.	Mortality	1975-2013).	 The	 5-year	 survival	 rate	 is	 also	 relatively	 stable	 at	 approximately	 90%	across	 the	 last	2	decades	 (http://seer.cancer.gov/statfacts/html/breast.html,	 SEER	18	2006-2012),	and	is	significantly	reduced	to	less	than	30%	in	patients	who	carry	distant	metastasis.		
Generally,	 the	 induction	of	breast	 cancer	demands	multiple	 genetic	 alterations.	However,	the	precise	mechanisms	involved	in	tumour	development	and	progression	are	still	not	 fully	recognised,	especially	 in	 triple	negative	breast	cancer	(tumours	negative	for	 estrogen	 receptor,	 progesterone	 receptor	 and	 HER-2	 (human	 epidermal	 growth	factor	receptor-2)).			
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1.1.4.2	PBF	Functions	in	Breast	Cancer		The	 binding	 partner	 of	 PBF,	 PTTG,	 was	 initially	 shown	 to	 be	 upregulated	 in	breast	 cancer,	 and	 to	 correlate	 with	 invasive	 ductal	 carcinoma	 and	 breast	 tumour	recurrent	disease	(Solbach	et	al.	2004).	Watkins	et	al.	then	investigated	the	role	of	PBF	in	breast	cancer.			
The	 PBF	 promoter	 contains	 putative	 estrogen	 receptor	 elements	 (ERE),	 and	treatment	with	oestrogen	analogues	such	as	17β-estradiol	(EST)	and	diethylstilbestrol	(DES)	 in	MCF7	 ERα	 positive	 breast	 cancer	 cells	 significantly	 induced	 PBF	mRNA	 and	protein	 expression,	 suggesting	 that	PBF	 is	 an	oestrogen	 regulated	gene	 (Figure	1.18A	and	1.18B)	(Watkins	et	al.	2010).	ICI	182780,	an	anti-oestrogen	drug,	blocked	oestrogen	induction	 of	 PBF	 protein	 expression	 as	 demonstrated	 in	 Figure	 1.18C	 (Watkins	 et	 al.	2010).	
	
	
	
Figure	1.18:	Oestrogen	treatment	 induces	PBF	expression	 in	breast	cancer	cells	 in	
vitro.	A,	relative	PBF	mRNA	expression	in	MCF7	cells	treated	with	diethylstilbestrol	(DES)	
A	 B	
C	
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or	17β-estradiol	(EST)	for	48	hours	in	different	concentrations	compared	to	VO	cells.	Data	
presented	as	ΔCT	±	SEM.	ΔCT	=	cycle	threshold	(Ct)	of	the	PBF	subtracted	from	the	Ct	of	
the	 internal	 reference	gene.	 SEM	=	 standard	error	of	mean.	B,	 scanning	densitometry	of	
PBF	 protein	 expression	 levels	 relative	 to	 β-actin	 in	 MCF7	 cells	 treated	 with	 the	 same	
conditions	as	in	Fig.	18A.	N=3	individual	experiments.	Inset	–	Western	blotting	of	PBF	and	
β-actin	expression	levels.	C,	Western	blotting	of	PBF	and	β-actin	expression	levels	in	MCF7	
cells	 treated	 with	 either	 17β-estradiol	 or	 anti-oestrogen,	 ICI	 182780,	 for	 48	 hours	
compared	to	vehicle	cells.		*P<0.05;	**P<0.01;	***P<0.001.	Taken	from	Watkins	et	al.	2010.	
	 Additionally,	 EREs	 in	 the	 proximal	 PBF	 promoter	 bind	 directly	 with	 ERα	 as	demonstrated	 in	 oligonucleotide	 pull-down	 assays	 (Watkins	 et	 al.	 2010).	 In	 human	breast	 cancer,	 PBF	 mRNA	 and	 protein	 expression	 were	 significantly	 upregulated	compared	 to	 normal	 breast	 samples	 (Watkins	 et	 al.	 2010),	 and	 breast	 cancer	 tissue	having	higher	numbers	of	ERE	repeats	carried	greater	PBF	mRNA	expression	compared	to	those	with	low	ERE	repeat	numbers	(Watkins	et	al.	2010).	Moreover,	an	escalation	in	the	variable	numbers	of	tandem	repeats	in	the	PBF	promoter	is	significantly	associated	with	an	increased	risk	of	ER	positive	breast	cancer	(Xiang	et	al.	2012).	
	 In	 common	 with	 the	 findings	 for	 HCT116	 colorectal	 cells	 (Figure	 1.17),	 PBF	overexpression	 significantly	 enhanced	 cellular	 invasion	 in	 MCF7	 breast	 cancer	 cells	compared	 to	 VO	 controls	 (Figure	 1.19).	 However,	 this	 invasive	 effect	 was	 entirely	abolished	using	specific	PBF	siRNA	treatment	(Watkins	et	al.	2010).	
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Figure	 1.19:	 PBF	 has	 pro-invasive	 properties	 in	 breast	 cancer	 cells	 in	 vitro.	
Representative	 graph	 demonstrating	 average	 numbers	 of	 invading	 cells	 in	 cell	 invasion	
assays	in	MCF7	cells	transfected	with	either	VO	or	PBF	at	24	and	48	hours,	with	different	
cell	density.	Data	presented	as	mean	±	SEM.	SEM	=	standard	error	of	mean.	**P<0.01.	N=3	
individual	 experiments.	 Inset	 -	 representative	 microscopic	 images	 of	 H&E	 staining	 of	
invading	cells	(arrows).	Taken	from	Watkins	et	al.	2010.	 	
Taken	together,	the	functions	of	PBF	have	been	determined	almost	exclusively	in	thyroid	(Section	1.1.2),	colon	(Section	1.1.3)	and	breast	(Section	1.1.4)	cancer	models.	PBF	is	able	to	bind	NIS	and	MCT8,	altering	their	subcellular	localisation,	and	hence	their	function	 (Figure	 1.20).	 Through	 interaction	 with	 p53,	 which	 has	 been	 studied	particularly	 in	 thyroid	 and	 colorectal	models,	 PBF	 over-expression	 is	 associated	with	altered	DNA	repair	response	(Figure	1.20).	PBF	induces	cell	 invasion	and	migration	in	colorectal	 and	breast	 cancer	 cells.	A	 transgenic	 thyroid	 line	demonstrated	 that	PBF	 is	mildly	 pro-proliferative	 in	 vivo,	 and	 soft	 agar	 assays	 showed	 that	 PBF	 induces	anchorage	 independent	 growth	 in	 vitro,	 and	 tumours	 in	 xenograft	 models.	 However,	despite	 being	 over-expressed	 in	 thyroid,	 colorectal	 and	breast	 tumours,	 to	 date	 there	
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have	 been	 fewer	 than	 20	 publications	 addressing	 PBF	 function,	 and	 its	 exact	 role	 in	tumourigenesis	requires	further	clarification.		
	
	
	
	
Figure	 1.20:	 Schematic	 diagram	 of	 the	 interactions	 between	 PBF	 and	 its	 binding	
partners.	Representative	diagram	illustrating	the	specific	 interactions	between	PBF	and	
its	binding	partners	NIS,	MCT8	and	p53.	T3	and	T4	denote	triiodothyronine	and	thyroxine,	
which	are	actively	 transported	by	MCT8,	while	 I	 –	 indicates	 iodine	 incorporated	 into	 the	
thyroid	 gland	 via	 NIS.	 A	 minus	 sign	 (-)	 shows	 negative	 regulation	 of	 the	 other	 protein	
function	by	PBF.			
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1.1.5.1	Catalogue	of	Somatic	Mutations	in	Cancer	(COSMIC)	Database	The	COSMIC	database	was	initiated	in	2004	to	collect	and	describe	information	on	 somatic	 mutations	 and	 related	 data	 detailing	 human	 cancer	(http://cancer.sanger.ac.uk).	 This	 database	 has	 recruited	 genomic	 data	 relating	 to	mutations	discovered	in	all	pre-malignant	and	cancerous	lesions	from	both	the	scientific	literature	and	from	the	cancer	genome	project	at	the	Sanger	Institute.	The	main	aim	of	this	project	 is	to	analyse	the	frequencies	and	specifics	of	somatic	mutations	in	various	human	cancers.	At	the	time	of	PhD	submission,	the	COSMIC	website	has	provided	more	than	2	million	point	mutations,	10,000	fusion	mutations,	nearly	30,000	gene	transcripts,	60,000	genetic	rearrangements,	700,000	copy	number	aberrations	and	60	million	gene	expression	variants	(Forbes	et	al.	2015).	The	information,	including	an	overview	of	each	gene,	 a	 schematic	 diagram	 of	 the	 gene	 view,	 complex	 phenotype-specific	 mutations,	tissue	discovered	mutations,	copy	number	variations	and	details	of	drug	sensitivity,	are	displayed	 on	 the	 website	 in	 a	 format	 for	 easy	 understanding	 and	 interpretation	(http://cancer.sanger.ac.uk).		
For	instance,	data	from	the	COSMIC	database	reveal	the	high	frequency	of	point	missense	 substitutions	 in	 BRAF	 (V-Raf	 Murine	 Sarcoma	 Viral	 Oncogene	 Homolog	 B	gene)	 (Figure	 1.21).	 These	mutations	 are	 discovered	 from	a	 variety	 of	 human	 tissues	such	 as	 thyroid,	 skin,	 lung,	 oesophagus,	 stomach	 and	 large	 intestine.	One	 of	 the	most	common	 BRAF	 genetic	 alterations	 is	 the	 BRAFV600E	 missense	 substitution	(http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF).	 The	 information	 from	this	 database	 leads	 to	 the	 identification	 of	 predictive	 and	 prognostic	 markers,	development	of	early	diagnostic	tools,	and	targeted	therapy	in	particular	cancers,	such	as	melanoma	and	thyroid	cancer	(Ascierto	et	al.	2012,	Kebebew	et	al.	2007).	
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Figure	1.21:	 Example	of	mutation	distribution	 in	 the	BRAF	gene	 from	 the	COSMIC	
database.	 Representative	 diagram	 showing	 distribution	 of	 BRAF	 mutations,	 including	
number	 of	 samples	 and	 percentages	 of	 each	mutation	 type,	 retrieved	 from	 the	 COSMIC	
database.	
	Loi	 et	 al.	 investigated	 a	 relationship	 between	 mutations	 of	 PIK3CA	(phosphatidylinositol-4,5-bisphosphate	 3-kinase	 catalytic	 subunit	 alpha)	 and	 the	effectiveness	of	 trastuzumab	treatment	 in	patients	diagnosed	with	breast	cancers	(Loi	et	 al.	 2013).	 This	 study	 started	 the	 project	 by	 using	 the	 COSMIC	 database	 to	 retrieve	data	 related	 to	 a	 variety	 of	 genes	 such	 as	 PIK3CA,	 BRAF,	 TP53	 and	 KRAS	 and	 their	recurrent	 hotspot	 mutations,	 before	 the	 samples	 in	 this	 project	 were	 sequenced	 to	ensure	the	coverage	of	all	significant	substitutions	in	these	genes	rather	than	restriction	to	only	well	known	mutated	areas	(Loi	et	al.	2013).	The	genetic	alterations	were	then	
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correlated	with	tumour	prognosis	and	trastuzumab	administration	(Loi	et	al.	2013).	The	result	 showed	 that	 most	 of	 the	 PIK3CA	 mutations	 were	 linked	 to	 small,	 well	differentiated	breast	cancers	with	estrogen	receptor	positive	status,	while	they	carried	a	potential	resistance	to	trastuzumab	treatment	(Loi	et	al.	2013).	Thus	information	from	the	COSMIC	database	can	be,	as	well	as	cataloguing	tumour	mutational	status,	used	to	drive	the	direction	of	translational	research.	Thus	this	joined	up	bioinformatic	approach	is	rapidly	becoming	an	essential	preliminary	step	to	 identify	driver	somatic	mutations	of	 interest	 in	 human	 cancer;	 however,	 most	mutations	 identified	 through	 large	 scale	untargetted	next	generation	sequencing	are	likely	to	be	passenger	mutations	that	do	not	directly	 affect	 tumour	 progression.	 Therefore,	 further	 biological	 experiments	 are	needed	to	validate	driver	genetic	mutations.	
	
1.1.5.2	The	Cancer	Genome	Atlas	(TCGA)	Database	The	pilot	 project	 of	 the	TCGA	database	 started	 in	 2006	 is	 a	 joint	 collaboration	between	the	National	Cancer	Institute	(NCI)	and	the	National	Human	Genome	Research	Institute	(NHGRI),	which	are	institutes	of	the	National	Institutes	of	Health	in	the	United	States.	 This	 database	 is	 an	 attempt	 to	 unite	 genome	 analysis	 technologies,	 including	microarrays	and	large-scale	whole	genome	sequencing,	as	well	as	bioinformatic	data	to	generate	 statistically	 significant	 conclusions,	 thereby	 improving	 the	 knowledge	 of	 the	molecular	 basis	 of	 human	 cancer	 (Tomczak,	 Czerwińska	 &	 Wiznerowicz	 2015).	 The	central	remit	of	TCGA	 is	creating	an	outline	of	key	genetic	alterations	 in	major	cancer	types	 including	papillary	 thyroid	cancer,	breast	carcinoma,	colorectal	adenocarcinoma	and	liver	hepatocellular	carcinoma.	The	TCGA	project	also	establishes	a	freely	available	website	 (https://tcga-data.nci.nih.gov)	 for	 any	 researchers	 to	 access	 the	 genetic	
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information	 and	 validate	 critical	 discoveries,	 in	 turn	 helping	 in	 the	 development	 of	diagnostic	 procedures,	 treatment	 and	 cancer	 prevention	 (Tomczak,	 Czerwińska	 &	Wiznerowicz	 2015).	 At	 the	 time	 of	 submission,	 the	 TCGA	 has	 processed	 tissue	collections	 from	 more	 than	 25,000	 patients,	 including	 tumour	 and	 matched	 normal	samples	 and	 sequences	 through	 large-scale	 whole	 genome	 sequencing,	 focusing	particularly	on	33	main	tumour	types	(Table	1.3).		
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Table	 1.3:	 Human	 tumour	 types	 collected	 in	 the	 TCGA	 project.	 Representative	
Available	Cancer	Types	 No.	cases	with	Data	
Date	Last	Updated		
(mm/dd/yy)	
Acute	Myeloid	Leukemia	 200	 05/02/16	
Adrenocor9cal	Carcinoma	 80	 04/27/16	
Bladder	Urothelial	Carcinoma	 412	 04/29/16	
Brain	Lower	Grade	Glioma	 516	 05/02/16	
Breast	Invasive	Carcinoma	 1097	 04/08/16	
Cervical	Squamous	Cell	
Carcinoma	and	Endocervical	
Adenocarcinoma	
307	 05/05/16	
Cholangiocarcinoma	 36	 04/29/16	
Colon	Adenocarcinoma	 461	 04/28/16	
Esophageal	Carcinoma	 185	 05/03/16	
Glioblastoma	Mul9forme	 528	 05/02/16	
Head	and	Neck	Squamous	Cell	
Carcinoma		
528	 05/03/16	
Kidney	Chromophobe	 66	 05/02/16	
Kidney	Renal	Clear	Cell	
Carcinoma	
536	 04/08/16	
Kidney	Renal	Papillary	Cell	
Carcinoma	
291	 04/08/16	
Liver	Hepatocellular	
Carcinoma	
377	 04/27/16	
Lung	Adenocarcinoma	 521	 04/08/16	
Lung	Squamous	Cell	
Carcinoma			
504	 05/02/16	
Lymphoid	Neoplasm	Diﬀuse	
Large	B-cell	Lymphoma	
48	 04/08/16	
Mesothelioma	 87	 04/08/16	
Ovarian	Serous	
Cystadenocarcinoma	
586	 05/02/16	
Pancrea9c	Adenocarcinoma	 185	 05/06/16	
Pheochromocytoma	and	
Paraganglioma	
179	 05/03/16	
Prostate	Adenocarcinoma	 498	 05/02/16	
Rectum	Adenocarcinoma	 171	 04/28/16	
Sarcoma	 261	 05/02/16	
Skin	Cutaneous	Melanoma	 470	 04/08/16	
Stomach	Adenocarcinoma	 443	 05/02/16	
Tes9cular	Germ	Cell	Tumours	 150	 05/03/16	
Thymoma	 124	 05/03/16	
Thyroid	Carcinoma	 507	 05/05/16	
Uterine	Carcinosarcoma	 57	 04/29/16	
Uterine	Corpus	Endometrial	
Carcinoma	
548	 04/28/16	
Uveal	Melanoma	 80	 04/29/16	
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available	 cancer	 types	 sequenced	 through	 large-scale	 whole	 genome	 sequencing	 and	
collected	via	the	TCGA	database.	Adapted	from	https://tcga-data.nci.nih.gov.	
The	cBioPortal	for	Cancer	Genomics	(http://www.cbioportal.org)	is	an	example	of	 the	 output	 of	 the	 TCGA	 database.	 It	 is	 an	 open	 website	 evolved	 by	 the	 Memorial	Sloan-Kettering	Cancer	Centre,	MSKCC,	 for	public	access,	 analysis	and	downloading	of	genetic	datasets	from	the	scientific	literature	and	the	TCGA	database	itself.	This	website	provides	 a	 panel	 of	 genomic	 information	 such	 as	 genetic	mutations,	 gene	 expression,	DNA	copy	number	variants,	DNA	methylation	as	well	as	related	clinical	data	and	patient	survival.		
	 As	one	example,	the	TCGA	project	has	to	date	collected	and	finalised	511	thyroid	cancer	samples	from	507	patients.	The	results	reveal	that	BRAF,	NRAS	(neuroblastoma	rat	 sarcoma	 viral	 oncogene	 homolog)	 and	 HRAS	 (V-Ha-Ras	 harvey	 rat	 sarcoma	 viral	oncogene	 homolog)	 are	 the	 three	 most	 commonly	 mutated	 genes	 in	 thyroid	 cancer	(https://tcga-data.nci.nih.gov).	It	also	provides	clinical	data	related	to	each	patient,	copy	number	 alterations	 and	 oncological	 outcome	 such	 as	 disease	 specific	 survival	 and	overall	 survival	 (https://tcga-data.nci.nih.gov).	 In	 turn,	 this	 has	 yielded	 bioinformatic	platforms	 to	assimilate	 the	data.	For	example,	 the	DOTS-Finder	 (Driver	Oncogene	and	Tumor	Suppressor	Finder)	has	utilised	data	from	the	TCGA	to	identify	potential	driver	genes	through	computational	approaches	(Melloni	et	al.	2014).	
	 Glioblastoma	 or	 GBM	was	 the	 first	 tumour	 type	 clarified	 in	 the	 TCGA	 project.	Brennan	 et	 al.	 used	 the	 data	 from	 the	 TCGA	 database	 combined	 with	 some	computational	analysis	programmes,	including	MutSig	(Mutational	Significance)	run	by	the	 Cancer	 Genome	 Analysis	 (CGA)	 group	 (www.broadinstitute.org/cancer/CGA),	 to	develop	 a	 directory	 of	 genetic	 modifications	 and	 to	 determine	 driver	 genes	 in	 GBM	
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(Brennan	 et	 al.	 2013).	 The	 outcome	 demonstrated	 a	 panel	 of	 well-known	 genes	harbouring	 significant	 mutations	 such	 as	 TP53,	 PIK3CA	 and	 RB1	 (retinoblastoma)	(Brennan	 et	 al.	 2013).	 They	 also	 identified	 the	 BRAFV600E	 substitution	 in	 the	 GBM	dataset,	which	 is	 the	same	mutation	determined	in	melanoma	patients	(Brennan	et	al.	2013).	 As	 vemurafenib	 is	 a	 drug	 used	 for	 treatment	 in	 some	 melanoma	 patients	(Chapman	et	al.	2011),	studies	using	this	drug	 in	GBM	patients	carrying	this	mutation	may	subsequently	determine	the	potential	of	targeted	therapies.		
	 The	 TCGA	 Pan-Cancer	 analysis	 is	 another	 example	 using	 information	 from	 the	TCGA	database	integrated	with	the	other	genomic	tools	such	as	the	UCSC	(University	of	California	Santa	Cruz)	Cancer	Genomics	Browser	(https://genome-cancer.ucsc.edu)	and	cbioportal	 data	 (http://www.cbioportal.org)	 to	 establish	 genetic	 correlation	 between	different	 tumour	 types	 and	 to	 identify	 the	 prognosis	 of	 cancer	 (Cline	 et	 al.	 2013).	 To	illustrate,	 this	 analysis	 linked	genetic	 clusters	 to	 the	 clinical	 outcome	of	patients	with	acute	 myeloid	 leukemia	 (Cline	 et	 al.	 2013).	 They	 demonstrated	 that	 tumours	 were	essentially	categorised	by	the	origin	of	tissue	(Cline	et	al.	2013).	Thus,	whilst	squamous	cell	carcinoma	(SCC)	of	lung	was	grouped	with	other	SCC	(for	example,	head	and	neck	SCC	and	bladder	cell	carcinoma),	 lung	adenocarcinoma	had	unique	characteristics	and	different	 overall	 survival	 compared	 to	 lung	 SCC,	 driving	 distinct	 patient	 treatment	regimens	(Cline	et	al.	2013).	
Taken	together,	the	COSMIC	and	the	TCGA	initiatives	have	rapidly	revolutionised	the	 genetic	 and	 epigenetic	 information	 available	 to	 researchers	 for	 human	 tumours.	Previously,	 sequencing	 initiatives	 were	 based	 on	 relatively	 small	 scale	 and	 disparate	approaches	 in	 single	 tumour	 types.	 Now,	 through	 unifying	 sequence	 data,	 new	mechanisms	 and	 insights	 are	 emerging	 into	 the	 processes	 which	 initiate	 and	 drive	
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tumourigenesis,	and	which	can	be	targeted	for	treatment.	
	
1.1.5.3	In	Vivo	PBF	Mutations		In	 2013,	 the	 first	 11	 PBF	 mutations,	 with	 10	 missense	 substitutions	 and	 1	synonymous	substitution,	were	reported	by	the	COSMIC	database,	as	demonstrated	 in	Figure	 1.22.	 However,	 further	 substitutions	 of	 the	 protein	 have	 subsequently	 been	discovered	in	both	the	COSMIC	and	the	TCGA	databases.	Currently,	the	data	from	whole	exome	sequencing	through	the	Wellcome	Trust	COSMIC	database,	which	was	updated	in	May	2016,	has	revealed	27	PBF	mutations	in	various	human	cancers,	with	20	missense	substitutions,	 four	 synonymous	 substitutions,	 two	 inframe	 deletions	 and	 one	 inframe	insertion	(Figure	1.22).	These	mutations	are	distributed	across	all	functional	domains	of	PBF,	especially	 the	PSI	domain,	 transmembrane	region	and	proximal	 to	NLS,	and	they	are	also	found	in	various	tumour	types,	such	as	lung,	colon,	stomach,	breast,	ovary	and	prostate.		
	
	
Figure	1.22:	Schematic	diagram	of	PBF	with	its	in	vivo	mutations	discovered	in	the	
COSMIC	 database.	 PBF	 schematic	 with	 all	 27	 reported	 amino	 acid	 residue	 changes	 in	
COSMIC.	The	 first	10	nonsynonymous	PBF	mutations	 that	were	discovered	 in	April	2013	
and	 investigated	 through	 this	 thesis	 are	 denoted	 in	 black.	 Ins	 denotes	 insertional	
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mutagenesis,	while	del	illustrates	deletion	mutation.	Adapted	from	COSMIC	database,	May	
2016.	
According	 to	 the	 TCGA	 database	 (http://www.cbioportal.org),	 there	 are	numerous	 genetic	 abnormalities	 of	 PBF	 found	 in	 multiple	 human	 cancers.	 However,	most	 of	 them	 are	 amplifications	 of	 PBF,	 while	 fewer	 than	 0.5%	 represented	 overall	mutations	 in	 the	 gene.	 There	 are	 also	 additional	 substitutions,	 such	 as	 A57V,	 P88L,	G94R,	 G101S	 and	 P129S,	 found	 in	 different	 domains,	 especially	 the	 transmembrane	region,	 suggesting	 that	 mutations	 in	 some	 critical	 domains	 may	 influence	 specific	protein	functions.	Nevertheless,	511	papillary	thyroid	cancer	samples	were	sequenced	but	 analysis	 of	 the	 data	 reveal	 that	 there	were	 no	mutations	 in	 PBF.	 In	 addition,	 our	group	 also	 sequenced	 the	 entire	 PBF	 coding	 region	 in	 24	 well-differentiated	 thyroid	cancer	samples,	and	failed	to	find	any	PBF	mutations	(Stratford	et	al.	2005).	Thus,	whilst	PBF	has	an	 integral	role	 in	regulating	thyroid	cell	 function	(Read	et	al.	2011),	 it	 is	not	commonly	mutated	 in	 thyroid	 cancer.	However,	 PBF	mutations	 are	more	 apparent	 in	other	 endocrine	 and	 non-endocrine	 tumour	 types,	 and	 study	 of	 these	mutations	may	reveal	novel	mechanisms	of	human	cancer.	
	 	
1.2	Approaches	to	Identify	Potentially	Oncogenic	
Mutations	1.2.1	Bioinformatic	Approaches	
As	discussed	above,	there	has	been	a	dramatic	increase	in	the	numbers	of	genetic	mutations	discovered	across	various	cancer	types	due	to	the	worldwide	application	of	next	 generation	 sequencing.	 However,	 only	 a	minority	 of	 them	 are	 likely	 to	 confer	 a	
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specific	 growth	 advantage,	 resulting	 in	 clonal	 expansion	 and	 development	 of	 tumour	(driver	 mutations),	 whilst	 the	 majority	 of	 the	 substitutions	 are	 predicted	 to	 be	passenger	 mutations,	 which	 have	 no	 direct	 effect	 on	 tumour	 development	 and	progression	 (Torkamani,	 Schork	 2008,	 Greenman	 et	 al.	 2007).	 The	 critical	 reason	 to	clarify	 the	 drivers	 is	 to	 gain	 translational	 information	 from	 research	 to	 the	 clinic,	including	 applying	 specific	 genes	 as	 being	 potentially	 diagnostic,	 prognostic	 or	therapeutic	markers	 for	particular	 types	of	human	cancer	and	also	understanding	 the	precise	molecular	mechanism	responsible	for	tumour	formation.		
	 For	 instance,	 one	 of	 the	 most	 well-known	 driver	 genes	 implicated	 in	 human	cancer	pathways	is	BRAF.	The	BRAF	V600E	point	mutation	is	observed	across	different	kinases,	 predicting	 an	 established	 role	 in	oncogenesis	 (Torkamani,	 Schork	2008),	 and	this	 knowledge	 has	 been	 applied	 in	 the	 use	 of	 the	 BRAF	 inhibitor	 vemurafenib	 as	 a	specific	targeted	therapy	for	treatment	of	melanoma	patients	who	harbour	the	mutation	(Ravnan,	 Matalka	 2012).	 Moreover,	 the	 NRAS	 mutation	 is	 also	 a	 biomarker	 for	melanoma,	 and	 patients	 having	 NRAS	 mutant-tumours	 derive	 sensitivity	 to	 MEK	(mitogen-activated	 protein/extracellular	 signal-regulated	 kinase	 kinase)	 inhibitors		(Flaherty,	Hodi	&	Fisher	2012).		
	 In	parallel	to	the	rapid	increase	in	the	number	of	discovered	somatic	mutations	in	 human	 cancer,	 a	 variety	 of	 statistical	 approaches	 based	 on	 bioinformatic	 data	analysis	have	been	adopted	 in	an	attempt	to	verify	driver	genes	and	mutations.	There	are	4	main	computational	approaches,	which	are	based	on	protein	 functional	changes	due	to	mutational	effect,	frequency	of	mutations,	pattern	of	mutations	within	genes	and	pathway-based	analysis	(Melloni	et	al.	2014).	Firstly,	protein	functional	approaches	can	be	used	 to	predict	 the	 risk	of	 functional	 changes	 caused	by	point	 substitutions	 (Reva,	
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Antipin	 &	 Sander	 2011,	 Ng,	 Henikoff	 2006,	 Ng,	 Henikoff	 2003).	 For	 example,	 Sorting	Intolerance	From	Tolerance	(SIFT)	is	one	of	the	protein	functional	approaches	based	on	the	 physical	 property	 of	 amino	 acids	 and	 sequence	 homology	 to	 predict	 whether	 an	amino	 acid	 substitution	 is	 likely	 to	 alter	 protein	 function	 (Ng,	 Henikoff	 2006,	 Ng,	Henikoff	2003).	Secondly,	the	frequentist	procedure	is	another	statistical	strategy	based	on	the	frequency	of	the	particular	mutations	compared	to	background	mutation	rate	for	a	 specific	 DNA	 region.	 However,	 this	 approach	 has	 a	 critical	 drawback	 due	 to	 the	requirement	 of	 the	 potentially	 unavailable	 background	 mutation	 rate	 in	 the	 whole	human	genome.	Thirdly,	 the	pattern-based	method	 is	a	 statistical	programme	used	 to	apply	mutational	details	such	as	 location	of	mutations	 found	 in	 the	gene,	and	types	of	mutation	such	as	missense	or	silent	substitutions	to	determine	the	probability	of	being	driver	mutations,	and	can	be	applied	to	tumour	suppressor	genes	as	well	as	oncogenes	(Vogelstein	 et	 al.	 2013).	 Indeed,	 typical	 genetic	 alterations	 in	 oncogenes	 are	 usually	concentrated	in	specific	protein	domains,	and	consist	of	missense	substitutions	that	are	located	 on	 key	 amino	 acid	 residues	 and	 do	 not	 cause	 a	 stop	 codon,	 and	 insertion	 or	deletion	 mutations	 having	 an	 unchanged	 reading	 frame	 (Melloni	 et	 al.	 2014).	 In	contrast,	mutations	in	tumour	suppressor	genes	are	generally	truncating	and	initiate	a	stop	 codon	 in	 a	 non-specific	 mutational	 pattern	 such	 as	 the	 mutation	 of	 APC	 in	colorectal	cancer	(Melloni	et	al.	2014).	The	fourth	procedure	is	pathway-oriented	which	is	the	analysis	of	a	group	of	mutations	in	a	specific	pathway	(Leiserson	et	al.	2013),	but	this	 procedure	 is	 more	 difficult	 for	 rare	 genetic	 mutations,	 where	 pathways	 may	 be	more	obscure.		
To	 illustrate,	 Vogelstein	 et	 al.	 used	 the	 pattern-based	 analysis	 to	 define	 driver	genes	in	human	cancer	using	the	“20/20	rule”	(Vogelstein	et	al.	2013).	In	this	study,	the	
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driver	 genes	 were	 identified	 and	 classified	 into	 2	 categories,	 oncogenes	 and	 tumour	suppressor	 genes	 (Vogelstein	 et	 al.	 2013).	 Indeed,	 a	 driver	 oncogene	 was	 a	 gene	containing	more	than	20%	of	reported	mutations	at	the	same	amino	acid	position,	such	as	missense	 substitutions	 in	 the	LDHA	 (Lactate	Dehydrogenase	A)	and	PIK3CA	genes,	whilst	a	driver	tumour	suppressor	gene	carried	20%	inactive	mutations	or	more,	such	as	in	RB1	and	VHL	(Von	Hippel-Lindau)	(Vogelstein	et	al.	2013).	
	 OncodriveCLUST	 is	 another	 computational	 programme	 based	 on	 patterns	 of	genetic	alterations,	and	provides	freely	accessible	via	http://bg.upf.edu/oncodriveclust		(Tamborero,	 Gonzalez-Perez	 &	 Lopez-Bigas	 2013).	 This	 analysis	 focuses	 on	 somatic	mutations	 that	 assemble	 in	 particular	 region	 of	 genes,	 especially	 clustered	 groups	within	5	amino	acid	residues	or	less,	before	calculating	a	score	used	to	predict	potential	driver	 genes	 (Tamborero,	 Gonzalez-Perez	 &	 Lopez-Bigas	 2013).	 This	 approach	 was	applied	 to	 some	 TCGA	 datasets,	 including	 breast,	 ovary	 and	 uterus,	 and	 novel	 driver	genes	 which	 were	 not	 identified	 using	 other	 strategies	 were	 determined	 with	 the	OncodriveCLUST	programme,	such	as	MMP14	(matrix	metallopeptidase	14),	 involving	in	disruption	of	extracellular	matrix,	and	PLA2G3	(phospholipase	A2	group	III),	relating	to	 cell	 death	 (Tamborero,	 Gonzalez-Perez	 &	 Lopez-Bigas	 2013).	 Nevertheless,	 each	statistical	strategy	has	advantages	and	disadvantages,	and	there	is	no	single	programme	that	can	accurately	determine	all	driver	genes.	
	 Another	 such	 statistical	 approach	 is	 the	 DOTS-Finder,	 a	 computational	programme	 based	 on	 3	 statistical	 steps,	 including	 protein	 function,	 frequentist	 and	pattern-based	principles,	 for	 the	prediction	of	potential	driver	genes	 in	human	cancer	(Melloni	 et	 al.	 2014).	 This	 tool	 can	be	utilised	with	 either	 the	 large-scale	 information	from	the	TCGA	database	or	with	the	data	of	 tumours	from	smaller	studies	to	estimate	
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the	driver	status.	The	DOTS-Finder	has	been	applied	to	34	individual	cancer	types	such	as	breast	and	 thyroid	 carcinoma	 to	 identify	driver	genes	and	 then	analyse	 the	 results	compared	to	predicted	mutations	from	other	projects	such	as	the	TCGA	database	or	the	TUSON	(Tumor	Suppressor	and	Oncogene)	Explorer	(Melloni	et	al.	2014).		
	 When	the	DOTS-Finder	was	applied	to	breast	cancer	samples,	a	poor	correlation	was	found	between	the	results	from	this	approach	and	the	TCGA	database.	Indeed,	the	DOTS-Finder	had	an	ability	 to	discriminate	 and	eliminate	 any	mutated	genes	 that	did	not	 correlate	with	human	cancer	such	as	RYR2	(Ryanodine	receptor	2)	 (Melloni	et	al.	2014).	 The	 DOTS-Finder	 also	 discovered	 novel	 putative	 driver	 genes	 such	 as	 AQP7	(Aquaporin-7)	(Melloni	et	al.	2014),	involving	in	cellular	proliferation	and	cell	migration	
in	 vitro	 and	 local	 invasion	 and	 metastasis	 of	 the	 tumour	 in	 vivo	 (Verkman,	 Hara-Chikuma	&	Papadopoulos	2008).		
The	DOTS-Finder	strategy	was	also	applied	to	326	thyroid	tumour	samples	from	the	 TCGA	 dataset.	When	 compared	 with	 the	 results	 from	 the	 TUSON	 Explorer,	 some	genes	such	as	BRAF	and	TG	were	identified	in	both	approaches.	Nevertheless,	the	DOTS-Finder	 also	 revealed	more	 putative	 driver	 genes	 such	 as	 EMG1	 (essential	 for	mitotic	growth	1)	and	IGF-1	(insulin-like	growth	factor	1)	(McMahon	et	al.	2010).	In	addition,	the	 DOTS-Finder	 also	 predicted	 that	 PBF	 may	 be	 one	 of	 12	 putative	 genes	 driving	thyroid	carcinogenesis	in	tumour	samples	from	the	TCGA	database	(Melloni	et	al.	2014).	Cifola	et	al.	also	applied	the	DOTS-Finder	programme	to	primary	plasma	cell	 leukemia	samples	 and	 identified	 14	 new	 potential	 driver	 genes	 playing	 critical	 roles	 in	 this	malignancy	(Cifola	et	al.	2015).	
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However,	although	statistical	 strategies	 such	as	 these	can	be	readily	applied	 to	large-scale	 genetic	 information	 and	 may	 predict	 rare	 driver	 mutations	 among	 all	somatic	 mutations,	 there	 is	 no	 current	 bioinformatic	 approach	 that	 can	 guarantee	definitive	driver	gene	status.	Therefore,	conventional	functional	studies	are	still	needed	to	 appraise	 potential	 driver	 mutations	 identified	 through	 bioinformatic	 screening	 of	mass	sequencing	data.		
	 	1.2.2	Laboratory	Approaches	
	 As	 driver	 genes	 are	 important	 for	 tumour	 formation	 and	 can	 be	 applied	 as	potential	 predictive	 and	 prognostic	 biomarkers	 for	 early	 diagnostic	 methods	 and	targeted	therapy	in	human	cancer,	confirmation	of	these	driver	genes	and	mutations	are	needed	 before	 the	 knowledge	 can	 be	 used.	 An	 oncogenic	 driver	 genes	 is	 a	 gene	 that	provides	 tumour	 growth	 benefit	 and	 induces	 clonal	 development	 of	 cancer	 (Stratton,	Campbell	&	Futreal	2009,	Haber,	Settleman	2007).	These	genes	or	mutations	generally	promote	their	oncogenic	functions	such	as	cellular	invasion	and	metastasis,	carry	a	high	recurrence	rate	in	cancer	samples	and	probably	cluster	in	specific	amino	acid	residues	or	 in	particular	domains	(Sakoparnig,	Fried	&	Beerenwinkel	2015,	Melloni	et	al.	2014,	Stratton,	 Campbell	&	Futreal	 2009).	 In	 addition,	 the	driver	 genes	 or	driver	mutations	are	 likely	 to	 retain	 the	 capability	 to	 transform	benign	 to	malignant	 cells	 in	 vitro,	 and	induce	tumourigenicity	in	vivo	(Hanahan,	Weinberg	2011,	Hanahan,	Weinberg	2000).		
	 As	 driver	 genes	 or	 mutations	 frequently	 have	 selective	 growth	 advantage,	cellular	 proliferation	 assessments	 such	 as	 MTS	 (3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium)	 or	 BrdU	
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(Bromodeoxyuridine)	assays	are	 commonly	used	 to	determine	 the	 impact	of	genes	or	mutations	 on	 the	 proliferative	 phenotype.	 If	 the	 cell	 turnover	 rate	 is	 significantly	increased,	 the	 investigated	 gene	 or	 mutation	 is	 potentially	 a	 driver.	 Other	 standard	biological	measures	such	as	cellular	invasion	and	cell	migration	are	useful,	as	are	gene	function-specific	 measures.	 Anchorage-independent	 growth	 remains	 a	 crucial	 feature	suggesting	malignant	transformational	ability	in	vitro.	Finally,	the	capacity	for	inducing	tumours	in	vivo	through	xenograft	or	transgenic	models	is	the	ultimate	test	to	establish	driver	gene	status.		
	 As	 an	 example,	 BRAF	 governs	 the	 MAPK/ERK	 pathway	 (mitogen-activated	protein	kinases/extracellular	signal-regulated	kinases),	involved	in	cellular	division,	cell	growth	 and	 differentiation.	 Perhaps	 unsuprisingly,	 BRAF	 was	 predicted	 through	 the	bioinformatic	approach	of	Melloni	et	al.	 to	be	a	driver	oncogene	 in	 thyroid	carcinoma	(Melloni	et	al.	2014).	The	BRAFV600E	substitution,	identified	in	both	the	COSMIC	and	the	TCGA	databases,	is	the	most	common	genetic	mutation	found	in	the	BRAF	gene,	and	is	apparent	 in	 a	 variety	 of	 human	 cancers,	 especially	 thyroid	 and	melanoma	 (Liu	 et	 al.	2007,	 Garnett,	 Marais	 2004).	 Overexpression	 of	 BRAFV600E	 in	 the	 thyroid	 gland	 of	 a	mouse	model	 induced	papillary	 thyroid	cancer	 (Knauf	et	al.	2005).	Depletion	of	BRAF	protein	expression	using	specific	BRAF	siRNAs	in	cells	carrying	the	BRAFV600E	mutation	significantly	 reduced	 cellular	 proliferation,	 colony	 formation	 and	 tumour	 growth	 in	nude	mice	(Liu	et	al.	2007).	Thus,	bioinformatic	and	laboratory	data	were	in	complete	agreement	for	BRAF	(Melloni	et	al.	2014).		 NRAS	is	another	gene	predicted	through	the	DOTS-Finder	to	be	a	potential	driver	gene	 in	 acute	 myeloid	 leukemia	 and	 thyroid	 cancer	 (Melloni	 et	 al.	 2014).	 This	 gene	interacts	 with	 PI3K	 (Phosphatidylinositol-3-Kinase),	 regulating	 the	 MAPK	 and	
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PI3K/AKT	(Phosphatidylinositol-3-Kinase/Protein	Kinase	B)	pathways,	and	influencing	cell	cycle,	differentiation	and	apoptosis	(Eisfeld	et	al.	2014).	The	amino	acid	G12	residue	is	also	the	recurrent	hot	spot	of	mutations	occurring	in	the	NRAS	gene,	and	NRASG12D	is	one	of	the	most	common	substitutions	established	in	the	COSMIC	and	the	TCGA	datasets	in	multiple	human	tumours	such	as	 leukemia,	 lymphoma,	colorectal	carcinoma,	breast	cancer	 and	 anaplastic	 thyroid	 cancer.	 Human	 skin	 fibroblast	 cells	 stably	 transfected	with	the	NRASG12D	mutant	showed	significantly	 induced	cellular	proliferation	via	BrdU	assays	 (Eisfeld	 et	 al.	 2014).	 Moreover,	 NIH	 3T3	 murine	 fibroblast	 cells	 stably	transfected	 with	 this	 mutation	 demonstrated	 enhanced	 cell	 transformation	 ability	through	 soft	 agar	 assays	 compared	 to	 controls	 (Eisfeld	 et	 al.	 2014).	 Therefore,	 the	NRASG12D	mutation	 is	 a	 clear	 driver	mutation	 both	 from	bioinformatic	 prediction	 and	standard	cell	biological	assays	(Melloni	et	al.	2014).		
	 By	 contrast,	 KRAS	 (V-Ki-ras2	 Kirsten	 rat	 sarcoma	 viral	 oncogene	 homolog)	 is	also	a	member	of	RAS	(rat	sarcoma)	subfamily,	but	is	not	anticipated	to	be	a	driver	gene	in	 thyroid	 cancer	 through	 computational	 analysis	 (Melloni	 et	 al.	 2014).	 However,	multiple	somatic	KRAS	mutations	in	a	variety	of	human	cancers	have	been	identified	in	the	 COSMIC	 and	 the	 TCGA	 databases,	 and	 the	 G12	 residue	 also	 has	 highly	 mutated	recurrence	rate	in	this	gene.	Furthermore,	KRASG12V	substitution	correlates	with	a	high	mortality	rate	and	aggressive	phenotype	in	human	colorectal	tumours	(Andreyev	et	al.	1998),	 and	 Caco-2	 colon	 cancer	 cells	 overexpressing	 KRASG12V	 showed	 enhanced	 cell	transformation	in	soft	agar	assays	(Oikonomou	et	al.	2009).	Thus,	although	KRAS	is	not	a	 predicted	 driver	 oncogene	 in	 thyroid	 cancer	 (Melloni	 et	 al.	 2014),	 the	 laboratory	results	suggest	that	this	gene	does	has	specific	growth	enhancement	and	is	indeed	likely	to	be	a	driver.		
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	 In	conclusion,	 laboratory	experiments	remain	necessary	for	the	confirmation	of	driver	gene	status	and	may	occasionally	contradict	bioinformatic	approaches.		
	
1.3	Hypothesis	and	Aims	
I	hypothesise	 that	PBF,	being	previously	classified	as	a	proto-oncogene,	may	 in	fact	be	an	oncogene,	with	 rare	amino	acid	 substitutions	 in	 some	residues	affecting	 its	mechanisms	of	action.	The	main	aim	of	this	study	is	to	analyse	the	functional	effect	of	the	first	10	discovered	nonsynonymous	mutations	in	PBF,	particularly	those	occurring	in	the	critical	PSI	domain,	transmembrane	region	and	proximal	to	the	NLS.	Further,	the	aim	of	this	thesis	is	to	study	the	effect	of	amino	acid	substitutions	on	protein	structure,	subcellular	 localisation	 of	 PBF,	 glycosylation,	 dimerisation,	 stability	 and	 known	functions	of	 the	protein,	 such	as	proliferation,	 invasion,	migration,	 radioiodine	uptake	ability,	transforming	ability	and	binding	partner	interaction.	Thus	the	overall	objectives	are	 to	determine	whether	mutations	 in	PBF	are	aetiological,	and	 in	doing	 this,	 to	gain	new	insight	into	the	mechanisms	of	action	of	this	under-characterised	gene.		
	
	
CHAPTER	2		- MATERIALS	AND	METHODS	
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2.1	Cell	Culture	and	Transfection	2.1.1	Cell	Lines	
TPC1	and	SW1736	are	thyroid	cancer	cell	lines	that	were	kindly	supplied	by	Dr	Rebecca	 Schweppe	 (Division	 of	 Endocrinology,	Metabolism,	 &	 Diabetes,	 University	 of	Colorado	Denver,	Aurora,	Colorado).	The	TPC1	cell	line	is	derived	from	human	papillary	thyroid	 carcinoma	which	expresses	wild	 type	of	BRAF,	HRAS,	KRAS,	NRAS,	PTEN	and	p53,	 but	 contains	 the	 RET/PTC1	 re-arrangement	 (Saiselet	 et	 al.	 2012,	 Ribeiro	 et	 al.	2008).	 The	 SW1736	 cell	 is	 originated	 from	 anaplastic	 thyroid	 cancer,	 with	 high	expression	of	several	cancer	stem	markers,	including	SOX2	(sex	determining	region	Y	-	box	 2),	 OCT4	 (octamer-binding	 transcription	 factor	 4)	 and	 SSEA4	 (stage	 specific	embryonic	antigen	4)	(Carina	et	al.	2013).	Both	cell	lines	were	cultured	in	RPMI	media	(Invitrogen,	 UK)	 containing	 10%	 (v/v)	 heat-inactivated	 foetal	 calf	 serum	 (FCS;	Invitrogen,	UK)	and	1%	Penicillin	(105	U/l)/Streptomycin	(100	mg/l).	
	 MCF7	 breast	 adenocarcinoma	 cancer	 cells	 were	 obtained	 from	 the	 European	Collection	of	Cell	Cultures	(ECACC).	This	cell	 line	was	first	isolated	from	the	malignant	pleural	 effusion	 of	 a	 female	 patient	 having	 adenocarcinoma	 of	 breast.	MCF7	 cells	 are	able	 to	 respond	 to	 estradiol	 via	 estrogen	 receptors	 and	 also	 contain	 progesterone	receptors.	 However,	 these	 cells	 have	 no	 amplification	 of	 ERBB2	 or	 erb-b2	 receptor	tyrosine-protein	kinase	2	gene	amplification	and	no	TP53	mutation	(Ross,	Perou	2001,	Soule	 et	 al.	 1973).	MCF7s	were	 routinely	maintained	with	 complete	 RPMI	 containing	10%	 (v/v)	 heat-inactivated	 foetal	 calf	 serum	 (FCS;	 Invitrogen,	 UK)	 and	 1%	 Penicillin	(105	U/l)/Streptomycin	(100	mg/l)	as	described	for	TPC1	and	SW1736	cells.	
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	 HeLa	 cells,	 a	 malignant	 epithelial	 cell	 line	 derived	 from	 a	 cervical	 carcinoma		(Scherer,	Syverton	&	Gey	1953),	were	utilised	as	a	human	cell	line	which	shows	highly	efficient	 transfection.	 Cells	 were	 cultured	 in	 Dulbecco	Modified	 Eagle’s	 Media	 DMEM	(Sigma,	 UK)	 supplemented	 with	 10%	 (v/v)	 heat-inactivated	 foetal	 calf	 serum	 (FCS;	Invitrogen,	UK),	1%	Penicillin	(105	U/l)/Streptomycin	(100	mg/l)	and	1%	L-glutamine	(Invitrogen,	UK).	Cells	were	incubated	and	then	passaged	twice	weekly.	
NIH	3T3	cells	are	mouse	embryonic	 fibroblast	cells	originating	 in	1962	at	New	York	University	School	of	Medicine	Department	of	Pathology.	These	cells	were	acquired	from	 the	 American	 Type	 Culture	 Collection	 (ATCC).	 Cells	 were	 maintained	 in	 DMEM	(Sigma,	UK)	supplemented	with	10%	(v/v)	calf	serum	(ATCC,	USA),	1%	Penicillin	(105	U/l)/Streptomycin	(100	mg/l)	and	1%	L-glutamine	(Invitrogen,	UK).		
All	cell	 lines	were	seeded	in	sterile	T75	tissue	culture	flasks	and	incubated	in	a	humidified	 incubator	 at	 37°C	 and	 5%	 CO2	 atmosphere.	 The	 appropriate	 seeding	 cell-density	 of	 all	 cell	 lines	 was	 determined	 by	 cell	 growing	 rate	 but	 they	 were	 usually	passaged	twice	weekly	as	required.	
	2.1.2	Plasmid	Purification	
2.1.2.1	Vector	(VO)	Overexpression	 of	 proteins	 of	 interest	was	 accomplished	 via	 transfection	with	mammalian	expression	vectors	carrying	specific	coding	sequence	cDNAs.	Plasmids	used	were	 pcDNA3.1(+)	 (Invitrogen,	 UK),	 pCI-Neo	 (Promega,	 USA)	 and	 pCMV6-Entry	(Origene,	 USA)	 as	 illustrated	 in	 Figure	 2.1A,	 2.1B	 and	 2.1C,	 respectively.	 All	 vectors	
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consist	of	the	origin	of	replication,	the	cytomegalovirus	promoter	and	sites	for	specific	antibiotic	resistance.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	2.1:	Schematic	diagram	of	pcDNA3.1(+/-),	pCI-neo	and	pCMV6-Entry	vectors.	
The	 figures	 illustrate	diagrams	of	 three	vectors	consisting	of	pcDNA3.1(+/-)	 (A),	pCI-neo	
A	
B	
C	
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(B)	and	pCMV6-Entry	vectors	(C),	with	origin	of	replication	(Ori),	Cytomegalovirus	(CMV)	
promoter	and	antibiotic	resistance	genes,	including	Ampicillin	(Amp),	Neomycin	(Neo)	and	
Kanamycin	(Kan)	resistance.	The	restriction	enzymes	sites	are	also	noted.		
	
2.1.2.2	Mutagenesis	Mutagenesis	 was	 performed	 using	 the	 Quick	 Change	 II	 XL	 site	 directed	mutagenesis	 kit	 (Agilent	 Technologies,	 UK).	 The	 first	 step	was	 to	 design	 individually	mutagenic	oligonucleotide	primers	(Sigma,	UK)	based	on	information	from	the	COSMIC	database.	Following	 the	manufacturer’s	 suggestions,	 the	desired	substitutions	were	 in	the	middle	 of	 the	 primer	with	 10–15	 bases	 of	 normal	 sequence	 on	 both	 sides,	 and	 a	length	 of	 25-45	 bases,	 with	 a	 melting	 temperature	 (TM)	 more	 than	 78°C	 (TM	 =	81.5+0.41(%GC)−(675/N)−%mismatch;	 N	 is	 the	 primer	 length	 in	 bases).	 In	 addition,	primers	were	designed	to	have	a	minimum	GC	content	of	40%	and	to	terminate	in	one	or	more	C	or	G	bases.		
	
2.1.2.3	Bacterial	Transformation		 Bacterial	transformation	was	performed	after	construction	of	mutated	plasmids.	Lysogeny	broth	 (LB)	 solution	was	prepared	 in	 concentration	20	g/l,	 and	LB	agar	was	assembled	with	a	proportion	of	4	g	LB	powder,	3	g	agar	and	200	ml	water.	Then,	after	being	warmed	until	melted,	LB	agar	was	supplemented	with	100	μg/ml	of	Ampicillin	or	50	μg/ml	of	Kanamycin,	and	poured	into	a	plate.	The	plate	was	left	at	room	temperature	until	set,	and	then	incubated	at	37°C	at	least	1	hour	before	used.	The	next	process	was	implemented	 using	 Subcloning	 EfficiencyTM	 DH5αTM	 Competent	 E.Coli	 Cells	
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(Invitrogen,	 UK)	 according	 to	 the	 manufacturer’s	 instructions.	 6	 ng	 of	 plasmid	 DNA	were	 added	 to	 50	 μl	 DH5αTM	 cells	 in	 a	 1.5	 ml	 Eppendorf	 tube.	 The	 tube	 was	 then	swirled	 gently	 to	mix	 them	 together	 and	 incubated	 on	 ice	 for	 30	minutes,	 before	 the	DH5αTM	cells	were	heat	shocked	at	42°C	for	20	seconds	and	left	on	ice	for	the	next	2	minutes.	950	μl	of	prepared	LB	solution	were	added	into	the	tube	and	the	sample	was	incubated	at	37°C	for	1	hour	in	a	shaking	incubator.	After	the	solution	was	centrifuged	at	13,000	rpm	for	3	minutes	at	room	temperature	to	form	the	cell	pellet	and	to	get	rid	of	the	supernatant,	the	cells	were	re-suspended	in	50	μl	of	LB	solution	and	then	aliquoted	onto	2	warmed	LB	plates.	The	plates	were	 incubated	at	37°C	 for	16	hours	to	 let	 them	form	colonies	used	for	the	next	steps	which	are	DNA	purification	(Miniprep)	and	DNA	amplification	(Maxiprep).	
	
2.1.2.4	Deoxyribonucleic	Acid	(DNA)	Purification	(Miniprep)	and	Sequencing		 DNA	purification	was	 accomplished	 using	 the	Wizard®	Plus	 SV	Miniprep	DNA	Purification	System	(Promega,	USA)	according	to	the	manufacturer’s	instructions.	After	a	 16-hour	 incubation	period	 in	 the	bacterial	 transformation	 step,	 a	 single	 colony	was	obtained	and	added	into	5	ml	LB	solution	containing	suitable	antibiotics	as	previously	described.	The	sample	was	then	incubated	at	37	°C	for	16	hours	in	a	shaking	incubator,	before	 the	 purification	 process	 was	 performed	 at	 room	 temperature.	 Firstly,	 the	suspension	solution	was	centrifuged	at	10,000	g	 for	5	minutes	 to	 form	the	pellet,	and	the	 supernatant	 was	 discarded.	 The	 pellet	 was	 next	 re-suspended	 thoroughly	 in	 Cell	Resuspension	 Solution	 (Promega,	 USA),	 before	 the	 cells	 were	 lysed	 using	 Cell	 Lysis	Solution	 (Promega,	 USA).	 Next,	 the	 sample	 was	 mixed	 and	 then	 incubated	 until	 the	
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suspension	 became	 cleared.	 After	 adding	 Alkaline	 Protease	 Solution	 (Promega,	 USA)	into	the	tube	and	mixing	to	inactivate	any	endonucleases	released	during	cell	lysis,	the	lysate	was	incubated	on	the	bench	for	5	minutes,	and	Neutralisation	Solution	(Promega,	USA)	was	then	supplemented.	The	tube	was	centrifuged	at	14,000	g	for	10	minutes.	All	further	 steps	 were	 carried	 out	 in	 a	 spin	 column	 combined	 with	 a	 collection	 tube	provided	 in	 the	 kit.	 After	 insertion	 of	 a	 spin	 column	 into	 a	 collection	 tube,	 the	 clear	supernatant	 was	 decanted	 into	 the	 column,	 and	 then	 centrifuged	 at	 14,000	 g	 for	 1	minute,	before	the	flowthrough	was	subsequently	discarded.	The	plasmid	was	washed	twice	 by	 using	Washing	 Solution	 (Promega,	 USA),	 and	 centrifuged	 at	 14,000	 g	 for	 1	minute	 and	 2	minutes,	 respectively,	 before	 discarded	 the	 flowthrough.	 After	 the	 spin	column	was	 transferred	 to	a	new	collection	 tube,	nuclease	 free	water	was	added	 into	the	 column	 and	 the	 sample	 was	 centrifuged	 at	 14,000	 g	 for	 1	 minute	 to	 elute	 the	plasmid	DNA.	The	DNA	 concentration	was	quantified	using	 the	NanoDrop©	ND-1000	Spectrophotometer	 (NanoDrop)	 and	 accompanying	ND-1000	 software	on	 the	DNA-50	setting.	The	plasmid	was	kept	at	-20°C.		
To	sequence	the	plasmid,	250-500	ng	of	 the	plasmid	DNA	were	added	with	3.2	pmol	of	forward	or	reverse	primers,	and	made	up	to	10	μl	in	total	volume	with	nuclease	free	 water.	 Primers	 for	 the	 pCI-neo	 vector	 were	 T7	 for	 forward	(TAATACGACTCACTATAGGG)	 and	 T3	 (ATTAACCCTCACTAAAGGGA)	 for	 reverse,	 while	primers	 for	 the	pcDNA3.1(+)	were	T7	 forward	 (TAATACGACTCACTATAGGG)	but	BGH	(bovine	 growth	 hormone	 terminator)	 reverse	 (TAGAAGGCACAGTCGAGG).	 For	 the	pCMV6-Entry	 vector,	 primers	 were	 forward	 primer	 VP1.5	 (GGACTTTCCAAAATGTCG)	and	reverse	primer	XL39	(ATTAGGACAAGGCTGGTGGG).	
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2.1.2.5	DNA	Amplification	(Maxiprep)	After	 sequencing	of	 the	plasmid	DNA,	DNA	amplification	was	 carried	out	using	the	GenEluteTM	HP	Plasmid	Maxiprep	Kit	(Sigma,	USA)	according	to	the	manufacturer’s	instructions.	 5	ml	 LB	 solution	were	 used	 to	 inoculate	 a	 starter	 culture	with	 a	 pipette	dipped	of	selected	glycerol	stock,	and	incubated	at	37°C	for	8	hours	in	shaking	incubator	at	 250-300	 rpm.	 Next,	 the	 starter	 culture	 was	 diluted	with	 LB	medium	 (1:500)	 with	appropriate	antibiotics,	and	the	sample	was	 then	cultured	at	37	°C	 for	12-16	hours	 in	orbital	shaker	at	250-300	rpm	to	gain	good	plasmid	yields.	The	processes	after	this	step	were	carried	out	at	room	temperature.	After	incubation	overnight,	the	suspension	was	centrifuged	at	5,000	g	for	10	minutes	to	create	the	pellet	and	discard	the	supernatant.	After	 the	 bacterial	 pellet	 was	 further	 re-suspended	 thoroughly	 with	 chilled	Resuspension/RNase	A	Solution	(Sigma,	USA),	lysing	the	cells	was	performed	with	Lysis	solution	(Sigma,	USA).	The	suspension	was	left	for	3-5	minutes	until	it	became	clear	and	viscous.	 The	 samples	was	next	 neutralised	by	using	 chilled	Neutralization	 Solution	 to	form	 a	 white	 aggregate,	 and	 Binding	 Solution	 was	 added	 to	 bind	 the	 plasmid	 DNA,	before	the	sample	was	 immediately	poured	into	the	prepared	syringe	and	 let	 to	stand	for	5	minutes.	While	waiting,	a	GenElute	HP	Maxiprep	Binding	Column	was	placed	into	a	50	ml	collection	tube	provided	in	the	kit,	and	washed	by	Column	Preparation	Solution,	before	being	spun	at	3,000	g	for	2	minutes	and	the	eluate	was	discarded.	Subsequently,	the	plunger	was	placed	into	the	filter	syringe	placed	over	the	binding	column,	and	then	gently	 applied	 to	 squeeze	 the	 cleared	 lysate	 to	 pass	 through	 the	 filter	 and	 go	 to	 the	binding	 column.	 The	 solution	 was	 centrifuged	 at	 3,000	 g	 for	 2	 minutes	 and	 the	flowthrough	was	 discarded,	 before	 the	DNA	was	washed	 twice	with	Wash	 Solution	 1	and	 Wash	 Solution	 2,	 and	 centrifuged	 at	 3,000	 g	 for	 2	 minutes	 and	 5	 minutes,	respectively.	 Finally,	 after	 the	 column	 was	 transferred	 to	 a	 new	 collection	 tube,	 and	
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Elution	solution	was	added	to	elute	the	plasmid,	the	sample	was	centrifuged	at	3,000	g	for	5	minutes.	The	eluate	DNA	was	transferred	to	a	new	Eppendorf	and	kept	at	-20°C.	The	 concentration	 of	 DNA	 was	 measured	 and	 the	 sequencing	 was	 performed	 as	described	in	section	2.1.2.4.		
	 2.1.3	Transfections	of	Plasmids	
TPC1	cells	were	seeded	at	75,000	cells	per	well	of	6-well	plates,	while	the	other	cells,	 including	 SW1736,	MCF7,	 HeLa	 and	HCT116,	were	 seeded	 into	 6	well	 plates	 at	150,000	cells	each	well. After	being	seeded	in	6-well	plates	and	incubated	at	37°C	and	5%	 CO2	 condition	 for	 24	 hours,	 cells	 were	 transfected	 at	 70-80%	 confluence	 with	TransIT®-LT1	 reagent	 (Mirus,	 USA).	 Prior	 to	 transfection,	 2	µg	 of	 plasmid	 DNA	were	added	into	200	µl	of	Opti-MEM	serum-free	media	(Invitrogen,	UK)	and	left	for	5	minutes	at	 room	temperature,	before	being	 incubated	with	6	µl	of	 transfection	reagent	 for	 the	next	20	minutes	 to	allow	complex	 formation.	After	 the	desired	 solution	was	added	 to	each	 well	 containing	 cells	 and	 incubated	 for	 further	 24-48	 hours,	 experiments	 were	performed.	No	media	change	was	done	for	all	cell	lines. 
	 2.1.4	Short	Interfering	(siRNA)	Transfection	
Cells	were	seeded	in	6-well	plates	as	described	in	section	2.1.3	and	incubated	at	37°C	and	5%	CO2	condition	for	24	hours.	Cells	were	transfected	at	70-80%	confluence	with	siPORT™	NeoFX™	(Invitrogen,	UK).	Prior	to	transfection,	10	µl	of	silencer	cortactin	siRNA	 4666	 and	 4667	 (concentration	 10	 µM,	 Invitrogen,	 UK)	 or	 2.5	 µl	 of	 negative	
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control	 siRNA	 or	 scramble	 siRNA	 (concentration	 40	µM,	 Invitrogen,	 UK)	were	 added	into	 100	 µl	 of	 Opti-MEM	 serum-free	 media	 (Invitrogen,	 UK)	 to	 make	 the	 final	concentration	50	nM.	In	the	meantime,	5	µl	of	siPORT™	NeoFX™	were	diluted	into	100	
µl	 of	 Opti-MEM	 serum-free	 media	 (Invitrogen,	 UK),	 and	 left	 for	 10	 minutes	 at	 room	temperature,	before	being	combined	and	incubated	at	room	temperature	for	the	next	10	minutes	for	allowing	complex	formation.	The	200	µl	of	transfection	solution	were	then	dispensed	 in	 each	 well	 and	 incubated	 for	 a	 further	 24	 hours	 before	 overexpression	experiments	were	performed.	
	
2.2	Protein	Extraction	and	Quantification	
(Bicinchoninic	Acid	Assay	or	BCA)	
After	 cells	 were	 washed	 with	 phosphate	 buffered	 saline	 (PBS),	 proteins	 were	harvested	with	RIPA	buffer	(50	mM	Tris-HCl,	pH	7.4,	150	mM	NaCl,	1%	(v/v)	Igepal	CA-630,	6	mM	sodium	deoxycholate	and	1	mM	ethylenediaminetetraacetic	acid	or	EDTA)	or	modified	RIPA	buffer	(50	mM	Tris-HCl,	pH	7.4,	150	mM	NaCl,	1%	(v/v)	Igepal	CA-630,	6	mM	Sodium	deoxycholate	 and	 1	mM	ethyleneglycol	 bis(2-aminoethyl	 ether)-N,N,N',N'	tetraacetic	 acid	 or	 EGTA)	 combined	 with	 a	 protease	 inhibitor	 (Sigma,	 USA)	 and	 two	phosphatase	inhibitor	cocktails	(Sigma,	USA)	in	proportion	of	1	ml:	60	µl:	10	µl:	10	µl,	respectively.	 For	 the	 phosphoprotein	 study,	 the	 cells	 were	 treated	 with	 pervanadate	(100	 µM)	 at	 37°C	 for	 20	 minutes	 before	 being	 harvested	 with	 modified	 RIPA	 as	described	 above.	 The	 samples	were	 then	 incubated	 at	 -20°C	 for	 20-30	minutes.	 Once	thawed,	the	plates	were	scraped	and	samples	were	centrifuged	at	13,200	rpm,	at	4°C	for	20	minutes	before	cell	debris	was	discarded.	
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Subsequently,	 the	Bicinchoninic	Acid	(BCA)	assay	was	carried	out	by	adding	80	
µl	of	BCA	reagents,	combining	BCA	reagent	A	and	reagent	B	(Fisher	Scientific,	UK)	in	the	ratio	 of	 50:1,	 in	 4	 µl	 of	 each	 protein	 sample,	 before	 protein	 concentration	 was	determined	 by	 measuring	 absorbance	 at	 560	 nm	 with	 a	 Wallac	 Victor3	 plate	 reader	(Perkin-Elmer,	USA).	This	value	was	used	to	calculate	the	quantity	of	protein	applied	in	Western	blotting	analysis.	
	
2.3	Protein	Homogenisation	
After	 weighing	 the	 frozen	 human	 tissues,	 the	 master	 mix	 containing	modified	RIPA	 (50	mM	Tris-HCl,	pH	7.4,	150	mM	NaCl,	1%	(v/v)	 Igepal	CA-630,	6	mM	Sodium	deoxycholate	and	1	mM	EGTA),	a	protease	inhibitor	(Sigma,	USA)	and	two	phosphatase	inhibitor	cocktails	(Sigma,	USA)	was	made	in	the	proportion	of	1	ml:	60	µl:	10	µl:	10	µl,	respectively.	Then,	350	µl	of	the	master	mix	were	aliquoted	into	the	polyethelene	tube	containing	 tissue	before	homogenisation.	After	 the	samples	were	centrifuged	at	1,000	rpm	for	1	minute	to	get	rid	of	air	bubbles	and	transferred	to	new	Eppendorf	tubes,	they	were	centrifuged	again	at	13,200	rpm	at	4	°C	for	20	minutes	to	get	rid	of	debris	and	the	supernatant	 was	 next	 transferred	 to	 new	 Eppendorf	 tubes.	 The	 Bicinchoninic	 Acid	(BCA)	assay	was	then	carried	out	as	described	in	section	2.2.	
	
2.4	RNA	(Ribonucleic	Acid)	Extraction	in	Cell	Lines	
After	 cells	 were	 seeded	 at	 an	 appropriate	 cell	 density	 in	 a	 6-well	 plate	 and	transfected	 for	 24-48	 hour,	 cells	 were	 washed	 with	 1	 ml	 phosphate	 buffered	 saline	
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(PBS),	before	being	harvested	with	500	μl	Tri-reagent	 (Sigma,	USA)	 in	each	well	of	6-well	plate.	Cells	were	next	scraped	and	the	content	was	transferred	to	new	Eppendorf	tubes	 and	 frozen	 at	 -80°C	 overnight.	 Once	 thawed,	 100	 μl	 (200	 μl/ml	 Tri-reagent)	Chloroform	(Sigma,	USA)	were	aliquoted	 into	each	Eppendorf	 tube	and	samples	were	shaken	vigorously	for	15	seconds,	before	being	left	to	stand	at	room	temperature	for	15	minutes.	Subsequently,	the	samples	were	centrifuged	at	12,000	g	for	15	minutes	at	4°C	to	 separate	 RNA	 content	 from	 protein	 and	 DNA.	 The	 clear	 aqueous	 layer	 was	transferred	to	new	Eppendorf	tubes	before	250	μl	(500	μl/ml	Tri-reagent)	isopropanol	(Sigma,	USA)	were	added	and	mixed	gently.	The	samples	were	then	left	to	stand	at	room	temperature	for	10	minutes	before	being	centrifuged	at	12,000	g	for	10	minutes	at	4°C.	Supernatant	was	removed	and	the	pellet	was	washed	with	500	μl	(1	ml/ml	Tri-reagent)	of	 75%	 ethanol	 and	 vortexed	 vigorously,	 before	 the	 Eppendorfs	 were	 centrifuged	 at	9,000	g	for	5	minutes	at	4°C.	After	the	ethanol	was	all	discarded	and	the	pellet	was	left	to	 air	 dry	 at	 room	 temperature	 for	 10	 minutes,	 30	 μl	 of	 nuclease	 free	 water	 were	applied	 to	 resuspend	 the	 pellet.	 The	 concentration	 of	 RNA	 samples	 were	 quantified	using	 the	 NanoDrop	 Spectrometer	 (NanoDrop	 Products,	 USA)	 and	 the	 extracted	 RNA	products	were	stored	at	-80°C.	
	 	
2.5	Western	Blotting	
After	 protein	 extraction,	 samples	 were	 prepared	 for	 Western	 blotting	 by	combining	 the	 proteins	 with	 4	 times	 Laemmli	 buffer	 (Biorad,	 USA),	 containing	 2-Mercaptoethanol	 (Sigma,	USA),	 and	 then	 they	were	 incubated	at	37°C	 for	30	minutes,	allowing	them	to	be	denatured.		
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12%	and	15%	sodium	dodecyl	sulphate-polyacrylamide	gels	were	used,	with	or	without	 5%	 stacking	 gels.	 Samples	 were	 loaded	 into	 each	 well	 alongside	 5	 µl	 of	Precision	 Plus	 protein	 standards	 dual	 colour	 (Biorad,	 USA),	 used	 as	 protein	 ladder	marker,	in	the	first	lane	of	each	gel.	Different	sizes	of	protein	were	run	and	separated	by	electrophoresis	at	70	V,	until	protein	markers	passed	 through	 the	stacking	gel,	before	increasing	the	voltage	to	140	V,	leading	them	to	run	through	the	bottom	of	the	resolving	gels.	Proteins	were	 transferred	 from	resolving	gels	 to	Polyvinylidene	Fluoride	 (PVDF)	membranes	(Fisher	Scientific,	UK)	in	wet	transferred	apparatus	at	360	mA	for	1	hour	15	minutes,	 before	 blocking	 membranes	 were	 performed	 with	 5%	 non-fat	 milk	 in	 Tris-Buffered	Saline	with	Tween	(TBS-T;	50	ml	of	1	M	Tris	pH	7.6,	20	gm	sodium	chloride,	0.625	ml	of	Tween	80	and	2447.5	ml	of	distilled	water)	or	5%	bovine	serum	albumin	(BSA)	in	TBS-T,	depending	on	the	primary	antibodies,	for	1	hour	at	room	temperature	to	reduce	non-specific	protein	binding.	After	being	probed	with	primary	antibodies	 in	5%	non-fat	milk	or	5%	BSA	in	TBS-T	(ranging	from	1:500	to	1:10000	concentration)	at	4°C	overnight,	the	membranes	were	washed	in	TBS-T	for	ten	minutes,	three	times,	and	then	 incubated	 with	 appropriate	 horseradish	 peroxidise	 conjugated	 secondary	antibodies	 in	 5%	 non-fat	 milk	 in	 TBS-T	 (1:2000)	 at	 room	 temperature	 for	 one	 hour	before	 being	 washed	 for	 additional	 three	 times	 of	 TBS-T.	 Finally,	 ECL-2	 (Thermo	Scientific,	 UK)	 or	 Supersignal	 West	 Pico	 Chemiluminescent	 Substrate	 (Thermo	Scientific,	UK)	was	applied	onto	the	membranes	to	visualise	protein	bands	on	films.	
The	primary	antibodies	used	for	Western	blotting	were	mouse	anti-flag	(1:500,	Sigma,	 USA),	mouse	 anti-HA	 (1:1000,	 Cambridge,	 UK),	 rabbit	 anti-NIS	 (1:500,	 Abcam,	USA),	 rabbit	 anti-PBF	 (1:500,	 In-house),	 mouse	 anti-cortactin	 (1:500,	 Merck	 and	
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Millipore,	 Germany),	 mouse	 anti-Myc	 Tag	 9B11	 (1:1000,	 Cell	 Signaling	 Technology,	USA)	and	mouse	anti-β-actin	AC-15	(1:10000,	Sigma,	USA).	
	
2.6	Immunofluorescence	Microscopy	
After	48	hours	of	transfection,	cells	on	coverslips	were	washed	with	phosphate	buffered	 saline	 (PBS)	 and	 then	 incubated	with	 fixing	 solution	 (0.1M	phosphate	buffer	Na2HPO4	(pH	7.4),	2%	paraformaldehyde	(PFA),	2%	glucose,	0.02%	sodium	azide)	 for	20	minutes	at	room	temperature.	After	rinsing	twice	with	PBS,	cells	were	permeabilised	by	 placing	 the	 coverslips	 in	 chilled	 100%	methanol	 for	 10	minutes.	 Next,	 cells	 were	briefly	washed	with	PBS	 two	 times	before	being	blocked	 in	10%	newborn	 calf	 serum	(NCS)	 (Invitrogen,	 UK)	 in	 PBS	 for	 further	 30	 minutes.	 Primary	 antibodies,	 including	mouse	anti-flag	(1:200,	Sigma,	USA),	mouse	anti-HA	(1:200,	Cambridge,	UK),	rabbit	anti-HA	 (1:200,	 Santa	 Cruz	 Biotechnology,	 UK),	 mouse	 anti-cortactin	 (1:100,	 Merck	 and	Millipore,	Germany),	mouse	anti-Myc	Tag	9B11	(1:500,	Cell	Signaling	Technology,	USA),	rabbit	anti-NIS	(1:500,	Abcam,	USA),	rabbit	anti-PBF	(1:100,	In-house)	and	rabbit	anti-phosphoPBF	(Y174,	1:50,	In-house),	were	added	into	1%	bovine	serum	albumin	(BSA)	(Jackson	Immunoresearch,	USA)	in	PBS.	The	coverslips	were	lowered	onto	the	antibody	solutions	for	one	hour	and	then	rinsed	three	times	with	PBS,	before	further	incubated	in	secondary	antibody	diluted	in	1%	NCS	in	1%	BSA	for	an	hour	at	room	temperature.	The	secondary	 antibodies	 comprised	 Alexa-Fluor-594-conjugated	 goat	 anti-rabbit	 IgG	(1:250,	 Invitrogen,	 UK),	 Alexa-Fluor-488-conjugated	 goat	 anti-mouse	 IgG	 (1:250,	Invitrogen,	 UK)	 and	 Hoechst	 (1:1000,	 Invitrogen,	 UK).	 The	 coverslips	 were	 returned	into	the	wells	and	washed	three	times	with	PBS,	before	mounted	onto	slides	with	Dako	Fluorescent	Mounting	 Solution	 (Dako,	Denmark)	 and	allowed	 to	dry.	 Finally,	 the	 cells	
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were	visualised	using	a	Zeiss	Axioplan	fluorescence	microscope	(Zeiss,	Germany)	with	10x	and	100x	objectives.	
	
2.7	Protein	Half-life	Studies	
MCF7	and	SW1736	 cells	were	 transfected	with	vector	only	 (VO),	HA	 tagged	or	FLAG-tagged	wild-type	PBF	and	PBF	mutants,	and	then	incubated	for	48	hours	at	37°C,	5%	 CO2.	 1	 ml	 of	 Opti-MEM	 serum-free	 media	 (Invitrogen,	 UK),	 containing	 5	 µl	 of	Anisomycin	(Sigma,	USA),	was	added	into	each	well	of	6-well	plate	and	then	incubated	for	0,	12	and	24	hours.	Subsequently,	protein	samples	were	harvested	as	above	before	Western	 blotting	was	 performed	with	mouse	 anti-HA,	 1:1000	 (Covance,	 USA),	mouse	anti-FLAG,	 1:500	 (Sigma,	 USA)	 and	 mouse	 anti-β-actin,	 1:10000	 (Sigma,	 USA)	 as	primary	antibodies,	while	the	secondary	antibody	was	rabbit	anti-mouse,	1:2000	(Dako,	UK).	 Densitometry	 was	 measured	 with	 Image	 J	 software	 to	 quantify	 the	 interested	bands	 taken	 from	 Western	 blotting	 and	 then	 the	 half-life	 of	 each	 mutation	 was	calculated	as	a	ratio	to	β-actin	to	assess	protein	stability,	compared	with	wild-type	PBF.	
	
2.8	Cell	Proliferation	Assays	2.8.1	3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium	(MTS)	Proliferation	Assays	
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The	CellTiter	96®	AQueous	One	Solution	Cell	Proliferation	Assays	(Promega,	UK)	contains	 a	 tetrazolium	 compound	 (3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium,	 inner	 salt;	 MTS)	 and	 an	electron	 coupling	 reagent	 (Phenazine	 Ethosulfate;	 PES),	 being	 combined	with	MTS	 to	form	 a	 stable	 complex	 solution.	 The	 MTS	 reagent	 is	 converted	 by	 NADPH	 in	metabolically	 active	 cells	 into	 a	 formazan	 product	 that	 is	 soluble	 in	 culture	medium.	This	conversion	results	 in	a	colorimetric	method	 for	quantifying	 the	number	of	viable	cells	in	proliferation	assays	comparing	between	wild-type	PBF	and	all	mutations.		
After	 24	 hours	 of	 transfection	 in	 6-well	 plates,	 transfected	 TPC1	 and	 SW1736	cells	 were	 reseeded	 into	 a	 96-well	 plate	 with	 six	 replicates	 in	 each	 experiment	 and	incubated	 at	 37°C	 for	 24	 hours.	 Subsequently,	 20	 µl	 of	 the	 reagent	 solution	 were	pipetted	into	each	well	and	the	samples	were	incubated	at	37°C	for	4	hours,	before	the	absorbance	 of	 the	 samples	was	measured	with	 a	 plate	 reader	 (Perkin-Elmer,	USA)	 at	absorbance	490	nm	and	then	analysed	with	Sigma	Stat	software	to	determine	statistical	significance.	
	 2.8.2	Cell	Proliferation	ELISA,	Bromodeoxyuridine	(BrdU)	Colorimetric	Assays		
The	 cell	 proliferation	 ELISA	 BrdU	 (colorimetric)	 assay	 (Roche,	 USA)	 is	 a	 non-radioactive	method	to	determine	cell	proliferation	based	on	the	measurement	of	BrdU	incorporation	 during	 DNA	 synthesis.	 This	 results	 in	 a	 colorimetric	 method	 used	 to	quantify	the	number	of	viable	cells	in	proliferation	assays	comparing	between	wild-type	PBF	and	all	mutations.		
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After	 24	 hours	 of	 transfection	 in	 6-well	 plates,	 the	 TPC1	 and	MCF7	 cells	were	reseeded	into	96-well	plates	with	eight	replicates	in	each	experiment	and	incubated	at	37°C	for	24	hours.	Subsequently,	10	µl	of	the	BrdU	labelling	solution	were	pipetted	into	each	well	 and	 the	 cells	were	next	 incubated	 for	4	hours	at	37°C,	before	200	µl	 of	 the	fixation	reagent	were	added	to	the	well	and	left	for	30	minutes.	Next,	the	fixing	solution	was	removed	and	then	100	µl	of	the	anti-BrdU-POD	working	solution	were	aliquoted	in	to	the	wells	and	the	samples	were	incubated	at	room	temperature	for	90	minutes.	After	washing	off	the	antibody	conjugate,	100	µl	of	the	substrate	solution	were	added,	and	the	samples	were	then	incubated	at	room	temperature	for	30	minutes.	Finally,	absorbance	of	 the	 samples	was	measured	with	 a	 plate	 reader	 (Perkin-Elmer,	USA)	 at	 absorbance	405	 nm	 and	 then	 analysed	 with	 Sigma	 Stat	 software	 to	 determine	 statistical	significance.	
	
2.9	Cell	Invasion	Assays	
After	 transfection	 for	 24-48	 hours,	 the	 complete	 media	 containing	 10%	 FCS	(Invitrogen,	 UK)	were	 changed	 to	 be	 complete	media	 containing	 2%	FCS	 (Invitrogen,	UK)	to	be	chemoattractant	to	drive	cell	invasion.	After	being	incubated	for	16	hours,	the	cells	 were	 trypsinised	 with	 0.25%	 trypsin	 and	 resuspended	 in	 complete	 media	containing	 2%	 FCS.	 Next,	 they	 were	 reseeded	 into	 8	 µm	 growth	 reducing	 invasive	chambers	 (BD	 bioscience,	 UK)	 depending	 on	 the	 appropriate	 cell-density	 in	 each	 cell	line,	and	incubated	at	37°C	and	5%	CO2	for	the	next	24	hours	before	starting	membrane	staining.	After	being	washed	with	PBS,	the	cells	were	fixed	in	95%	ethanol	for	5	minutes	and	incubated	for	the	next	10	minutes	with	Haematoxylin	solution	(Sigma,	USA).	Then,	
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the	membranes	 were	 briefly	 rinsed	 with	 tap	 water,	 before	 being	 placed	 in	 Scott	 tap	water	(3.5	gm	NaHCO3,	20	gm	MgSO4	in	1	litre	of	water)	for	5	minutes	and	incubated	in	95%	ethanol	for	the	next	2	minutes.	After	Eosin	was	applied	to	the	cells	for	5	minutes	and	the	cells	were	quickly	washed	in	tap	water,	they	were	placed	for	2	minutes	in	70%	and	95%	ethanol,	respectively.	The	cells	were	left	to	be	dry	before	being	mounted	with	Distyrene	 Plasticizer	 Xylene	 (DPX)	 (Sigma,	 USA)	with	 the	 cells	 facing	 up.	 The	 images	were	captured	and	the	cells	were	counted	with	Image	J	software.	
	
2.10	Co-immunoprecipitation	(Co-IP)	
After	48	hours	of	 transfection,	 cells	were	washed	with	PBS,	 and	proteins	were	harvested	with	500	µl	of	RIPA	buffer	(50	mM	Tris-HCl,	pH	7.4,	150	mM	NaCl,	1%	(v/v)	Igepal	CA-630,	6	mM	sodium	deoxycholate	and	1	mM	EDTA)	combined	with	a	protease	inhibitor	 (Sigma,	 USA)	 and	 two	 phosphatase	 inhibitor	 cocktails	 (Sigma,	 USA)	 in	 the	proportion	of	1	ml:	60	µl:	10	µl:	10	µl,	respectively	and	incubated	on	a	rocker	at	4°C	for	30	 minutes.	 Then	 the	 flasks	 were	 scraped	 and	 samples	 were	 sonicated	 twice	 at	 a	medium	speed	setting	for	30	seconds,	before	being	incubated	on	a	rotator	at	4°C	for	an	hour.	The	samples	were	next	centrifuged	at	13,200	rpm,	at	4°C	 for	20	minutes	before	cell	debris	was	discarded.	Subsequently,	50	µl	of	protein	samples	were	aliquoted	 into	new	 Eppendorfs	 for	 Western	 blotting	 analysis	 as	 whole	 cell	 lysate	 samples.	 The	remaining	samples	were	incubated	with	2.5	µl	of	primary	antibodies,	 including	mouse	anti-flag	 (Sigma,	 UK),	 mouse	 anti-HA	 (Cambridge,	 UK),	 rabbit	 anti-HA	 (Santa	 Cruz	Biotechnology,	 UK),	mouse	 anti-cortactin	 (Merck	 and	Millipore,	 Germany)	 and	mouse	anti-Myc	(Cell	Signaling	Technology,	USA),	at	4°C	overnight.	After	that,	50	µl	of	protein	G	
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SepharoseTM	4	 Fast	 Flow	beads	 (GE	Healthcare,	USA)	 per	 sample	were	 centrifuged	 at	2,000	g,	4°C	for	1	minute	to	remove	ethanol,	before	being	washed	with	500	µl	of	RIPA	buffer	at	the	same	speed,	for	one	minute,	three	times	and	then	resuspended	in	50	µl	of	RIPA	 per	 sample.	 Subsequently,	 after	 being	 added	 into	 the	 protein	 samples	 and	incubated	on	a	rotator	at	4°C	for	2	hours,	the	beads	were	rinsed	with	500	µl	of	RIPA	at	2,000	 g	 for	 one	minute	 three	 times.	 The	 protein	 was	 then	 denatured	 in	 2x	 Laemmli	buffer	 (LB)	 containing	 β-mercaptoethanol	 (0.72	 mM)	 at	 37°C	 for	 30	 minutes	 before	being	centrifuged	to	discard	the	beads.	The	bound	protein	samples	were	transferred	to	new	Eppendorfs	and	used	for	Western	blotting	analysis	alongside	the	whole	cell	lysate	samples.		
	
2.11	Reverse	Transcription	(RT)	
	After	obtaining	RNA	samples,	 reverse	 transcription	 is	 required	 to	obtain	 cDNA	for	 the	 quantitative	 polymerase	 chain	 reaction	 (qPCR)	 assay.	 500	 ng	 of	 RNA	 samples	were	aliquoted	into	each	Eppendorf	tube	and	nuclease	free	water	was	added	to	make	a	total	 volume	 of	 4.9	 μl.	 The	 samples	 were	 incubated	 at	 70°C	 for	 10	 minutes	 before	placing	 them	on	 ice,	while	 preparing	 a	master	mix	 of	 the	 reverse	 transcription	 assay	(Promega,	 USA).	 The	 master	 mix	 contained	 2	 μl	 25	 mM	MgCl2,	 1	 μl	 10x	 RT	 reaction	buffer,	1	μl	10	mM	dNTP	(deoxynucleotide	triphosphate),	0.25	μl	RNasin	(ribonuclease	inhibitor),	0.3125	μl	AMV	RT	(Avian	Myeloblastosis	Virus	reverse	transcriptase)	buffer	and	0.5	μl	random	hexamer	primers	for	each	sample,	and	5	μl	of	the	master	mix	were	then	aliquoted	to	each	Eppendorf	tube.	After	leaving	to	stand	at	room	temperature	for	10	minutes,	the	samples	were	heated	at	42°C	for	1	hour,	95°C	for	5	minutes	and	4°C	for	
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5	 minutes.	 Finally,	 10	 μl	 of	 nuclease	 free	 water	 were	 added	 to	 achieve	 the	 final	concentration	of	25	ng/μl	of	cDNA	before	stored	at	-20°C.	
	 	
2.12	Quantitative	Real-time	Polymerase	Chain	
Reaction	(qPCR)	
Quantitative	real-time	polymerase	chain	reaction	or	qPCR	was	used	to	determine	the	 mRNA	 expression	 of	 specific	 genes	 of	 interest	 compared	 to	 those	 for	 internal	reference	 genes.	 These	 experiments	 were	 performed	 using	 an	 ABI	 7500	 Sequence	Detection	System.	
Pre-optimised	 Taqman	 probes	 consisted	 of	 a	 quencher,	 TAMRA	 (6-carboxy-tetramethyl-rhodamine)	 at	 the	 3’	 end,	 and	 a	 reporter	 fluorophore	 FAM	 (6-carboxy-fluorescein)	 or	VIC	 (full	 chemical	 name	patent	 protected)	 at	 the	 5’	 end.	 Basically,	 the	quencher	suppresses	the	emission	of	fluorescence	from	the	fluorophore.	However,	5’	to	3’	 exonuclease	 activity	 of	 the	 Taq	 polymerase,	 due	 to	 PCR	 amplification,	 extends	 the	primers	 and	 degrades	 the	 probes,	 resulting	 in	 breaking	 down	 the	 probes’	 close	proximity	 to	 the	 quencher,	 releasing	 the	 fluorophore,	 and	 thereby	 instigating	 a	fluorescence	 signal.	 The	 level	 of	 detected	 fluorescence	 is	 directly	 proportional	 to	 the	amount	of	cDNA	or	RNA	present	in	the	reaction.	
The	PCR	assay	was	carried	out	in	20	μl	volumes	on	96-well	plates,	with	2	μl	(10	ng/μl)	cDNA,	1	μl	specific	target	gene	expression	assay	(Fisher	Scientific,	UK),	10	μl	2x	GoldStar	Taqman	PCR	master	mix	(Eurogentec,	UK)	and	7	μl	nuclease	free	water	in	each	reaction.	All	specific	 target	genes	were	 labelled	with	FAM	and	the	housekeeping	gene,	
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18S,	with	VIC.	The	thermal	cycle	steps	were	as	follows:	50°C	for	2	minutes,	95°C	for	10	minutes,	40	cycles	95°C	for	15	seconds	and	60°C	for	1	minute.		
The	end	data	were	derived	from	ΔCt	values,	which	is	the	cycle	threshold	(Ct)	of	the	target	gene	subtracted	from	the	Ct	of	the	internal	reference	gene.	A	ΔΔCt	value	was	calculated	(ΔΔCt	=	ΔCt	of	an	experimental	group	–	ΔCT	of	a	control	group),	and	used	to	ascertain	a	fold	change	with	an	equation:	2-(ΔCt	of	an	experimental	group	–	ΔCT	of	a	control	group)	or	2-
ΔΔCt.	
	
2.13	Stable	Cell	Line	Generation	
	 The	 lowest	 passage	 number	 of	 TPC1	 thyroid	 cancer	 and	 NIH	 3T3	 murine	fibroblast	 cell	 lines	 was	 selected	 to	 produce	 stable	 cell	 lines	 used	 in	 cell	 migration,	colony	 formation	 and	 soft	 agar	 assays.	 These	 cells	 were	 cultured	 and	 passaged	 in	specific	 media	 as	 described	 in	 section	 2.1.1.	 TPC1	 cells	 were	 transfected	 with	pcDNA3.1(+)	 vectors	 containing	 VO,	WT-PBF,	 C51R	 and	 R140W	 plasmids,	 while	 NIH	3T3	 cells	 were	 transfected	 with	 pCI-neo	 carrying	 the	 same	 plasmid	 DNA	 using	TransIT®-LT1	 reagent	 (Mirus,	 USA)	 as	 described	 in	 section	 2.1.3.	 After	 24	 hours	 of	transfection,	the	appropriate	antibiotic,	G418	(1mg/ml),	was	applied	into	the	media	to	select	transfected	cells.	The	cells	were	supplemented	with	fresh	media	containing	ATB	twice	 a	week,	 and	 continuously	 cultured	 for	 2	weeks,	 to	 kill	 untransfected	 cells.	 	 The	transfected	cells	were	 then	diluted	and	re-seeded	 in	a	60	mm	Petri	dish	with	a	single	cell	 suspension,	 and	maintained	until	 noticeable	 colonies	 developed.	Distinct	 colonies	were	 selected	 and	 re-seeded	 in	 individual	wells,	 and	 next	 cultured	 in	 normal	 fashion	
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until	 the	 cells	 filled	 T75	 flasks.	 The	 protein	 and	mRNA	 PBF	 expression	 of	 individual	colonies	were	determined	using	Western	blotting	and	TaqMan	RT-PCR,	respectively.	
	
2.14	Statistical	Analysis	
Statistical	 analysis	 was	 only	 calculated	 on	 data	 sets	 with	 a	 minimum	 of	 3	independent	replicates	carried	out	on	2	separate	occasions.	The	normality	of	 the	data	was	 determined	 using	 the	 Kolmogorov-Smirnov	 test.	 Data	were	 statistically	 analysed	using	the	student’s	t	test	and	Mann-Whitney	U	test	for	comparison	between	two	groups	of	parametric	and	nonparametric	data,	 respectively.	Analysis	of	variance	and	Kruskal-Wallis	tests	were	used	for	between-group	comparisons	of	multiple	groups	of	parametric	and	nonparametric	data,	respectively.	Significance	was	taken	as	P<0.05.	
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3.1	Introduction	
	Only	a	minority	of	genetic	mutations	are	likely	to	be	driver	mutations,	conferring	a	 specific	 growth	 advantage	 in	 vivo,	 and	 resulting	 in	 clonal	 expansion	 and	 tumour	development.	 Indeed,	 the	 majority	 of	 substitutions	 reported	 via	 recent	 sequencing	strategies	 such	 as	 the	 Catalogue	 of	 Somatic	 Mutations	 in	 Cancer	 (COSMIC)	 and	 the	Cancer	Genome	Atlas	(TCGA)	are	likely	to	be	passenger	mutations	(Torkamani,	Schork	2008,	Greenman	et	al.	2007).	Functional	clarification	is	now	urgently	needed	to	discern	the	 driver	 mutations	 which	 may	 represent	 new	 or	 refined	 diagnostic,	 prognostic	 or	therapeutic	markers	 for	 particular	 types	 of	 cancer,	 and	 to	more	 fully	 understand	 the	mechanisms	responsible	for	tumour	formation.		
	We	 previously	 characterised	 PBF	 as	 a	 proto-oncogene,	 based	 on	 oncogenic	expression	inducing	tumours	in	xenograft	models	(Stratford	et	al.	2005).	We	and	others	have	 demonstrated	 that	 PBF	 is	 overexpressed	 in	 pituitary,	 colon,	 breast,	 and	 thyroid	tumours	 (McCabe	 et	 al.	 2003,	 Read	 et	 al.	 2016,	 Watkins	 et	 al.	 2010,	 Stratford	 et	 al.	2005),	 and	 that	 upregulation	 of	 the	 gene	 is	 significantly	 associated	 with	 poorer	oncological	 outcome	 in	 a	 range	 of	 tumours.	 For	 instance,	 papillary	 thyroid	 cancer	patients	 with	 high	 PBF	 expression	 at	 the	 time	 of	 diagnosis	 show	 decreased	 disease-specific	survival	compared	to	those	who	have	low	PBF	expression	(Hsueh	et	al.	2013).	Colorectal	tumours	which	show	extramural	vascular	invasion	have	significantly	higher	PBF	expression	 (Read	et	 al.	 2016),	 and	high	PBF	promoter	 activity	 is	 associated	with	poorer	 clinical	 outcome	 and	 increased	 metastatic	 risk	 in	 breast	 cancer	 (Xiang	 et	 al.	2012).	 However,	 whilst	 transgenic	 PBF	 mice	 demonstrated	 increased	 Akt	phosphorylation,	 thyroid	 gland	 enlargement,	 hyperplasia	 and	 macrofollicular	 lesions,	
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they	 did	 not	 routinely	 develop	 tumours	 (Read	 et	 al.	 2011).	 The	 role	 of	 PBF	 in	tumourigenesis	is	therefore	unclear.	
	PBF	 is	 ubiquitously	 expressed	 across	 a	 broad	 range	 of	 cell	 types	 and	 is	 highly	conserved	between	diverse	species	(Smith,	Franklyn	&	McCabe	2011).	It	interacts	with	a	range	of	proteins	impacting	on	intracellular	signalling.	For	instance,	PBF	binds	to	the	sodium	 iodide	 symporter	 (NIS)	 and	 the	 monocarboxylate	 transporter	 8	 (MCT8),	modulating	their	subcellular	localisation,	and	regulating	radioiodine	uptake	and	thyroid	hormone	 efflux,	 respectively	 (Read	 et	 al.	 2011,	 Smith	 et	 al.	 2009,	 Smith	 et	 al.	 2012).	Furthermore,	 overexpression	 of	 PBF	 increases	 p53	 ubiquitination,	 resulting	 in	dysregulated	p53	cellular	function	(Read	et	al.	2014).	Recent	in	silico	efforts	to	identify	driver	 genes	 amongst	 next	 generation	 sequencing	 data	 identified	 PBF	 as	 a	 putative	oncogene	(Melloni	et	al.	2014).	
	Classically,	proto-oncogenes	are	oncogenic	 through	over-expression	of	 the	wild	type	form	of	the	gene.	The	TCGA	and	the	COSMIC	are	now	revealing	mutational	changes	in	 proto-oncogenes,	 opening	 the	 possibility	 that	 proto-oncogenes	 may,	 in	 rare	 cases,	also	 act	 as	 oncogenes	 through	 disrupted	 function,	 rather	 than	 simply	 enhanced	expression.	 Utilising	 PBF	 as	 a	 paradigm	 of	 this	 idea,	 the	 first	 10	 reported	 non-synonymous	mutations	of	PBF	in	the	COSMIC	were	assessed	to	determine	whether	they	might	 have	 oncogenic	 gain	 of	 function.	 The	 predicted	 influence	 of	 these	 10	 in	 vivo	missense	 substitutions	 of	 PBF	 was	 screened	 using	 Iterative	 Threading	 Assembly	Refinement	 (I-TASSER)	 server	 and	 Sorting	 Intolerant	 From	 Tolerant	 or	 SIFT	assessment.	 The	 work	 presented	 in	 Chapter	 3	 therefore	 initially	 addresses	 the	hypothesis	 that	 the	 first	 ten	 PBF	 missense	 substitutions	 in	 human	 cancer	 might	 be	oncogenic.	
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3.2	Materials	and	Methods	3.2.1	Catalogue	of	Somatic	Mutations	in	Cancer	(COSMIC)	
The	COSMIC	database,	 started	 in	2004,	 is	designed	 to	exhibit	 somatic	mutation	information	and	contains	clinical	details	relating	to	human	cancers.	There	are	two	ways	that	 this	 database	 collects	 data,	 consisting	 of	 getting	 data	 either	 from	 scientific	literature	reviews	or	from	the	Cancer	Genome	project	at	the	Sanger	Institute.	
This	website	currently	contains	information	on	more	than	19,000	publications.	It	also	 displays	 the	data	 of	 complex	phenotype-specific	mutations	 in	 a	 graph	 format	 for	easy	understanding	and	interpretation	(http://cancer.sanger.ac.uk)	(Forbes	et	al.	2015,	Forbes	et	al.	2011,	Forbes	et	al.	2008).	
	 3.2.2	The	Cancer	Genome	Atlas	(TCGA)	
The	 TCGA	 database	 was	 launched	 in	 2006	 and	 is	 supervised	 by	 the	 National	Cancer	 Institute	 (NCI)	 and	 the	 National	 Human	 Genome	 Research	 Institute	 (NHGRI).	This	 project	 uses	 genetic	 sequencing	 and	 bioinformatic	 data	 to	 display	 mutations	apparent	 in	 human	 cancers	 and	 also	 to	 generate	 statistically	 significant	 conclusions	from	information	generated	(https://tcga-data.nci.nih.gov)	(Cline	et	al.	2013,	Guo	et	al.	2013).	
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3.2.3	Predicted	3-dimensional	(3D)	Modeling	(Iterative	Threading	Assembly	Refinement	(I-TASSER)	Server)	
This	 program,	 an	 online	website	 begun	 in	 the	 Yang	 Zhang	 lab	 at	 University	 of	Michigan,	 is	 a	 method	 used	 for	 the	 prediction	 of	 the	 three-dimensional	 structure	 of	proteins	 originating	 from	 the	 sequence	 of	 amino	 acid	 residues,	 allowing	 them	 to	 be	estimated	 in	 terms	 of	 protein	 damage	 (http://zhanglab.ccmb.med.umich.edu)	 (Yang,	Zhang	2015,	Zhang	2008).	
	 3.2.4	Prediction	of	Protein	Damage	(Sorting	Intolerant	From	Tolerant	or	SIFT)	
SIFT	 is	 a	program	used	 to	predict	whether	 an	 amino	acid	 substitution	 impacts	upon	protein	function	and	may	be	responsible	for	phenotypic	differences.	Based	on	this	principle,	if	there	is	a	substitution	in	an	amino	acid	residue	that	does	not	impact	on	the	subtype	of	 amino	 acid,	 such	 as	 a	 change	 from	a	hydrophobic	 to	 another	hydrophobic	amino	 acid,	 this	 alteration	 is	 predicted	 to	 be	 a	 tolerated	 protein.	 Nevertheless,	 if	 a	mutation	 causes	 a	 considerable	 adaptation	 in	 alignment	 to	 another	 amino	 acid	character	 (such	 as	 polar	 type),	 it	 is	 expected	 to	 be	 a	 ‘damaged	 protein’,	 with	 a	 SIFT	calculated	 score	of	 less	 than	0.05.	A	genetic	 substitution	with	a	SIFT	score	more	 than	0.05	 is	 predicted	 to	be	 a	 ‘tolerated	protein’	 (http://sift.bii.a-star.edu.sg)	 (Ng,	Henikoff	2006,	Ng,	Henikoff	2003).		
	
3.3	Results	
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3.3.1	Discovered	Mutations	
3.3.1.1	Catalogue	of	Somatic	Mutations	in	Cancer	(COSMIC)	At	 the	outset	of	 this	PhD	study	(April	2013),	whole	exome	sequencing	 through	the	Wellcome	Trust	COSMIC	database	initially	identified	ten	missense	PBF	substitutions	in	human	cancers	(Figure	3.1).	The	mutations	occurred	across	all	functional	domains	of	PBF,	with	no	obvious	‘hot-spots’	other	than	3	substitutions	at	residue	G106,	within	the	transmembrane	 region	 (Figure	 3.1).	 The	 8	mutated	 amino	 acid	 residues	were	 highly	conserved	 across	 various	 species	 as	 demonstrated	 in	 Figure	 3.1.	 The	 multiple	substitutions	 in	 this	 protein	were	 also	 found	 in	 various	 tumour	 types,	 such	 as	 colon,	breast,	 ovary	 and	 prostate,	 suggesting	 that	 PBF	may	 potentially	 be	 oncogenic	 in	 vivo,	and	 that	 substitutions	 in	 some	 domains	 may	 affect	 functions	 of	 the	 protein	 and	prognosis	of	cancers.	These	first	reported	10	non-synonymous	mutations	discovered	in	the	COSMIC	in	April	2013	which	occurred	at	8	different	amino	acid	residues	within	PBF	were	chosen	as	the	panel	of	mutations	to	pursue	throughout	this	PhD.	
	
	
	
Figure	 3.1:	 Schematic	 diagram	 of	 PBF.	 The	 first	 10	 reported	 missense	 amino	 acid	
residue	changes	denoted	in	black	with	amino	acid	conservation	at	each	site	in	5	different	
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species.	An	asterisk	(*)	denotes	amino	acid	which	is	fully	conserved	residue,	while	a	colon	
(:)	 indicates	 a	 conservation	 site	 between	 amino	 acids	 with	 strongly	 similar	 properties.	
There	 are	 four	mutations	 in	 the	 PSI	 domain,	 consisting	 of	 C51R,	 V55I,	W59F	 and	R87C,	
while	substitutions	of	S103L,	G106R,	G106V	and	G106W	are	present	in	the	transmembrane	
region.	In	addition,	mutations	being	proximal	to	the	NLS	(nuclear	localisation	signal)	are	
R140W	and	R146W.	The	other	17	PBF	mutations	discovered	in	the	COSMIC	database	after	
April	2013	are	highlighted	in	red.	Ins	denotes	insertional	mutagenesis,	while	del	illustrates	
deletion	mutation.	Adapted	 from	https://ebi.ac.uk/Tools/msa/clustalo/	 and	 the	COSMIC	
database,	May	2016.		
The	most	 common	 cancer	 harbouring	 in	 vivo	 PBF	mutations	was	 colon	 cancer	(Table	3.1).	There	were	7	PBF	mutations	(8	patients)	 identified	 in	colon	cancer,	while	the	 other	 mutations	 were	 found	 in	 prostate,	 lung	 and	 ovary	 tumours	 (Table	 3.1).	However,	 there	was	 no	 obvious	 correlation	 between	 clinicopathological	 data,	 such	 as	gender,	 age,	 tumour	differentiation,	 staging	or	vascular	 invasion,	 and	 the	 specific	PBF	mutations	(Table	3.1).	
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Table	 3.1:	 Clinical	 and	 histological	 data	 of	 patients	 having	 PBF	 mutations	
discovered	in	various	human	cancers.	M	=	male,	F	=	female.	T	=	tumour,	N	=	node,	M	=	
metastasis.	
	
3.3.1.2	The	Cancer	Genome	Atlas	(TCGA)	Whilst	the	first	10	missense	mutations	in	PBF	were	described	via	the	COSMIC	in	2013,	 subsequent	 sequencing	 via	 the	 TCGA	 initiative	 has	 revealed	 other	 numerous	genetic	 abnormalities	 of	 PBF	 in	 multiple	 human	 cancers.	 Most	 of	 these	 are	 genetic	amplifications	of	PBF,	while	 fewer	 than	0.5%	of	reported	changes	represented	overall	mutations	in	this	gene	(Figure	3.2).		
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Figure	3.2:	The	percentages	of	cross	cancer	alterations	of	 the	PBF	gene	 in	various	
human	 tumours.	 The	 figure	 was	 taken	 from	 http://www.cbioportal.org/public-
portal/cross_cancer.do?cancer_study_id.	Data	was	adapted	in	May	2016.	
Some	 substitutions,	 such	 as	Q42E,	 C121del,	 P129S,	 R140Q,	R144Q	 and	E171Q,	were	additionally	identified	in	this	database	(Table	3.2).	Nevertheless,	in	May	2016,	511	papillary	 thyroid	cancer	samples	and	117	poorly	differentiated	and	anaplastic	 thyroid	cancers	 were	 sequenced	 but	 there	 were	 no	 mutations	 in	 PBF	 (www.cbioportal.org).	Thus,	 whilst	 PBF	 has	 an	 integral	 role	 in	 regulating	 thyroid	 cell	 function	 (Read	 et	 al.	2011),	 it	 is	 not	 commonly	 mutated	 in	 thyroid	 cancer.	 However,	 mutations	 are	 more	common	in	other	endocrine	and	non-endocrine	tumour	types.	
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Sample	ID	
	
Cancer	
Study	
AA	change	
	
Type	
	
COSMIC	
	
MS	
	
VS	
	
Mutation	
Assessor	
Allele	Freq	
(T)	
#Mut	in	
Sample	
TCGA-N9-
A4Q1-01	
Uterine	CS		 C121del	 IF	del	 1	 S	 U	 	 0.05	 48	
TCGA-JW-
A5VL-01	
Cervical		 Q42E	 Missense	 	 S	 U	 Neutral	 NA	 1762	
TCGA-EE-
A29R-06	
Melanoma		 P129S	 Missense	 1	 S	 U	 Low	 0.60	 535	
TCGA-DX-
A7EF-01	
Sarcoma		 N94Mfs*4	 FS	del	 	 S	 U	 	 NA	 55	
TCGA-BR-
8382-01	
Stomach		 K164Nfs*89	 FS	del	 	 S	 U	 	 0.16	 747	
TCGA-BR-
8382-01	
Stomach		 K164Nfs*89	 FS	del	 	 S	 U	 	 NA	 744	
TCGA-BR-
6452-01	
Stomach		 R140Q	 Missense	 2	 U	 U	 Low	 0.25	 6437	
TCGA-BR-
6452-01	
Stomach		 R140Q	 Missense	 2	 S	 U	 Low	 NA	 6415	
TCGA-A8-
A0A7-01	
Breast		 E153K	 Missense	 	 U	 U	 Medium	 0.06	 119	
TCGA-13-
0760-01	
Ovarian	 G106R	 Missense	 4	 S	 V	 Medium	 NA	 147	
TCGA-13-
0760-01	
Ovarian		 G106R	 Missense	 4	 S	 V	 Medium	 NA	 149	
PR-00-
1165	
Prostate		 V55I	 Missense	 1	 S	 U	 Medium	 NA	 707	
pfg011T	 Stomach		 R144Q	 Missense	 2	 U	 U	 Medium	 NA	 84	
P01_Rec	 Glioma		 A114T	 Missense	 	 U	 U	 Neutral	 0.45	 1200	
ESCC-153T	
Esophagus	
SCC	
	
E171Q	
Missense	 1	 S	 U	 Neutral	 0.22	 143	
Table	3.2:	The	in	vivo	substitutions	of	amino	acid	residues	of	PBF	found	in	various	
cancers,	 reported	 by	 the	 TCGA	 database.	 COSMIC	 =	 number	 of	 occurrences	 in	
Chapter	3	 	 		
83	
overlapping	mutations	 with	 the	 COSMIC	 database,	MS	 =	mutational	 status;	 U-unknown	
and	 S-somatic,	 VS	 =	 validation	 status;	 U-unknown	 and	 V-valid,	 Mutation	 assessor	 =	
predicted	impact	score	from	www.mutationaassessor.org;	low	or	neutral	-	predicted	non-
functional	mutations	and	medium	or	high	-	predicted	functional	mutations,	Allele	Freq	=	
variant	 allele	 frequency	 in	 the	 tumour	 sample,	 ♯Mut	 in	 Sample	 =	 total	 number	 of	
nonsynonymous	 mutations	 in	 the	 sample.	 The	 figure	 was	 adapted	 in	 May	 2016	 from	
http://www.cbioportal.org/public-portal/cross_cancer.do?cancer_study_id.		
Thus,	 whilst	 subsequent	 TCGA	 sequencing	 has	 recently	 revealed	 further	mutations	in	PBF,	some	of	which	overlap	with	the	COSMIC	initiative,	all	data	presented	in	this	thesis	relate	to	the	first	10	missense	mutations	reported	via	the	COSMIC.	
	 3.3.2	Predicted	3-dimensional	(3D)	Modeling	
	 Analysis	of	the	10	amino	acid	changes	via	the	I-TASSER	server	yielded	predicted	3-dimensional	protein	structures	of	wild-type	PBF,	compared	with	the	mutated	proteins	(Figure	3.3).		
	
	 					
	WT	
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R87C%
C51R% V55I%
W59F%
G106R&
G106V& G106W&
S103L&
R140W& R146W&
					
	
	
	
	
	
	
	
	
	
Figure	3.3:	3-dimentional	structures	of	WT-PBF	and	all	10	in	vivo	mutations,	based	
on	 the	 physical	 properties	 of	 amino	 acid	 changes.	 For	 this	 analysis,	 the	 N-terminal	
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signal	 peptide	 (amino	 acids	 1-32),	 which	 is	 predicted	 to	 be	 cleaved	 off	 during	 PBF	
processing	 (Stratford	 et	 al.	 2005),	 was	 omitted	 to	 clarify	 the	 putative	 structure	 of	 fully	
processed	PBF.	For	most	mutations,	substitution	of	one	residue	within	PBF	often	implied	a	
considerable	change	in	another	part	of	the	protein.	The	PSI	domain,	the	transmembrane	
region,	 the	 NLS	 and	 the	 sorting	 signal	 were	 denoted	 with	 yellow,	 pink,	 green	 and	 red,	
respectively.	
	 	Overall,	missense-substitution	of	only	one	amino	acid	residue	caused	significant	predicted	 changes	 in	 3-dimensional	 protein	 structure,	 suggesting	 that	 these	modifications	 may	 impact	 on	 protein	 function.	 Indeed,	 mutant	 G106R	 showed	 the	biggest	effect	on	3D	structure	of	PBF	with	a	predicted	transition	of	a	long	helix	(shown	in	white	 in	 Figure	 3.3)	 to	 a	 helix-loop-helix	 structure.	 This	 helix	 is	 part	 of	 a	 putative	coiled	coil	domain,	which	may	therefore	impact	on	the	ability	of	PBF	to	dimerise	and	/or	interact	with	other	proteins.	In	addition,	access	to	the	C-terminus	of	PBF	may	be	altered	affecting	 the	 potential	 binding	 of	 proteins	 within	 this	 region.	 Given	 the	 C-terminal	location	of	 the	NLS	and	 the	sorting	signal	at	 tyrosine	174,	 this	may	result	 in	aberrant	nuclear	translocation,	endocytosis	and	phosphorylation	of	PBF.	
	3.3.3	Prediction	of	Protein	Damage	(Sorting	Intolerant	From	Tolerant	or	SIFT)	
	 SIFT	assessment,	based	on	sequence	homology	and	physical	properties	of	amino	acids,	 was	 applied	 for	 all	 missense	 PBF	mutations	 to	 predict	 whether	 specific	 amino	acid	substitutions	might	alter	protein	function	(Table	3.3).		
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User Input Position Reference Substitution Prediction SIFT score 
ENSP00000328325,C51R 51 C R DAMAGING 0 
ENSP00000328325,V55I 55 V I DAMAGING 0.05 
ENSP00000328325,W59F 59 W F DAMAGING 0.02 
ENSP00000328325,R87C 87 R C DAMAGING 0 
ENSP00000328325,S103L 103 S L DAMAGING 0.01 
ENSP00000328325,G106R 106 G R DAMAGING 0.01 
ENSP00000328325,G106V 106 G V TOLERATED 0.12 
ENSP00000328325,G106W 106 G W DAMAGING 0 
ENSP00000328325,R140W 140 R W DAMAGING 0 
ENSP00000328325,R146W 146 R W DAMAGING 0 !
Table	3.3:	SIFT	scores	taken	 from	the	SIFT	prediction	of	potential	protein	damage	
for	all	 substitutions.	 Scores	 less	 than	0.05	are	expected	 to	affect	protein	 function.	User	
input	=	protein	ID	plus	name	of	mutation,	ESPN	=	protein	ID,	Pos	=	position	of	amino	acid	
change,	Ref	=	amino	acid	reference,	Subst	=	amino	acid	substitution,	Prediction	=	results	of	
predicted	 protein	 damage;	 tolerated	 =	 a	 predicted	 tolerated	 protein	 and	 damaging	 =	 a	
predicted	damaged	protein,	SIFT	score	=	score	predicted	potential	protein	damage	in	each	
substitution,	with	range	from	0-1.	
According	to	SIFT	analysis,	all	mutations	except	G106V	were	predicted	to	elicit	protein	 damage.	 However,	 the	 3-dimensional	 predicted	 G106V	 structure	 illustrated	considerable	 changes	 in	 the	 PSI	 domain	 and	 transmembrane	 region,	 and	 so	 all	 ten	substitutions	were	considered	as	candidate	changes	to	investigate	in	vitro	in	subsequent	Chapters.		
		
3.4	Discussion	
Chapter	3	 	 		
87	
	 Recent	 initiatives	 such	 as	 the	 COSMIC	 and	 the	 TCGA	 are	 unearthing	 myriad	mutational	events	 in	 thousands	of	human	tumours.	However,	only	a	minority	of	 these	will	confer	selective	growth	advantage	and	clonal	expansion	of	the	cells	 in	which	they	are	found.	The	silent	majority,	passenger	mutations,	are	likely	to	represent	the	product	of	 the	 unstable	 genetic	 environments	 which	 generally	 develop	 during	 cancer	progression,	and	are	unlikely	to	significantly	impact	upon	protein	function.	
A	 number	 of	 statistical	 approaches	 have	 been	 utilised	 to	 help	 predict	 driver	mutations	 and	 driver	 genes,	 based	 largely	 on	 protein	 function,	mutational	 frequency,	pathway-oriented	 and	 pattern-based	 principles.	 One	 such	 statistical	 approach,	 the	Driver	Oncogene	and	Tumor	Suppressor	Finder,	developed	a	computational	program	to	identify	 driver	 genes	based	on	 statistical	 approaches	 including	pattern-based,	 protein	function	and	frequentist	methods	(Melloni	et	al.	2014).	This	strategy	predicted	that	PBF	may	be	one	of	12	genes	driving	thyroid	carcinogenesis	in	326	tumour	samples	from	the	TCGA	 database	 (Melloni	 et	 al.	 2014).	 The	 McCabe	 lab	 has	 previously	 appraised	 the	oncogenic	 function	 of	 PBF	 in	 numerous	 studies	 (Read	 et	 al.	 2014,	 Read	 et	 al.	 2011,	Watkins	et	al.	2010),	and	has	reported	significantly	 induced	expression	of	 the	gene	 in	thyroid,	 breast,	 pituitary,	 and	 colorectal	 tumours	 (Smith,	 Franklyn	 &	 McCabe	 2010,	Read	et	al.	2011,	Watkins	et	al.	2010,	McCabe	et	al.	2003,	Read	et	al.	2016).		
PBF	 is	 a	 widely	 expressed	 glycoprotein	 with	 a	 180	 amino	 acid	 sequence	possessing	 an	 N-terminal	 signal	 peptide,	 a,	 PSI	 domain,	 a	 transmembrane	 region,	 a	bipartite	nuclear	localisation	signal	and	a	putative	tyrosine	sorting	signal.	PBF	shares	no	significant	 homology	 to	 any	 other	 human	 proteins	 but	 is	 well-conserved	 among	 a	diverse	range	of	animal	species.	 In	addition,	PBF	expression	 is	significantly	correlated	
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with	 poorer	 oncological	 outcomes	 in	 thyroid,	 breast	 and	 colon	 cancers	 (Hsueh	 et	 al.	2013,	Xing	et	al.	2005,	Read	et	al.	2016).	
According	 to	 the	 COSMIC	 and	 the	 TCGA,	 the	 reported	 PBF	 mutations	 were	apparent	across	all	domains	of	PBF	at	specific	residues	which	are	highly	conserved	 in	various	 animal	 species,	 such	 as	 pongo	 abelii,	 pan	 troglodytes,	 canis	 lupus,	 bos	 taurus	and	 macaca	 fascicularis,	 suggesting	 that	 these	 amino	 acid	 residues	 are	 functionally	important	 (Figure	 3.1).	 However,	 there	 has	 been	 a	 recent	 increase	 in	 the	 number	 of	identified	PBF	substitutions	due	to	further	sequencing	initiatives	since	the	start	of	this	project.	 Currently,	 there	 are	 27	 reported	 PBF	mutations	 in	 the	 COSMIC	 database,	 the	vast	 majority	 being	 single	 amino	 acid	 substitutions.	 The	 overall	 incidence	 of	 PBF	mutations	across	all	cancers	sequenced	to	date	via	the	TCGA	is	less	than	0.5%.	No	PBF	mutations	have	been	reported	in	thyroid	cancer;	indeed	the	majority	in	this	study	were	apparent	 in	 colorectal	 cancer.	 In	 this	 Chapter,	 we	 also	 found	 no	 correlation	 between	PBF	mutation	 status	 and	 clinical	 outcome	 in	 colorectal	 cancer.	 This	 is	 in	 contrast	 to	previously	published	clinical	associations	in	colorectal	cancer,	as	well	as	in	thyroid	and	breast	 neoplasias,	 where	 PBF	 expression	 significantly	 correlated	 with	 tumour	 grade	and/or	 patient	 outcome	 as	 mentioned	 above.	 Nevertheless,	 even	 though	 a	 range	 of	genetic	mutations	has	been	reported,	only	a	few	of	them	are	likely	to	impact	on	cancer	cell	 initiation	 and	 development	 (Melloni	 et	 al.	 2014).	 Therefore,	 in	 this	 study,	 we	focused	 on	 the	 first	 10	 discovered	 non-synonymous	 PBF	 mutations	 in	 the	 COSMIC	database.		
	 The	 I-TASSER	results	were	applied	 to	amino	acid	sequences	of	WT-PBF	and	all	10	 in	vivo	missense	PBF	mutants,	 and	revealed	 that	all	 amino	acid	substitutions	were	predicted	 to	modify	 3D	 protein	 structure	 compared	 to	wild-type.	Moreover,	 the	 SIFT	
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assessment,	a	programme	used	to	predict	altered	protein	 function,	affirmed	that	most	mutations	were	 predicted	 to	 cause	 protein	 damage,	 except	 G106V.	 There	 are	 further	ways	 to	 assess	 for	 prediction	 of	 the	 functional	 protein	 impact	 of	 amino	 acid	substitutions	in	proteins,	such	as	Mutation	assessor	or	PolyPhen	approaches.	However,	there	 is	 still	 no	 definitive	 computational	 programme	 for	 the	 confirmation	 of	 driver	mutation	status.	It	therefore	remains	necessary	to	carry	out	a	range	of	experiments,	as	described	 in	 the	subsequent	Chapters,	 to	clarify	whether	 the	PBF	 in	vivo	 substitutions	are	driver	genetic	mutations	or	not.	
	
	
CHAPTER	4		- EFFECT	OF	AMINO	ACID	
SUBSTITUTIONS	IDENTIFIED	IN	VIVO	ON	
SUBCELLULAR	LOCALISATION,	
GLYCOSYLATION,	DIMERISATION,	PBF	
STABILITY	AND	CELLULAR	PROLIFERATION	
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4.1	Introduction	
	 Several	previous	studies	have	revealed	that	a	monomeric	band	of	PBF	is	usually	observed	ranging	between	22-30	kDa	in	Western	blotting	(Smith	et	al.	2012,	Boelaert	et	al.	 2007,	 Chien,	 Pei	 2000),	 with	 the	 size	 range	 presumably	 reflecting	 differential	glycosylation	 (Smith	et	al.	2010).	PBF	also	appears	as	a	putative	oligomer	 in	Western	blotting,	 running	 at	 approximately	 50	 and	 75	 kDa	 for	 dimeric	 or	 trimeric	 bands,	respectively.	However,	the	functional	importance	of	PBF	glycosylation	and	dimerisation	remain	 inconclusive.	 Broadly,	 glycosylation	 is	 one	 of	 the	 most	 common	 post-translational	alterations	of	multiple	proteins	(Lisowska,	Jaskiewicz	2012),	and	also	has	a	tendency	to	 impact	on	various	protein	configurations	and	their	stability	(Arey	2012,	Shental-Bechor,	 Levy	 2008).	 This	 process	 is	 also	 vital	 for	 some	 secreted	 proteins	 in	modulating	their	activity	when	they	bind	to	protein	ligands	or	receptors,	and	may	play	an	important	role	in	protein-protein	interaction	(Arey	2012).	
Furthermore,	 oligomerisation	 is	 another	 mechanism	 which	 may	 influence	protein	 stabilisation	 and	 the	 ability	 of	 proteins	 to	 bind	 to	 other	molecules	 (Mei	 et	 al.	2005,	Monod,	Wyman	&	Changeux	1965).	Changes	 in	protein	 structure	 also	generally	contribute	 to	 alteration	 of	 protein	 stability,	 modulating	 protein	 functions	 in	 various	models	 (Ng,	 Henikoff	 2006,	 Bromberg,	 Rost	 2009).	 Multiple	 factors	 impact	 on	 the	stabilisation	 of	 proteins,	 including	 amino	 acid	 substitutions,	 hydrophobic	 binding,	hydrogen	 bonds	 and	 polar	 interactions	 (Gromiha	 2003,	 Vogt,	 Woell	 &	 Argos	 1997,	Menéndez-Arias,	 Argosf	 1989,	 Imanaka,	 Shibazaki	 &	 Takagi	 1986).	 Regarding	 genetic	mutations,	publications	from	multiple	groups	have	demonstrated	that	most	amino	acid	substitutions	cause	significant	modifications	to	protein	stability	(DePristo,	Weinreich	&	Hartl	 2005,	 Ponnuswamy,	 Muthusamy	 &	 Manavalan	 1982)	 as	 well	 as	 protein	
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biochemistry,	including	glycosylation	and	dimerisation.	Consequently,	the	effect	of	PBF	mutations	identified	in	vivo	on	these	characteristics	needs	to	be	determined.		
In	 terms	 of	 cellular	 proliferation,	 we	 previously	 discovered	 that	 PBF	overexpression	 induced	cell	 turnover	 in	various	models,	 including	 thyroid,	breast	and	colon	(Read	et	al.	2011,	Watkins	et	al.	2010,	Read	et	al.	2016).	PBF	 is	 transforming	 in	
vitro	 and	 tumourigenic	 in	 vivo:	 stable	 overexpression	 of	 PBF	 in	 NIH	 3T3	 murine	fibroblast	cells	significantly	 induced	colony	 formation	 in	soft	agar	assays	compared	to	VO	control	cells,	reflecting	anchorage	independent	growth	or	transforming	ability	of	the	transfected	 cells	 (Stratford	 et	 al.	 2005).	 In	 parallel	 in	 vivo	 studies,	 subcutaneous	injection	of	cells	stably	overexpressing	PBF	stimulated	large	and	aggressive	tumours	in	nude	 mice,	 with	 histopathological	 evaluation	 showing	 high-grade	 malignant	 cancers	invading	 skeletal	 muscle	 and	 adipose	 tissue	 (Stratford	 et	 al.	 2005).	 Read	 et	 al.	 also	investigated	 a	 role	 of	 PBF	 upregulation	 on	 cellular	 proliferation	 by	 using	 a	 murine	transgenic	 model	 and	 targeting	 PBF	 overexpression	 to	 thyroid	 gland	 (PBF-Tg	 mice)	(Read	et	al.	2011).	PBF-Tg	mice	showed	a	significant	increase	in	the	size	of	their	thyroid	glands	which	contained	hyperplastic	and	macrofollicular	lesions	(Read	et	al.	2011).	The	immunostaining	of	histopathologic	 specimens	also	 revealed	an	 increase	 in	markers	of	thyroid	cell	(thyrocyte)	proliferation	such	as	cyclin	D1	(Read	et	al.	2011).	Moreover,	the	study	demonstrated	 a	 significant	 upregulation	 of	 TSHR	 (thyroid	 stimulating	 hormone	receptor)	and	phosphorylated	AKT	(protein	kinase	B)	in	PBF-Tg	mice,	while	total	AKT	was	not	changed	(Read	et	al.	2011).	The	data	in	human	multinodular	goitre	(MNG)	also	exhibited	a	strongly	significant	induction	of	PBF	and	TSHR	protein	levels	compared	to	normal	thyroid	tissue	(Read	et	al.	2011).	However,	PBF-Tg	mice	had	unchanged	thyroid	function	 tests,	 including	 T3,	 T4	 and	 TSH,	 and	 also	 no	 significant	 alteration	 in	mRNA	
Chapter	4	
93	
levels	 of	 growth	 factors,	 such	 as	 VEGF	 (vascular	 epidermal	 growth	 factor),	 TGFβ	(transforming	 growth	 factor	 beta)	 or	 IGF-1	 (insulin-like	 growth	 factor-1)	 (Read	 et	 al.	2011).	 It	 is	 likely	 therefore	 that	 PBF	 induces	 cellular	 proliferation	 and	 independently	governs	cell	growth	through	the	TSHR	and	PI3K/AKT	pathways	in	thyroid	cells	(Read	et	al.	2011).			 Chapter	3	revealed	that	most	amino	acid	substitutions	of	PBF	determined	in	vivo	were	predicted	 to	 elicit	 protein	damage.	This	Chapter	 therefore	determined	 the	basic	functional	 consequences	 of	 PBF	 induced	 by	 these	 mutations,	 including	 alterations	 in	subcellular	localisation	of	PBF,	glycosylation,	dimerisation,	protein	stability	and	cellular	proliferation,	and	sought	to	narrow	down	from	10	initial	mutations	to	a	smaller	number	of	mutants	for	further	studies.		 	
4.2	Materials	and	Methods	4.2.1	Mutagenesis,	DNA	Purification	(Miniprep),	DNA	Amplification	(Maxiprep)	and	Sequencing	
	 According	 to	 the	 results	 from	 the	 I-TASSER	 server	 and	 the	 SIFT	assessment	 in	Chapter	3,	 ten	amino	acid	substitutions	were	made	in	the	wild-type	PBF	plasmid	with	pcDNA3.1(+)	backbone,	and	were	labelled	with	or	without	an	HA	tag	at	the	C-terminus	or	with	a	FLAG	tag	at	the	N-terminus,	as	described	in	section	2.1.2.2.	All	plasmids	were	transformed	into	Subcloning	EfficiencyTM	DH5αTM	Competent	E.Coli	Cells	(Invitrogen),	before	 Minipreps	 were	 performed	 to	 purify	 the	 plasmids	 as	 mentioned	 in	 sections	2.1.2.3	and	2.1.2.4,	 respectively.	After	sequencing	 to	confirm	the	correct	substitutions,	
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the	DNA	plasmids	were	amplified	and	sequenced	to	use	in	subsequent	experiments	as	described	in	section	2.1.2.5.		
	 4.2.2	Cell	Culture	and	Transfection	
PBF	 functions	 have	 previously	 best	 been	 characterised	 in	 thyroid,	 breast	 and	colorectal	cell	models	(Read	et	al.	2016,	Read	et	al.	2014,	Smith	et	al.	2013,	Smith	et	al.	2012,	 Smith,	 Franklyn	 &	 McCabe	 2011,	 Watkins	 et	 al.	 2010,	 Smith	 et	 al.	 2009).	Throughout	 the	 results	 chapters	 of	 this	 thesis,	 PBF	 is	 therefore	 examined	predominantly	in	these	models,	but	also	occasionally	in	COS7	and	HeLa	cells,	where	for	example	immunofluorescent	detail	is	required.	
	 TPC1,	SW1736,	MCF7,	HeLa	and	COS7	cells	were	employed	in	the	experiments	in	this	Chapter.	HeLa	and	COS7	cells	were	maintained	in	DMEM	containing	10%	FCS	while	TPC1,	SW1736	and	MCF7	cells	were	supplemented	with	RPMI	containing	10%	FCS	as	described	 in	 section	 2.1.1.	 These	 cells	 were	 transfected	 with	 VO	 and	 HA-tagged	 or	untagged	WT-PBF	and	all	PBF	mutations	as	described	 in	section	2.1.3.	Transfection	of	FLAG-tagged	 WT-PBF,	 C51R-PBF	 and	 R140W-PBF	 was	 also	 carried	 out	 for	 half-life	studies	and	immunofluorescence	microscopy.	
	4.2.3	Immunofluorescence	Microscopy	
	 HeLa	 and	MCF7	 cells	were	 plated	 on	 coverslips	 and	 then	 transfected	with	 VO,	HA-tagged	WT	and	all	PBF	mutations	or	FLAG-tagged	WT-PBF,	C51R-PBF	and	R140W-PBF	as	described	in	section	2.1.3.	They	were	then	processed	as	described	in	section	2.6.	
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Primary	 antibodies	 were	 mouse	 monoclonal	 anti-HA	 (1:200,	 Covance,	 USA),	 mouse	monoclonal	 anti-FLAG	 (1:200,	 Sigma,	 USA),	 rabbit	 polyclonal	 anti-PDI	 (1:200,	 Cell	Signaling	Technology,	USA)	and	rabbit	monoclonal	anti-Golgin-97	(1:200,	Cell	Signaling	Technology,	USA).	
	4.2.4	Protein	Extraction	and	Quantification	(Bicinchoninic	Acid	Assay	or	BCA)	
	 After	harvesting	proteins	in	RIPA	solution,	absorbances	were	measured	using	the	bicinchoninic	acid	(BCA)	assay	kit	as	described	in	section	2.2,	with	cell	lysates	compared	to	bovine	serum	albumin	(BSA)	standards	of	0,	0.125,	0.25,	0.5,	0.75,	1,	1.5,	2,	2.5	and	5	mg/ml	in	RIPA	solution.	The	Wallac	gamma	counter	was	used	as	mentioned	in	section	2.2	to	measure	the	absorbance.	Finally,	protein	concentration	was	determined	using	the	standard	 curve	 from	 the	 BSA	 standards	 and	 then	 applied	 to	 calculate	 the	 protein	volume	used	in	subsequent	Western	blotting.	
	
4.2.5	Western	Blotting	
Western	 blotting	 for	 half-life	 studies	 and	 for	 confirmation	 of	 transfection	 was	carried	 out	 as	 described	 in	 Section	 2.5.	 The	 primary	 antibodies	 used	 in	 this	 Chapter	were	 mouse	 monoclonal	 anti-FLAG	 (1:500,	 Sigma,	 USA),	 mouse	 monoclonal	 anti-HA	(1:1000,	 Covance,	 USA),	 rabbit	 polyclonal	 anti-PBF	 (1:500,	 In-house)	 and	 mouse	monoclonal	anti-β-actin	AC-15	(1:10000,	Sigma,	USA).	
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	 4.2.6	Half-life	Studies	
	 MCF7	and	SW1736	were	utilised	 for	half-life	studies	and	protein	samples	were	harvested	at	0,	12	and	24	hours	after	adding	Anisomycin	as	described	in	section	2.7.		
	 	4.2.7	Cellular	Proliferation	Assays	
4.2.7.1	3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium	(MTS)	Proliferation	Assays		 	TPC1,	MCF7	 and	 SW1736	 cells	were	 used	 in	MTS	 assays	 to	 determine	 cellular	proliferation	as	mentioned	in	section	2.8.1.	After	being	seeded	into	6-well	plates	for	24	hours,	 cells	 were	 transfected	 with	 VO,	 WT-PBF,	 C51R,	 G106R,	 G106V,	 G106W	 and	R140W	for	24	hours	as	in	section	2.1.3,	before	re-seeding	into	96-well	plates,	and	then	MTS	assays	were	performed	24	hours	later.		
	
4.2.7.2	Cell	Proliferation	ELISA,	Bromodeoxyuridine	(BrdU)	Colorimetric	Assays		 TPC1	and	MCF7	cells	were	seeded	 into	6-well	plates	and	then	 transfected	with	VO,	WT-PBF,	C51R,	V55I,	R140W	and	R146W	for	24	hours	as	explained	in	section	2.1.3.	After	re-seeding	into	96-well	plates	for	24	hours,	BrdU	assays	were	applied	as	described	in	section	2.8.2.	
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4.3	Results	4.3.1	The	Subcellular	Localisation	of	10	PBF	Mutations	Identified	in	Vivo	
After	 the	 plasmids	 were	 sequenced	 to	 confirm	 the	 correct	 substitutions	 as	illustrated	in	Figure	4.1,	all	ten	mutations	were	examined	for	subcellular	localisation	of	each	 HA-tagged	 mutant	 (green)	 within	 HeLa	 cells	 (Figure	 4.2).	 However,	 HA-tagged	R140W	 was	 difficult	 to	 detect	 through	 immunofluorescent	 microscopy,	 and	 a	 FLAG-tagged	 R140W	 version	was	 therefore	 used	 and	 compared	 to	 wild	 type-FLAG	 (Figure	4.3).		
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Figure	4.1:	 Example	of	 sequencing	 result	 of	 C51R	mutation.	 The	 illustrations	 reveal	
that	there	was	only	one	substitution	of	a	nucleotide	at	position	151	from	T	to	C	in	the	PBF	
nucleotide	sequence,	as	denoted	by	the	red	arrow.	
C51_1.1 
 
Alignment of Sequence_1:  [Untitled Sequence #1] with  Sequence_2: [Sequence 
Window #2]  
 
Similarity : 541/1219 (44.38 %) 
 
Seq_1  1     CAACGTTTTAATTAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTCA  60 
                                                                        | 
Seq_2  1     -----------------------------------------------------------A  1 
 
 
Seq_1  61    TGGCGCCCGGA-TGGCCCGCGGGCCGACGCCGTACTGGAGGTTGCGCCTCGGTGGCGCCG  119 
             ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  2     TGGCGCCCGGAGTGGCCCGCGGGCCGACGCCGTACTGGAGGTTGCGCCTCGGTGGCGCCG  61 
 
 
Seq_1  120   CGCTGCTCCTGCTGCTCATCCCGGTGGCCGCCGCGCAGGAGCCTCCCGGAGCTGCTTGTT  179 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  62    CGCTGCTCCTGCTGCTCATCCCGGTGGCCGCCGCGCAGGAGCCTCCCGGAGCTGCTTGTT  121 
 
 
Seq_1  180   CTCAGAACACAAACAAAACCTGTGAAGAGCGCCTGAAGAACGTCTCCTGTCTTTGGTGCA  239 
             ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
Seq_2  122   CTCAGAACACAAACAAAACCTGTGAAGAGTGCCTGAAGAACGTCTCCTGTCTTTGGTGCA  181 
 
 
Seq_1  240   ACACTAACAAGGCTTGTCTGGACTACCCAGTTACAAGCGTCTTGCCACCGGCTTCCCTTT  299 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  182   ACACTAACAAGGCTTGTCTGGACTACCCAGTTACAAGCGTCTTGCCACCGGCTTCCCTTT  241 
 
 
Seq_1  300   GTAAATTGAGCTCTGCACGCTGGGGAGTTTGTTGGGTGAACTTTGAGGCGCTGATCATCA  359 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  242   GTAAATTGAGCTCTGCACGCTGGGGAGTTTGTTGGGTGAACTTTGAGGCGCTGATCATCA  301 
 
 
Seq_1  360   CCATGTCGGTAGTCGGGGGAACCCTCCTCCTGGGCATTGCCATCTGCTGCTGCTGCTGCT  419 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  302   CCATGTCGGTAGTCGGGGGAACCCTCCTCCTGGGCATTGCCATCTGCTGCTGCTGCTGCT  361 
 
 
Seq_1  420   GCAGGAGGAAGAGGAGCCGGAAGCCGGACAGGAGTGAGGAGAAGGCCATGCGTGAGCGGG  479 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  362   GCAGGAGGAAGAGGAGCCGGAAGCCGGACAGGAGTGAGGAGAAGGCCATGCGTGAGCGGG  421 
 
 
Seq_1  480   AGGAGAGGCGGATACGGCAGGAGGAACGGAGAGCAGAGATGAAGACAAGACATGATGAAA  539 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  422   AGGAGAGGCGGATACGGCAGGAGGAACGGAGAGCAGAGATGAAGACAAGACATGATGAAA  481 
 
 
Seq_1  540   TCAGAAAAAAATATGGCCTGTTTAAAGAAGAAAACCCGTATGCTAGATTTGAAAACAACT  599 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  482   TCAGAAAAAAATATGGCCTGTTTAAAGAAGAAAACCCGTATGCTAGATTTGAAAACAACT  541 
 
 
Seq_1  600   AAAGCGCTCCAGCTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTC  659 
             ||                                                           
Seq_2  542   AA----------------------------------------------------------  543 
 
 
Seq_1  660   TAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGC  719 
                                                                          
Seq_2  544   ------------------------------------------------------------  543 
 
 
Seq_1  720   CACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTG  779 
                                                                          
Seq_2  544   ------------------------------------------------------------  543 
 
 
Seq_1  780   TCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAA  839 
                                                                          
Seq_2  544   ------------------------------------------------------------  543 
 
 
Seq_1  840   TAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTG  899 
                                                                          
Seq_2  544   ------------------------------------------------------------  543 
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Figure	4.2:	The	effect	of	PBF	substitutions	on	subcellular	localisation.	Representative	
immunofluorescent	 microscopy	 of	 PBF-HA	 (mouse,	 anti-HA,	 green)	 and	 DAPI	 (blue)	 in	
HeLa	cells	transfected	with	HA-tagged	WT-PBF	and	all	10	PBF	mutants.	Magnification	=	
100x.	Scale	bars	=	20	μm.	
	
	
	
	
Figure	 4.3:	 R140W	 substitution	 detected	 through	 FLAG	 tagging	 shows	 altered	
subcellular	 localisation	 compared	 to	 WT-PBF-FLAG.	 Representative	
immunofluorescent	microscopy	of	PBF-FLAG	(mouse,	anti-FLAG,	green)	and	DAPI	(blue)	in	
HeLa	 cells	 transfected	 with	 FLAG-tagged	WT-PBF	 and	 R140W	mutant.	 Magnification	 =	
100x.	Scale	bars	=	20	μm.	
	 Overall,	wild	type	PBF	was	predominantly	localised	in	late	endosomes	and	at	the	plasma	membrane,	as	reported	previously	(Smith	et	al.	2009).	Most	mutants	retained	a	wild	 type	 vesicular	 subcellular	 localisation,	 apart	 from	 C51R	 and	 G106R,	 which	appeared	to	be	localised	predominantly	to	the	endoplasmic	reticulum	(Figure	4.2),	and	R140W,	which	appeared	to	be	mainly	confined	to	the	Golgi	apparatus	(Figure	4.3).	The	precise	subcellular	localisations	of	C51R	and	R140W	are	defined	in	further	detail	later	within	this	Chapter.	
	
WT-FLAG	 R140W-FLAG	
Chapter	4	
101	
4.3.2	The	Influence	of	Amino	Acid	Substitutions	on	Glycosylation	and	Dimerisation	
	 In	 the	 previous	 Chapter,	we	 revealed	 that	most	 amino	 acid	 substitutions	were	speculated	 to	 modify	 the	 predicted	 3-dimensional	 protein	 structures	 and	 protein	function	 compared	 to	WT-PBF.	 Therefore,	 we	 next	 determined	 the	 effect	 of	 the	 PBF	mutations	on	the	basic	biochemical	glycosylation	and	dimerisation	of	the	protein	using	Western	blotting	analysis	(Figure	4.4).		
	
	
	
	
Figure	 4.4:	 Influence	 of	 the	 genetic	 alterations	 on	 PBF	 glycosylation	 and	
dimerisation.	A,	COS7	cells	were	transiently	transfected	with	vector	only	(VO),	wild-type	
(WT)	 PBF-HA	 and	 all	 HA	 tagged	 PBF	 mutants.	 PBF	 bands	 were	 detected	 by	 Western	
blotting	with	a	mouse	monoclonal	anti-HA	antibody	(1:1000)	and	mouse	monoclonal	anti-
β-actin	(1:10000).	B,	COS-7	cells	were	transfected	with	FLAG-tagged	WT-PBF	and	R140W-
PBF	mutant.	PBF	bands	were	detected	by	Western	blotting	with	a	mouse	monoclonal	anti-
FLAG	antibody	(1:500)	and	mouse	monoclonal	anti-β-actin	(1:10000).	Red	square	denotes	
W
T
-F
	
R
1
4
0
W
-F
	
β	ac-n	
75	kDa--	
	
	
48	kDa--	
	
35	kDa--	
	
	
25	kDa--	
FLAG-PBF	
40	kDa--	
W
T-
F	
R
14
0W
-F
	
β	ac-n	
75	kDa--	
	
	
48	kDa--	
	
35	kDa--	
	
	
25	kDa--	
FLAG-PBF	
40	kDa--	
HA	Ab	
B	ac(n		
75	kDa--	
50	kDa--	
37	kDa--	
25	kDa--	
44	kDa--	
HA	Ab	
B	ac(n		
75	kDa--	
50	kDa--	
37	kDa--	
25	kDa--	
44	kDa--	
W
T-
F	
R1
40
W
-F
	
β	ac-n	
75	kDa--	
	
	
48	kDa--	
	
35	kDa--	
	
	
25	kDa--	
FLAG-PBF	
40	kDa--	
W
T-
F	
R
14
0W
-F
	
β	ac-n	
75	kDa--	
	
	
48	kDa--	
	
35	kDa--	
	
	
25	kDa--	
FL - 	
40	kDa--	44	kDa--	
W
T-
F	
R1
40
W
-F
	
β	ac-n	
75	kDa--	
	
	
48	kDa--	
	
35	kDa--	
	
	
25	kDa--	
FLAG-PBF	
40	kDa--	44	kDa--	
HA-PBF	
A	 B	
Chapter	4	
102	
putative	 PBF	 dimers	 at	 ~50	 kDa,	 while	 the	 blue	 square	 illustrates	 the	 predominant	
monomeric	and	glycosylated	forms	of	the	protein	(~25-37	kDa).	
	 Western	blotting	revealed	that	all	mutations	were	broadly	evident	at	the	protein	level	and	showed	similar	molecular	weights	to	monomeric	WT	PBF	(~25	kDa;	Fig.	4.4).	However,	R140W	could	not	be	detected	via	HA-tagging	through	either	Western	blotting	(Figure	4.4A)	or	IF	(Figure	4.2).	Putative	dimers	of	PBF	were	also	apparent	at	~50	kDa,	with	mutants	C51R	and	G106R	showing	reduced	expression	(Figure	4.4A).	Interestingly,	different	amino	acid	substitutions	at	residue	106	illustrated	very	different	biochemical	properties	of	the	protein,	with	G106R	showing	significantly	reduced	glycosylation	and	dimerisation,	 whereas	 G106V	 and	 G106W	 demonstrated	 wild	 type	 levels	 of	 PBF	glycosylation	and	dimerisation	(Figure	4.4A).	
	 Since	no	PBF	band	was	detected	for	R140W-HA,	a	FLAG	tagged	R140W	plasmid	was	 created.	 Although	 R140W-FLAG	 showed	 altered	 subcellular	 localisation	 (Figure	4.3),	the	Western	blotting	illustrated	that	this	mutation	still	provided	both	monomeric	and	 dimeric	 bands	 similar	 to	wild-type	 PBF,	 albeit	with	 significantly	 reduced	 protein	expression	(Figure	4.4B).		
	 4.3.3	Amino	Acid	Substitutions	Alter	PBF	Stability	
	 We	investigated	the	effect	of	all	missense	PBF	substitutions	on	protein	stability	through	half-life	studies	in	MCF7	cells	transfected	with	VO,	HA	tagged	WT-PBF	and	all	PBF	mutations	 except	 R140W-HA.	 For	 this	mutant,	 stability	was	 determined	 through	FLAG-tagged	PBF	in	additional	experiments,	due	to	the	difficulty	in	detecting	the	HA	tag	with	this	mutant.	  
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Scanning	densitometry	of	the	monomeric	form	revealed	that	mutants	C51R	and	V55I,	both	within	the	PSI	domain	of	PBF,	demonstrated	similar	protein	stability	to	wild	type,	with	a	half-lives	of	around	22	hours	(Figure	4.5A	and	4.5B).	Figure	4.6	illustrates	that	 FLAG-tagged	R140W	was	 also	 relatively	 stable	 compared	 to	 FLAG-WT	PBF,	 even	though	R140W-FLAG	showed	 lower	protein	 expression.	Differences	between	 levels	of	FLAG-tagged	WT	PBF	protein	(Figure	4.6)	and	HA-tagged	WT	PBF	(Figure	4.5)	suggest	that	either	a	FLAG-tag	at	 the	N-terminus	of	PBF	might	reduce	protein	stability	or	a	C-terminal	HA	tag	may	increase	PBF	protein	stability.	 In	contrast,	all	other	substitutions	were	markedly	less	stable	than	WT,	ranging	up	to	12	hours	(Figure	4.5A	and	4.5B).	In	addition,	the	substitutions	at	the	‘hot	spot’	106	amino	acid	residue	provided	a	range	of	the	 stability,	with	 G106R	 carrying	 the	 least	 stability,	while	 G106V	 had	~50%	 greater	stability	 than	 G106R	 (Figure	 4.5A	 and	 4.5B).	 Indeed,	 the	 predicted	 3D	 structure	 of	G106R	substitution	demonstrated	in	Chapter	3	revealed	a	significant	disruption	of	the	long	 helix	 at	 the	 C-terminus	 of	 PBF	 (Figure	 3.3),	 which	 may	 make	 mutant	 G106R	particularly	unstable,	resulting	in	the	complete	disappearance	of	the	protein	by	the	12-hour	time	point.	It	is	possible	that	the	half-life	of	G106R	is	only	minutes	which	further	decreases	the	likelihood	of	any	sustained	oncogenic	activity.	
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Figure	4.5:	PBF	substitutions	modify	protein	stability.	A,	representative	Western	blot	
analysis	of	Anisomycin	half-life	assays	in	MCF7	cells	transfected	with	WT	PBF-HA	and	all	
HA	 tagged	 PBF	 mutants,	 except	 the	 R140W	 substitution,	 at	 0,	 12	 and	 24	 hours	 after	
adding	 Anisomycin.	 PBF	 bands	 were	 detected	 by	 Western	 blotting	 with	 a	 mouse	
monoclonal	anti-HA	antibody	(1:1000)	and	mouse	monoclonal	anti-β-actin	(1:10000).	B,	
representative	quantification	of	protein	stability	of	the	~25	kDa	isoform	of	PBF	compared	
to	 β-actin	 from	 N=2	 separate	 experiments,	 comparing	 WT	 PBF	 and	 all	 substitutions,	
except	the	R140W	mutation.	
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Figure	4.6:	R140W-FLAG	is	relatively	stable	compared	to	WT-PBF.	Western	blotting	of	
half-life	study	in	MCF7	cells	transiently	transfected	with	WT-FLAG	and	R140W-FLAG	at	0,	
12	and	24	hours	after	adding	Anisomycin.	PBF	bands	were	detected	by	Western	blotting	
with	a	mouse	monoclonal	anti-FLAG	antibody	(1:500)	and	mouse	monoclonal	anti-β-actin	
(1:10000).		4.3.4	Amino	Acid	Substitutions	Alter	Cellular	Proliferation	
4.3.4.1	Hot	Spot	G106	Amino	Acid	Residue	To	date,	PBF	 function	has	been	 studied	most	 extensively	 in	 thyroid	and	breast	cancer	cell	models	(Smith	et	al.	2012,	Read	et	al.	2014,	Read	et	al.	2011,	Watkins	et	al.	2010).	 In	 vivo,	 PBF	 overexpression	 has	 a	 modest	 pro-proliferative	 influence,	 as	evidenced	by	thyroid	enlargement	in	transgenic	mice	(Read	et	al.	2011).	We	therefore	sought	 to	 identify	 whether	 any	 of	 the	 described	 mutations	 conferred	 a	 growth	advantage.	 Given	 that	 the	 G106	 residue	 carried	 3	 mutations	 (G106R,	 G106V	 and	G106W),	initial	proliferation	assays	were	carried	out	in	TPC1	and	SW1736	thyroid	cells	transfected	with	WT	and	the	G106	mutants	at	48	hours	after	transfection.		
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Figure	 4.7:	 Substitutions	 at	 the	 G106	 residue	 do	 not	 affect	 cellular	 proliferation	
compared	 to	 wild-type	 PBF.	MTS	 proliferation	 assays	 in	 TPC1	 (A)	 and	 SW1736	 (B)	
thyroid	 cancer	 cells	 transfected	 with	 WT-PBF,	 G106R,	 G106V	 and	 G106W.	 All	 3	
substitutions	 at	 residue	 G106	 failed	 to	 significantly	 alter	 mitochondrial	 activity	 (cell	
proliferation	 (absorbance	 at	 490	 nm)),	 as	 a	 marker	 of	 cell	 number.	 Data	 presented	 as	
mean	±	SEM.	SEM	=	standard	error	of	mean.	N=3	individual	experiments.	
As	 all	 3	 substitutions	 at	 the	 G106	 amino	 acid	 residue	 failed	 to	 significantly	modify	proliferative	capacity	in	MTS	assays	(Figure	4.7	A	and	4.7B),	residue	G106	was	subsequently	considered	not	to	be	a	hot-spot	of	functional	mutational	activation.	
	
4.3.4.2	BrdU	Assays	
		 As	 most	 PBF	 mutations	 altered	 the	 PBF	 stability	 compared	 to	 WT-PBF,	 MTS	proliferation	assays	of	wild-type	and	all	10	PBF	substitutions	were	conducted	(data	not	shown).	Most	PBF	substitutions	had	similar	proliferative	phenotypes	to	WT-PBF	(data	not	 shown).	 These	 preliminary	 results	 therefore	 enabled	 us	 to	 narrow	 down	 our	
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research	to	2	mutations	 in	 the	PSI	domain	(C51R	and	V55I),	and	2	mutations	close	 to	nuclear	 localisation	 signal	 or	 NLS	 (R140W	 and	 R146W).	 Thus	 BrdU	 assays	 were	conducted	at	48	hours	after	cell	transfection	to	investigate	the	consequence	of	these	4	substitutions	 on	 cellular	 proliferation,	 via	 the	 assessment	 of	 DNA	 replication	 as	 an	indirect	marker	of	cell	division.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 4.8:	Mutations	 in	 the	 PSI	 domain	 are	 generally	 pro-proliferative,	 whereas	
mutants	proximal	 to	 the	NLS	 reduce	 cellular	proliferation.	After	 transfection	 for	48	
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hours,	BrdU	cellular	proliferation	experiments	were	performed	in	TPC1	(A)	and	MCF7	(B)	
cells	 transfected	 with	 VO,	 WT-PBF,	 C51R,	 V55I,	 R140W	 and	 R146W	 mutants.	 Inset	 –	
Western	blots	demonstrate	PBF	expression	relative	to	β-actin	levels	to	assess	transfection.	
Data	 presented	 as	 mean	 ±	 SEM.	 SEM	 =	 standard	 error	 of	 mean.	 *P<0.05,	 **P<0.01,	
***P<0.001.	N=3	separate	experiments.	
Principally,	 three	 individual	 BrdU	 assays	 in	 TPC1	 thyroid	 and	 MCF7	 breast	cancer	cells	suggested	that	C51R	and	V55I	induced	cell	proliferation	compared	with	WT,	whilst	R140W	and	R146W	were	broadly	anti-proliferative	(Figure	4.8). 	
	
4.3.4.3	MTS	Assays		 Following	findings	of	the	BrdU	assays	in	the	previous	section,	we	performed	MTS	assays	 to	 validate	 the	 results	 of	 the	 consequence	 of	 PBF	 substitutions	 on	 a	 different	marker	of	cell	turnover.	However,	as	mutant	V55I	showed	inconsistent	results	between	2	cell	 lines	and	mutant	R146W	demonstrated	 less	proliferative	change	 than	 the	other	two	substitutions,	especially	 in	MCF7	cells	(Figure	4.8),	we	carried	out	these	assays	in	TPC1	and	MCF7	cell	transfected	with	only	VO,	WT-PBF,	C51R	and	R140W.	
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Figure	4.9:	MTS	assays	in	TPC1	(A)	and	MCF7	(B)	cells.	48	hours	post	transfection	with	
VO,	 WT-PBF,	 C51R	 and	 R140W	 cDNA	 constructs,	 MTS	 assays	 were	 performed.	 Inset	 –	
Western	blots	demonstrate	PBF	expression	relative	to	β-actin	levels	to	assess	transfection.	
Data	 presented	 as	 mean	 ±	 SEM.	 SEM	 =	 standard	 error	 of	 mean.	 N=3	 separate	 assays.	
*P<0.05,	**P<0.01,	***P<0.001.	
	 	The	 MTS	 assays	 at	 48	 hours	 after	 transfection	 revealed	 a	 small	 but	 non-significant	 increase	 in	 cell	 turnover	 for	 mutation	 C51R,	 but	 confirmed	 that	 R140W	significantly	repressed	proliferation	compared	to	WT-PBF	(Figure	4.9).	
	
4.3.4.4	Subcellular	Localisation	of	C51R	and	R140W	Substitutions		 For	 subsequent	 investigations	 we	 therefore	 confined	 ourselves	 to	 the	 2	mutations	 which	 (i)	 showed	 the	 most	 obvious	 differences	 in	 cellular	 proliferation	compared	 with	 WT,	 (ii)	 were	 potentially	 damaging	 to	 the	 cell	 via	 SIFT,	 (iii)	 were	apparent	 in	 the	 same	 tumour	 category	 (Table	 3;	 colon	 cancer),	 (iv)	 showed	 altered	
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subcellular	distribution	compared	to	WT,	(v)	occurred	at	evolutionarily	conserved	sites,	and	(vi)	were	clearly	expressed	in	vitro;	C51R	(N-terminal,	within	the	PSI	domain)	and	R140W	 (C-terminal,	 adjacent	 to	 the	 nuclear	 localisation	 signal).	 Therefore,	immunofluorescence	studies	were	applied	to	investigate	in	more	detail	the	subcellular	localisation	of	PBF	caused	by	these	two	amino	acid	missense	substitutions.	Assays	were	carried	out	in	HeLa	cervical	cancer	and	MCF7	breast	cancer	cells	transfected	with	FLAG-tagged	WT,	C51R	and	R140W	mutants,	 and	 then	co-localisation	with	 the	endoplasmic	reticulum	(ER)	marker	or	the	Golgi	apparatus	marker	assessed	(Figure	4.10).	
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Figure	 4.10:	 Mutant	 C51R	 is	 mostly	 located	 in	 the	 endoplasmic	 reticulum,	 while	
R140W	 is	mainly	observed	 in	 the	Golgi	apparatus.	Representative	 immunoflorescent	
microscopy	of	PBF-FLAG	(green),	endogenous	PDI	(ER	marker;	red),	endogenous	golgin-97	
(Golgi	marker;	red),	cell	nuclei	(DAPI;	blue)	and	co-localisation	(yellow)	in	HeLa	(A)	and	
MCF7	 (B)	 cells	 transfected	 with	 WT-PBF-FLAG,	 C51R-FLAG	 and	 R140W-FLAG.	
Magnification	=	100x.	Scale	bars	=	20	μm.	
	 Figure	4.10A	and	4.10B	illustrate	that	whilst	WT-PBF	was	mainly	located	in	late	endosomes	and	at	the	plasma	membrane,	as	we	have	shown	before	(Smith	et	al.	2009),	the	 C51R	 mutant	 was	 predominantly	 apparent	 in	 the	 endoplasmic	 reticulum,	demonstrated	by	 co-localisation	with	 the	 anti-PDI	 antibody	 (ER	marker),	 and	R140W	was	mainly	 confined	 to	 the	 Golgi	 apparatus,	with	 co-localisation	 between	 the	mutant	and	 anti-golgin-97	 antibody	 (Golgi	 marker).	 Following	 the	 investigations	 of	 this	
B	
MCF7	
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Chapter,	mutations	C51R	and	R140W	were	selected	to	explore	in	more	functional	depth	in	subsequent	studies.	
 
4.4	Discussion	
It	remains	difficult	to	determine	the	actual	functional	consequences	of	mutations	discovered	 in	 human	 cancers.	 Computational	 approaches	 do	 not	 as	 yet	 provide	unequivocal	evidence	of	whether	DNA	changes	represent	driver	gene	mutations,	or	are	simply	 passenger	 mutations	 apparent	 in	 a	 given	 tumour.	 In	 this	 Chapter,	 we	investigated	 the	 outcome	 of	 all	 of	 the	 first	 10	 non-synonymous	mutations	 of	 PBF	 on	subcellular	 localisation,	 glycosylation,	 dimerisation,	 protein	 stability	 and	 cellular	proliferation	as	a	way	of	assessing	their	likely	basic	biochemistry.	
Since	 we	 know	 that	 changing	 the	 subcellular	 location	 of	 proteins	 generally	causes	protein	functional	modification,	we	started	with	immunofluorescence	studies	to	determine	 the	 subcellular	 localisation	of	PBF.	Figure	4.2	and	Figure	4.3	 illustrate	 that	WT	PBF	and	most	missense	substitutions	were	mainly	confined	to	late	endosomes	and	the	 plasma	 membrane	 as	 has	 been	 reported	 previously	 (Smith	 et	 al.	 2009).	 Whilst	endosomal	 and	 plasma	 membrane	 markers	 were	 not	 used	 specifically,	 no	 obvious	deviation	 from	 WT	 localisation	 was	 evident.	 Mutants	 C51R,	 G106R	 and	 R140W,	however,	did	show	markedly	different	localisations	to	WT	in	HeLa	cervical	cancer	cells.	Indeed,	 the	 C51R	 mutant	 was	 predominantly	 located	 in	 the	 endoplasmic	 reticulum,	whilst	R140W-PBF	was	mainly	localised	in	the	Golgi	apparatus	(Figure	4.10).	Although	G106R	was	not	examined	for	co-localisation	with	the	ER	marker	PDI,	its	localisation	was	noticeably	similar	to	C51R-PBF.		
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Most	mutants	identified	in	vivo	failed	to	alter	basic	PBF	biochemistry,	as	assessed	via	 glycosylation	 and	 dimerisation,	 although	 mutations	 C51R	 and	 G106R	 exhibited	reduced	glycosylated	and	oligomerised	forms	of	PBF.	However,	 in	Anisomycin	half-life	studies,	 mutants	 C51R	 and	 V55I	 in	 the	 PSI	 domain	 and	 R140W	 close	 to	 C-terminus	showed	unchanged	PBF	stability,	while	G106R	had	the	least	stability	compared	to	WT-PBF.	 Indeed,	 all	 substitutions	 were	 less	 stable	 than	 wild-type	 PBF.	 Heterozygous	mutations	 resulting	 in	 unstable	 proteins	 would	 ultimately	 lead	 to	 a	 reduction	 in	 the	level	 of	 functional	 PBF	 protein.	 This	 is	 unlikely	 to	 drive	 oncogenesis	 and	 may	 even	counter	 the	 overexpression	 of	 WT	 PBF	 thereby	 decreasing	 oncogenic	 activity.	Therefore,	 amino	 acid	 substitutions	 resulting	 in	 modulation	 of	 PBF	 subcellular	localisation	might	not	be	directly	related	to	either	glycosylation,	dimerisation	nor	PBF	stability,	 which	 differs	 from	 other	 proteins,	 such	 as	 receptor	 signalling	 proteins	 or	hormones	(DePristo,	Weinreich	&	Hartl	2005,	Ponnuswamy,	Muthusamy	&	Manavalan	1982).	 Moreover,	 modifications	 of	 PBF	 glycosylation	 and	 dimerisation	 do	 not	necessarily	impact	the	protein	stability.	It	is	important	to	note,	however,	that	the	actual	glycosylation	 patterns	 and	 oligomeric	 forms	 of	 the	 PBF	 protein	 have	 not	 been	empirically	 determined	 in	 previous	 studies,	 and	 hence	 for	 the	 purpose	 of	 this	 thesis	they	must	be	considered	putative.		
	 PBF	has	a	mild	pro-proliferative	characteristic	 in	vivo	 (Read	et	al.	2011).	When	we	 examined	 the	 consequence	 of	 cell	 turnover	 caused	 by	 three	 substitutions	 at	 the	G106R	 residue,	 MTS	 proliferation	 assays	 demonstrated	 that	 the	 G106	 amino	 acid	residue,	 which	 was	 mutated	 in	 4	 separate	 patients,	 was	 not	 associated	 with	 any	significant	change	in	cell	turnover	(Figure	4.7),	and	lacked	any	correlation	with	altered	localisation,	 glycosylation,	 dimerisation	 or	 stability.	 Nevertheless,	 BrdU	 assays	 were	
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applied	 to	 determine	 whether	 other	 mutations	 altered	 cellular	 proliferation,	 and	 we	interestingly	 found	 that	 mutants	 in	 PSI	 domain,	 C51R	 and	 V55I,	 generally	 induced	proliferative	ability	compared	to	WT-PBF,	whereas	mutations	close	 to	C-terminal	end,	R140W	 and	 R146W,	 repressed	 proliferation	 down	 to	 the	 levels	 of	 VO	 control	 cells	(Figure	 4.8).	We	 also	 re-assessed	 cellular	 proliferation	using	MTS	 assays	 to	 challenge	the	results	through	an	alternative	technical	approach,	which	revealed	that	WT-PBF	still	significantly	 increased	proliferative	ability	as	we	previously	described	before	(Read	et	al.	 2011).	Moreover,	 the	MTS	 results	were	 broadly	 consistent	with	BrdU	 assays,	with	C51R	 showing	 a	 mild	 pro-proliferative	 effect,	 while	 R140W	 had	 anti-proliferative	characteristic	compared	to	WT-PBF	(Figure	4.9).	
	 Based	on	the	basic	biochemistry	of	 the	 first	10	missense	mutations	reported	 in	the	 COSMIC,	 we	 narrowed	 our	 subsequent	 functional	 studies	 to	 2	 potentially	 key	substitutions:	 C51R	 and	 R140W.	 One	 criticism	 of	 this	 approach	 is	 that	 we	may	 have	missed	genuinely	oncogenic	activities	in	the	8	other	mutations	which	we	did	not	pursue	in	 depth.	 However,	 it	 was	 impractical	 to	 perform,	 for	 example,	 simultaneous	 2D	invasion	 assays	 for	 all	 10	 mutations,	 and	 initial	 proliferation	 data	 suggested	 no	significant	alterations	in	cell	turnover.	Our	initial	thought	was	that	residue	G106	might	represent	 a	 hot-spot	 of	mutational	 activation.	 Nevertheless,	 as	 discussed	 above,	 all	 3	substitutions	at	G106	 residue,	G106V/R/W,	 failed	 to	 significantly	 enhance	markers	of	cell	 proliferation	 compared	 to	 WT-PBF.	 It	 is	 possible	 that	 mutations	 of	 G106	 may	enhance	other	oncogenic	properties	of	PBF,	such	as	its	pro-invasiveness.	However,	the	G106	mutants	were	 particularly	 unstable	 in	 half-life	 studies	 reducing	 their	 oncogenic	potential.	Thus,	although	this	locus	may	be	a	mutation	hot-spot,	it	is	unlikely	to	result	in	increased	oncogenic	activity	and	induced	tumour	growth	and	development.		
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For	 our	 subsequent	 investigations	 we	 therefore	 confined	 ourselves	 to	 the	 2	mutations	 which	 showed	 the	 most	 obvious	 differences	 in	 cellular	 proliferation	compared	with	WT,	were	 potentially	 damaging	 to	 the	 cell	 via	 SIFT,	were	 apparent	 in	patients	within	the	same	cancer	subtype,	and	were	clearly	expressed	in	vitro;	C51R	(N-terminal,	 within	 the	 PSI	 domain)	 and	 R140W	 (C-terminal,	 adjacent	 to	 the	 nuclear	localisation	signal).	
CHAPTER	5		- EFFECT	OF	PBF	MUTATIONS	
C51R	AND	R140W	ON	CELL	INVASION	AND	
MIGRATION	
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5.1	Introduction	
Our	group	initially	characterised	a	potential	role	for	PBF	in	breast	and	colon	cell	invasion	 and	 cell	 migration	 in	 vitro	 (Watkins	 et	 al.	 2010,	 Read	 et	 al.	 2016).	 Indeed,	upregulation	 of	 PBF	 significantly	 promoted	 cell	 invasion	 in	MCF7	 breast	 cancer	 cells	and	induced	cell	migration	in	HCT116	colon	cancer	cells.	Furthermore,	recent	evidence	from	 three	 different	 studies	 in	 breast,	 colon	 and	 papillary	 thyroid	 cancers	 has	circumstantially	 linked	PBF	 to	 the	process	of	 tumour	 invasion,	metastasis	 and	poorer	oncological	 outcomes	 in	 vivo	 (Xiang	 et	 al.	 2012,	 Read	 et	 al.	 2016,	Hsueh	 et	 al.	 2013).	Firstly,	overexpressed	PBF	significantly	increases	risk	of	breast	cancer	metastasis,	and	higher	variable	numbers	of	tandem	repeats	in	the	promoter	of	PBF	also	correlate	with	a	significant	 rise	 in	 risk	 of	 ER	 positive	 breast	 cancer	 (Xiang	 et	 al.	 2012).	 Secondly,	 the	presence	 of	 extramural	 vascular	 invasion	 in	 colorectal	 tumours	 is	 significantly	associated	with	higher	PBF	expression	 (Read	et	al.	2016).	Thirdly,	patients	diagnosed	with	papillary	thyroid	cancer	who	have	high	PBF	expression	also	harbour	a	higher	risk	of	early	 locoregional	recurrence	and	distant	metastasis	(Hsueh	et	al.	2013).	Thus,	 it	 is	possible	that	PBF	is	integral	to	tumour	cell	invasion	in	vivo.	
One	of	 the	critical	mechanisms	 in	cell	 invasion	concerns	how	actin	congregates	and	 forms	protrusive	 structures	 at	 the	 leading	 edge	of	 cancer	 cells	 (Friedl,	Alexander	2011).	 There	 are	 various	 molecules	 in	 the	 Rho	 family	 of	 GTPases	 such	 as	 Rho	 (Ras	homologous),	 Cdc42	 (cell	 cycle	 division	 42)	 and	Rac	 (Ras-related	 C3	 botulinum	 toxin	substrate),	 which	 modulate	 regulation	 of	 actin	 and	 migration	 (Ridley	 2011,	 Parsons,	Horwitz	 &	 Schwartz	 2010,	 Lee,	 Dominguez	 2010,	 Etienne-Manneville,	 Hall	 2002).		However,	 the	mechanistic	 impact	of	 actin	polymerisation	 in	 the	 tumour	 is	 still	 poorly	understood.	
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Cortactin	 (CTTN)	 is	a	 scaffold	protein	active	predominantly	at	 the	periphery	of	cells	 which	 promotes	 actin	 polymerisation	 by	 binding	 and	 activating	 the	 Arp2/3	complex,	 as	well	 as	 inhibiting	debranching	of	 actin	networks	 (Weaver	 et	 al.	 2001).	 In	this	way,	 CTTN	 is	 able	 to	 exert	 a	 potent	 influence	 upon	 cell	movement	 and	 invasion	(Figure	 5.1)	 (MacGrath,	 Koleske	 2012,	 Kirkbride	 et	 al.	 2011,	 Pollard,	 Borisy	 2003).	Indeed,	 over-expression	 of	 CTTN	 is	 associated	 with	 increased	 cellular	 motility	 and	invasiveness	in	multiple	cancer	settings	(MacGrath,	Koleske	2012,	Kirkbride	et	al.	2011,	Kowalski	 et	 al.	 2005).	 CTTN	 function	 is	 however	multifaceted	 and	has	been	 linked	 to	numerous	processes,	including	vesicular	trafficking	(Kirkbride	et	al.	2012,	Kirkbride	et	al.	 2011),	 focal	 adhesion	 dynamics	 (Tomar	 et	 al.	 2012),	 extracellular	 matrix	 (ECM)	secretion	 (Sung	 et	 al.	 2011),	 cell-cycle	 progression	 (Croucher	 et	 al.	 2010)	 and	degradation	of	growth	factor	receptors	(Timpson	et	al.	2005)	(Figure	5.1).	These	studies	emphasise	 the	 importance	 of	 CTTN	 as	 a	 key	 player	 in	 aggressive	 cancers	 (MacGrath,	Koleske	2012),	but	indicate	that	further	work	is	required	to	establish	the	precise	role	of	CTTN	in	different	tumour	settings.	Of	key	relevance	to	the	current	Chapter,	our	previous	unpublished	 mass	 spectometry	 data	 suggested	 that	 cortactin	 is	 a	 potential	 binding	partner	 of	 PBF	 (Sharma	 2014).	 However,	 the	 mechanism	 of	 how	 PBF	 interacts	 with	cortactin	and	the	specific	binding	sites	between	the	two	proteins	still	remains	elusive.	
Given	 that	 PBF	 appears	 to	 have	 roles	 in	 multiple	 tumourigenic	 processes,	including	 cell	 invasion	 and	migration	 in	 vitro	 (Watkins	 et	 al.	 2016,	Manuscript	 under	revision),	 the	 potential	 mechanism	 of	 PBF	 in	 cell	 invasion	 and	 migration	 was	investigated,	to	determine	how	PBF	interacts	with	cortactin	and	whether	the	C51R	and	R140W	substitutions	alter	these	properties.			
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Figure	5.1:	Schematic	diagram	of	cortactin	functions	to	induce	cell	motility	and	cell	
invasion.	Representative	diagram	illustrating	potential	binding	partners	and	functions	of	
cortactin.	CTTN	=	cortactin,	FAK	=	focal	adhesion	kinases,	GFR	=	growth	factor	receptors,	
MMPs	=	matrix	metalloproteinases,	CDC42	=	cell	 cycle	division	42	and	Arp	2/3	=	actin	 -	
related	proteins	2	and	3.	
	
5.2	Materials	and	Methods	5.2.1	Cell	Culture	and	Transfection	
	 TPC1,	 SW1736	 thyroid	 and	MCF7	 breast	 cancer	 cells	were	 supplemented	with	RPMI	containing	10%	FCS,	whilst	HCT116	colon	cancer	cells	were	cultivated	in	McCoy’s	5a	 media	 consisting	 of	 10%	 FCS,	 and	 HeLa	 cervical	 cancer	 cells	 were	 maintained	 in	
CTTN	
Plasma	
membrane	
ARP2/3	
Nucleus	
FAK	 MMPs	
GFR	
CDC42	
é  Degrada'on	of	
						growth	factor	receptors	
é  Focal	adhesion	
dynamics	
é  Lamellipodia	
persistence	
é  Cell	mo'lity	
Cell	cycle	progression	
é  Vesicular	traﬃcking	of	MMPs	
é  Extracellular	matrix	
degrada'on	
é  Ac'n	polymerisa'on	
é  Cell	movement	
Chapter	5	
120	
DMEM	 containing	 10%	 FCS	 as	 described	 in	 section	 2.1.1.	 TPC1	 cells	 were	 seeded	 at	75,000	 cells	 per	 well	 of	 6-well	 plates,	 while	 SW1736,	 MCF7,	 HCT116	 and	 HeLa	 cells	were	seeded	 into	6	well	plates	at	150,000	cells	each	well. The	cells	were	 incubated	at	37°C	 and	 5%	 CO2	 condition	 for	 24	 hours	 before	 the	 transfection	 was	 carried	 out.	SW1736,	HCT116	and	MCF7	cells	were	transfected	with	VO	and	HA-tagged	WT-PBF	in	cell	 invasion	 assays	used	 to	 explore	 the	 effect	 of	 cortactin	knockdown.	Moreover,	VO,	WT-PBF,	C51R	and	R140W	mutants	were	used	 in	 the	 transfection	of	TPC1	and	MCF7	cells	to	investigate	the	effect	of	2	PBF	substitutions	on	cell	invasion.	
	 5.2.2	Short	Interfering	Ribonucleic	Acid	(siRNA)	Transfection	
After	 being	 seeded	 in	 6-well	 plates	 for	 24	 hours	 as	 described	 in	 section	 5.2.1,	SW1736,	HCT116	and	MCF7	cells	were	transfected	with	silencer	cortactin	siRNAs	4666	and	 4667	 or	 negative	 control	 siRNA	 combined	 with	 siPORT™	 NeoFX™	 transfection	reagent	(Invitrogen,	UK)	as	described	in	section	2.1.4.	The	cells	were	then	incubated	for	24	hours,	before	PBF	overexpression	was	determined	as	previously	described	in	section	2.1.3.	
	 5.2.3	Cell	Invasion	Assays	
SW1736	thyroid,	MCF7	breast	and	HCT116	colon	cancer	cells	were	seeded	in	6-well	plates	 for	24	hours	as	described	in	section	5.2.1.	Then,	 the	cells	were	transfected	with	 two	 silencing	 CTTN	 siRNAs	 to	 knockdown	 CTTN	 for	 24	 hours,	 followed	 by	transfection	 with	 VO	 or	 PBF-HA	 for	 the	 next	 24	 hours,	 before	 actual	 cell	 invasion	experiments	were	performed.	However,	for	the	modification	of	cell	invasion	caused	by	
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PBF	mutations,	TPC1	 thyroid	and	MCF7	breast	cancer	cells	were	 transfected	with	VO,	WT-PBF,	 C51R-PBF	 and	R140W-PBF	plasmids	 for	 48	hours	 before	 starting	 the	 actual	steps	of	cell	invasion	assays.	The	cells	were	transfected	with	duplicate	samples	in	each	separate	experiment.	Post	transfection,	the	transfection	reagent	was	then	removed	and	replaced	with	complete	medium	containing	2%	FCS	to	drive	cell	invasion.	After	16-hour	incubation,	the	cells	were	harvested	and	reseeded	into	8	μm	growth	reducing	invasive	chambers	(BD	bioscience,	UK)	in	triplicate	fashion	for	each	sample,	and	then	incubated	for	24	hours	to	let	cells	invade.	Finally,	membrane	staining	was	performed	as	described	in	section	2.9.	The	experiments	were	individually	replicated	twice.	
	 5.2.4	Cell	Migration	Assays	
After	 clonal	 selection	 of	 NIH	 3T3	 cells	 stably	 overexpressing	 pCI-neo	 vectors	containing	VO,	WT-PBF,	C51R-PBF	and	R140W-PBF,	cells	were	seeded	into	6-well	plates	in	triplicate.	The	stable	cells	were	incubated	until	becoming	100%	confluent,	before	one	scratch	wound	in	each	well	was	created	by	standard	scraping	with	a	P10	pipette	tip.	The	images	were	captured	at	0,	4,	6,	and	8	hours	after	creating	the	wounds,	and	taken	for	3	different	areas	in	each	well.	The	area	and	percentages	of	wound	closure	were	analysed	using	Image	J	software.	The	assays	were	carried	out	in	3	separate	experiments.	
	5.2.5	Immunoflorescence	Microscopy	
	 HeLa	and	MCF7	cells	were	seeded	at	150,000	cells	per	well	of	6-well	plates	and	incubated	 for	 24	hours,	 before	 being	 transfected	with	VO,	WT-PBF-HA,	 C51R-PBF-HA	and	CTTN-Myc	as	described	 in	 section	2.1.3.	The	 cells	were	 then	used	 to	examine	co-
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localisation	 between	 PBF	 or	 Y174	 phospho-PBF	 and	 cortactin	 (CTTN)	 through	immunofluorescence	microscopy	as	explained	 in	 section	2.6.	Primary	antibodies	were	rabbit	 polyclonal	 anti-HA	 (1:200,	 Santa	 Cruz	 Biotechnology,	 UK),	 mouse	 monoclonal	anti-Myc	(9B11,	1:500,	Cell	Signaling,	UK),	mouse	monoclonal	anti-CTTN	(1:100,	Merck	and	 Millipore,	 Germany),	 rabbit	 polyclonal	 anti-PBF	 (1:100,	 In-house)	 and	 rabbit	polyclonal	 anti-phosphoPBF	 (Y174,	 1:50,	 In-house).	 The	 cells	were	 visualised	 using	 a	Zeiss	Axioplan	fluorescence	microscope	(Zeiss,	Germany)	with	10x	and	100x	objectives.	Subcellular	 co-localisation	 of	 PBF	 or	 Y174	 phospho-PBF	 and	 cortactin	 (CTTN)	 was	additionally	 investigated	 in	 HeLa	 and	 MCF7	 cells	 using	 a	 LSM510	 META	 confocal	microscope	with	63x	and	100x	objective	lens	(Zeiss,	Germany).	
	
5.2.6	Protein	Extraction	and	Quantification	(Bicinchoninic	Acid	Assay	or	BCA)	
Protein	 samples	 were	 extracted	 to	 confirm	 overexpression	 or	 knockdown	conditions,	and	BCA	assays	were	performed	as	described	in	section	2.2.	After	measuring	the	 absorbance,	 protein	 concentrations	 and	 volumes	 were	 determined	 to	 apply	 in	further	Western	blotting	analysis.	
	 5.2.7	Co-immunoprecipitation	(Co-IP)	
	 The	 interaction	 between	 PBF	 and	 CTTN,	 including	 endogenous	 and	 exogenous	circumstances,	 was	 analysed	 using	 co-IP	 experiments	 as	 defined	 in	 section	 2.11.	 The	antibodies	used	for	pull	down	were	mouse	monoclonal	anti-CTTN	(Merck	and	Millipore,	
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Germany),	 mouse	 monoclonal	 anti-Myc	 (9B11,	 Cell	 Signaling,	 UK)	 and	 mouse	monoclonal	anti-HA	(Covance,	USA).		
	 5.2.8	Proximity	Ligation	Assays	(PLA)	
	 To	detect	specific	interaction	between	endogenous	CTTN	and	PBF	in	single	cells,	we	applied	Proximity	Ligation	Assays	(PLA)	in	HeLa	and	MCF7	cells.	Protein	interaction	was	determined	using	Duolink®	In	Situ	reagents	 from	Olink®	Bioscience	(Sigma,	UK)	and	 the	 primary	 antibodies	 for	 mouse	 monoclonal	 anti-CTTN	 (1:100,	 Merck	 and	Millipore,	Germany),	rabbit	polyclonal	anti-PBF	(1:100,	In-house),	and	rabbit	polyclonal	anti-phospho-PBF	(pY174,	1:50,	In-house).	The	PLA	probes	(Sigma,	UK)	were	Plus	and	Minus	probes	raised	in	different	species	depending	on	the	required	primary	antibodies.	A	 pair	 of	 the	 PLA	 probes,	 visualised	 as	 an	 individual	 fluorescent	 red	 spot	 in	 specific	subcellular	localisation,	yields	a	signal	only	when	the	probes	are	held	together	in	close	proximity.		
The	cells	were	seeded	at	a	density	of	150,000	cells/well	on	a	cover	slip	placed	into	a	well	in	a	6-well	plate	and	then	leaving	for	48	hours.	After	washing	with	PBS,	the	cells	 were	 fixed	 using	 fixing	 solution	 (0.1M	 phosphate	 buffer	 Na2HPO4	 (pH	 7.4),	 2%	paraformaldehyde	 (PFA),	 2%	 glucose,	 0.02%	 sodium	 azide)	 for	 20	 minutes	 at	 room	temperature.	Subsequently,	cells	were	permeabilised	with	100%	chilled	methanol	and	blocked	 in	 10%	 NCS	 in	 PBS	 (Invitrogen,	 UK)	 as	 described	 in	 section	 2.6.	 After	 the	primary	antibodies	were	diluted	 into	1%	BSA	(Jackson	Immunoresearch,	USA)	 in	PBS,	80	 μl	 of	 the	 solution	were	 applied	 to	 the	 cells.	 After	 1	 hour	 incubation	 in	 humidified	chambers,	 coverslips	 were	 washed	 with	 PBS	 for	 5	 minutes,	 two	 times,	 and	 next	
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incubated	with	80	μl	of	diluted	two	PLA	probes	(1:5)	in	1%	NCS	and	1%	BSA	in	PBS	at	37°C	for	one	hour.	The	cells	were	then	washed	for	5	minutes	twice	with	1x	Wash	Buffer	A	(provided	in	the	kit)	under	gentle	agitation.	 	In	the	meantime,	the	Ligase	was	added	1:40	in	diluted	Ligation	Stock	(1:5	in	purified	water)	and	mixed	by	vortexing,	before	the	ligation-Ligase	solution	was	aliquoted	on	to	each	cover	slip.	After	incubation	at	37°C	for	an	 hour,	 the	 sample	 was	 washed	 with	 1x	Wash	 Buffer	 A	 twice	 for	 2	 minutes	 under	shaking	 condition.	 Subsequently,	 the	 Polymerase	was	 immediately	 diluted	 1	 in	 80	 in	diluted	Amplification	Stock	(1:5	in	purified	water),	before	being	applied	to	the	cells	and	then	incubated	at	37°C	for	100	minutes.	The	cover	slip	was	then	washed	twice	with	1x	Wash	Buffer	B	(provided	in	the	kit)	for	10	minutes,	rinsed	with	0.01x	Wash	Buffer	B	for	1	 minute,	 and	 dried	 at	 room	 temperature	 in	 the	 dark.	 Finally,	 the	 cover	 slip	 was	mounted	 using	Duolink	 In	 Situ	Mounting	Medium	with	DAPI	 (Sigma,	 UK),	 and	 sealed	with	 nail	 polish.	 The	 slide	 was	 analysed	 using	 confocal	 fluorescence	microscopy	 and	stored	at	-20	°C	in	the	dark.	
	
5.3	Results	5.3.1	Interaction	between	PBF	and	Cortactin	
5.3.1.1	Endogenous	PBF	and	CTTN			 Our	group	recently	performed	extensive	mass	spectrometry	in	papillary	thyroid	K1	and	TPC1	cells	in	order	to	identify	possible	binding	partners	of	PBF	with	roles	in	cell	motility.	 Potential	 proteins	 interacting	 with	 PBF-HA	 were	 isolated	 through	 co-immunoprecipitation	(co-IP)	using	anti-HA	(Covance,	USA)	and	then	separated	by	SDS-PAGE.	 Following	 destaining,	 proteins	 were	 reduced,	 alkylated	 and	 trypsinised	 before	
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undergoing	 tandem	 mass	 spectrometry	 (Bruker,	 USA).	 Mass	 spectrographs	 were	analysed	via	 the	Mascot	search	engine	 (v2.2.06,	Matrix	Science,	UK)	and	ProteinScape	(v3.0.0.446,	Bruker,	USA).	Multiple	separate	runs	were	performed	to	identify	consistent	protein	interactors.	We	identified	the	cortical	actin	binding	protein	CTTN	to	be	the	top	hit	 across	 all	 runs	 (12	 peptide	 hits,	 average	 score	 per	 peptide	 =	 40.0,	 n	 =	 5	 runs)	(Sharma	2014).	Given	CTTN’s	pivotal	role	in	cell	migration	and	invasion,	and	since	PBF	is	 shown	 to	 induce	 2D	 cell	 invasion	 in	 breast	 cancer	 cells	 (Watkins	 et	 al.	 2010),	 we	appraised	 the	 mass	 spectrometry	 data	 using	 co-IP	 assays	 (Figure	 5.2),	 proximity	ligation	 assays	 (Figure	 5.3)	 and	 immunofluorescence	 studies	 (Figure	 5.4)	 in	 HeLa,	MCF7,	SW1736	and	HCT116	cells.		
	
5.3.1.1.1	Co-IP	Studies	 		 The	 co-IP	 experiments	 were	 performed	 to	 evaluate	 a	 potential	 interaction	between	PBF	and	CTTN	in	HeLa	cervical,	MCF7	breast	and	HCT116	colon	cancer	cells.	10	μl	anti-CTTN	antibody	were	applied	to	pull	down	PBF	or	phosphorylated	PBF	in	each	positive	 condition,	 while	 the	 HA	 antibody,	 from	 the	 same	 IgG1	 isotope	 as	 the	 CTTN	antibody,	was	used	as	a	negative	control.	Additionally,	no	antibody	(Nab)	controls	were	used	as	a	second	negative	control.	All	co-IPs	were	performed	on	at	 least	 two	separate	occasions.		
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Figure	 5.2:	 PBF	 and	 CTTN	 bind	 in	 vitro	 through	 co-IP	 assays.	Representative	 co-IP	
experiments	between	 total	PBF	and	CTTN	or	Y174	phospho-PBF	(pPBF)	and	CTTN	 from	
HeLa,	MCF7	and	HCT116	cells.	+	indicates	the	co-IP	condition	where	anti-CTTN	antibody	
(ab)	was	used	to	pull	down	PBF	or	phospho-PBF,	while	Iso	denotes	HA	ab	applied	to	co-IP	
samples	 as	 a	 negative	 control.	 Nab	 =	 no	 antibodies	 used	 to	 pull	 down	 the	 protein.	 Red	
squares	illustrate	specific	interaction	between	2	proteins.		
The	 results	 showed	 that	 endogenous	 phosphorylated	 Y174	 PBF	 specifically	interacted	 with	 CTTN	 (Figure	 5.2),	 whereas	 ‘total’	 PBF	 failed	 to	 show	 specific	interaction	with	CTTN.	This	 is	 likely	to	reflect	 the	fact	 that	our	 in-house	PBF	antibody	does	not	detect	phosphorylated	PBF	(Smith	et	al.	2013,	Smith	et	al.	2009).	Further,	the	predominant	interaction	was	with	the	putatively	oligomeric	form	of	pY174	at	around	75	kDa,	and	not	monomeric	PBF,	 suggesting	both	 that	oligomeric	PBF	 is	phosphorylated,	and	that	CTTN	preferentially	binds	when	PBF	is	an	oligomer.	
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5.3.1.1.2	Proximity	Ligation	Assays	(PLA)	We	 challenged	 our	 co-IP	 findings	with	 the	 separate	methodology	 of	 proximity	ligation	assays	 (PLA).	The	 interaction	between	CTTN	and	PBF	was	confirmed	 in	HeLa	(Fig.	5.3A)	and	MCF7	(Fig.	5.3B)	cells,	through	which	binding	is	visualised	as	subcellular	fluorescence	(Figure	5.3).	
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Figure	 5.3:	 PBF	 and	 CTTN	 bind	 in	 vitro	 via	 PLA	 assays.	 Representative	
immunofluorescent	 confocal	microscopy	 of	 PLA	 experiments	 in	 HeLa	 (A)	 and	MCF7	 (B)	
cells.	CTTN	indicates	the	condition	where	only	anti-CTTN	ab	was	used,	while	pPBF	denotes	
the	condition	where	only	anti-phosphoPBF	(Y174)	ab	was	applied.	CTTN+pPBF	illustrates	
the	condition	where	both	anti-CTTN	and	anti-phosphoPBF	(Y174)	antibodies	were	applied	
simultaneously.		Red	spots	indicate	specific	interaction	between	2	proteins.	Zoomed	image	
shows	 that	 Y174	 phospho-PBF	 and	 CTTN	 interaction	 occurs	 predominantly	 at	 the	 cell	
periphery.	Magnification	=	100x.	Scale	bars	=	20	μm.	
Specific	 interaction	 (red	 spots)	 occurred	 predominantly	 towards	 the	 cellular	periphery	 of	 HeLa	 cervical	 (Figure	 5.3A)	 and	 MCF7	 breast	 (Figure	 5.3B)	 cells	 when	endogenous	phosphorylated	PBF	and	CTTN	were	co-expressed,	which	was	not	apparent	in	control	PLA	experiments.	In	addition,	we	could	not	detect	any	particular	interaction	between	total	PBF	using	our	‘total’	PBF	antibody	and	CTTN	(data	not	shown)	in	keeping	with	the	co-IP	results	(Figure	5.2).			
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MCF7	
Chapter	5	
129	
DAPI	 CTTN	 PBF	 MERGE	
DAPI	 CTTN	 PBF	 MERGE	
HeLa	
MCF7	
DAPI	 CTTN	 pPBF	 MERGE	
DAPI	 CTTN	 pPBF	 MERGE	
HeLa	
MCF7	
	
5.3.1.1.3	Immunofluorescence	Confocal	Microscopy		 The	 interaction	 between	 PBF	 and	 CTTN	 was	 also	 investigated	 through	immunofluorescence	 assays	 in	HeLa	and	MCF7	 cells.	These	 results	determined	where	CTTN	and	PBF	were	in	the	cells	and	where	co-localisation	occurred.	
	
Figure	 5.4:	 PBF	 and	 CTTN	 co-localise	 in	 vitro	 via	 immunofluorescence	 confocal	
microscopy.	Representative	confocal	 images	demonstrating	co-localisation	between	PBF	
A	
B	
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and	CTTN	(A)	or	Y174	phospho-PBF	and	CTTN	(B).	Representative	figures	showing	CTTN	
(green),	PBF	(red),	Y174	or	phospho-PBF	(red),	DAPI	(blue)	and	co-localisation	(yellow)	in	
HeLa	and	MCF7	cells.	Magnification	=	100X.	Scale	bars	=	20	μm.	
Immunofluorescence	microscopy	confirmed	co-localisation	between	endogenous	phosphorylated	PBF	and	CTTN	predominantly	at	 the	plasma	membrane	of	 cancer	cell	lines	in	vitro	(Figure	5.4B).		
	 	
5.3.1.2	Co-localisation	between	Exogenously	Overexpressed	PBF	and	CTTN	The	 experiments	 above	 revealed	 that	 endogenous	 phosphorylated	 PBF	 and	CTTN	 interact	 in	 vitro.	 However,	 due	 to	 the	 fact	 that	 our	 in-house	 PBF	 antibody	struggles	 to	 detect	 pY174	PBF	 (Smith	 et	 al.	 2009),	 it	was	 important	 to	 define	 the	 co-localisation	between	PBF	and	CTTN	more	thoroughly.	Exogenous	proteins	tagged	with	HA	 (PBF)	 and	Myc	 (CTTN)	were	 therefore	 utilised	 in	 additional	 immunofluorescence	microscopy	experiments.	
Immunofluorescence	 microscopy	 in	 HeLa	 and	 SW1736	 cells	 was	 used	 to	determine	subcellular	location	and	co-localisation	between	PBF-HA	and	CTTN-Myc.	The	cells	were	co-transfected	with	VO	control	or	HA	tagged	WT-PBF	and	Myc	tagged	CTTN	for	48	hours	as	described	in	section	2.1.3.	
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Figure	 5.5:	 Overexpressed	 WT-PBF	 co-localises	 with	 CTTN-Myc	 in	 vitro	 via	
immunofluorescence	 assays.	 Representative	 IF	 microscopy	 illustrating	 CTTN-Myc	
(mouse	anti-Myc	antibody,	green),	WT-PBF-HA	(rabbit	anti-HA	antibody,	red),	DAPI	(blue)	
and	co-localisation	(yellow)	in	HeLa	(A)	and	SW1736	(B)	cells.	Magnification	=	100X.	Scale	
bars	=	20	μm.	
	 Figure	5.5	 shows	 that	 cortactin	was	 located	 in	 intracellular	 vesicles	 and	 at	 the	plasma	 membrane,	 while	 PBF	 was	 mostly	 noticeable	 in	 late	 endosomes	 within	
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cytoplasm,	as	reported	previously	(Smith	et	al.	2009).	The	co-localisation	between	the	proteins	 in	 intracellular	 portions	 of	 both	 cell	 lines	 was	 also	 observed,	 with	 a	 small	amount	 apparent	 at	 the	 plasma	 membrane	 (Figure	 5.5).	 Together	 these	 IF	 results	indicate	that	overexpressed	CTTN,	as	well	as	endogenous	CTTN,	colocalises	with	PBF.		
	 5.3.2	Alteration	of	Cell	Invasion	with	Cortactin	Knockdown	
	 According	 to	 data	 published	 previously,	 either	 PBF	 or	 cortactin	 (CTTN)	 is	capable	of	enhancing	cellular	motility	and	cell	invasion	(Watkins	et	al.	2010,	MacGrath,	Koleske	2012,	Kirkbride	et	al.	2011,	Pollard,	Borisy	2003).	 Importantly,	CTTN	was	the	top	 hit	 for	 potential	 protein-binding	 partners	 of	 PBF	 identified	 through	 mass	spectrometry	 (Sharma	 2014).	 However,	 the	 precise	 mechanism	 how	 PBF	 and	 CTTN	interact	remains	obscure.	
	 Therefore,	 in	 this	 study,	 we	 investigated	 the	 capability	 of	 PBF	 to	 induce	 cell	invasion	 when	 CTTN	was	 depleted	 in	 a	 panel	 of	 cancer	 cell	 lines,	 including	 SW1736	thyroid,	 HCT116	 colon	 and	 MCF7	 breast	 cancer	 cells,	 using	 2D	 Boyden	 cell	 invasion	assays	(Figure	5.6).		
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Figure	5.6:	Depletion	of	CTTN	blocks	the	ability	of	PBF	to	induce	cellular	invasion.	A,	
representative	graph	shows	quantification	of	CTTN	protein	levels	relative	to	β-actin	from	
siRNA	 experiments	 in	 SW1736,	 HCT116	 and	 MCF7	 cells.	 B,	 C	 and	 D	 representative	
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quantification	 of	 number	 of	 invading	 cells	 per	 well	 from	 2D	 Boyden	 invasion	 assays	 in	
SW1736	(B),	HCT116	(C)	and	MCF7	(D)	cells	treated	with	specific	siRNAs	for	CTTN	(siRNA	
1	and	2)	or	control	siRNA	(CON)	for	24	hours,	and	then	transfected	with	VO	or	PBF-HA	in	
duplicate.	 Graphs	 represent	mean	 from	 two	 independent	 experiments,	while	 above	 inset	
shows	 representative	 photomicrographs	 of	 2D	 Boyden	 assay	 chamber	 cell	 invasion	
experiments.	Inset	-	Western	blots	of	CTTN	and	PBF	expression	for	each	cell	line	as	above	
in	response	to	siRNA	treatments.	PBF	bands	were	detected	with	a	mouse	monoclonal	anti-
HA	 antibody	 (1:1000),	 while	 CTTN	 bands	 were	 demonstrated	 with	 a	 monoclonal	 anti-
CTTN	antibody	(1:500)	compared	to	β-actin.	N=2.	
The	results	revealed	that	knockdown	of	CTTN	by	two	different	CTTN	siRNAs	was	associated	 with	 a	 significant	 reduction	 in	 the	 invasive	 capacity	 of	 SW1736	 (P<0.01),	HCT116	 (P<0.001)	 and	 MCF7	 cells	 (P<0.05)	 transfected	 with	 PBF	 (Figure	 5.6).	 Of	importance,	 the	 invasive	 capacity	 of	 CTTN-depleted	 cells	 transfected	 with	 PBF	 was	equivalent	 (P=NS)	or	 lower	(P<0.05)	 than	VO-control	cells	similarly	depleted	of	CTTN	(Figure	5.6).	Together	 these	 results	provide	evidence	 that	 the	potent	 induction	of	 cell	invasion	by	PBF	is	driven	in	its	entirety	via	CTTN.	
	5.3.3	Alteration	of	Cell	Invasion	and	Cell	Migration	due	to	C51R	and	R140W	PBF	Mutations	
5.3.3.1	Effects	of	Mutants	C51R	and	R140W	on	Cell	Invasion		Chapter	4	narrowed	down	the	PBF	substitutions	discovered	in	vivo	to	2	mutants,	C51R	and	R140W.	 In	 this	section,	having	better	defined	the	mechanism	by	which	PBF	and	CTTN	interact	in	the	process	of	cell	invasion,	the	impact	of	these	2	mutations	on	cell	
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invasion	was	examined	through	2-dimensional	cell	invasion	assays	in	TPC1	thyroid	and	MCF7	 breast	 cancer	 cells	 transfected	 with	 VO,	 WT-PBF,	 C51R	 and	 R140W	 mutants	(Figure	5.7).		
	 
	
	
	
	
		 	 	
	
	
	
	
	
	
	
Figure	5.7:	Invasive	properties	of	C51R	and	R140W	mutants.	Number	of	invading	cells	
per	well	from	2D	Boyden	invasion	assays	in	TPC1	(A)	and	MCF7	(B)	cells	transfected	with	
VO,	WT-PBF,	 C51R	 and	 R140W	mutants	 in	 duplicate.	 Graphs	 represent	mean	 from	 two	
independent	 experiments,	 with	 representative	 photomicrographs	 shown	 above.	 Inset	 -	
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Western	blots	demonstrate	PBF	expression	relative	to	β-actin	levels	to	assess	transfection.	
N=2.	
As	 in	Figure	5.6,	wild-type	PBF	was	markedly	pro-invasive	compared	 to	VO,	 in	TPC1	 and	 MCF7	 cells	 (Figure	 5.7).	 However,	 both	 C51R	 and	 R140W	 substitutions	entirely	 lost	 invasive	capacity,	and	 in	 fact	had	significantly	repressed	cellular	 invasion	compared	with	VO-control	cells	(Figure	5.7).	
	
5.3.3.2	Effects	of	Mutants	C51R	and	R140W	on	Cell	Migration		As	cell	invasion	is	related	to	and	encompasses	cell	migration,	cell	migration	was	examined	 to	 determine	 whether	 oncogenic	 PBF	 over-expression	 is	 pro-migratory.		Stable	murine	NIH3T3	 cells	 over-expressing	VO,	WT-PBF,	 C51R-PBF	 and	R140W-PBF	were	therefore	used	to	determine	the	effect	of	the	PBF	substitutions	on	cell	migration	via	 classical	 scratch	 wound	 assays.	 Construction	 of	 these	 stable	 cell	 lines	 over-expressing	 PBF	 (>20-fold	 increase	 in	 PBF	mRNA,	 data	 not	 shown)	was	 performed	 as	described	 in	 section	 2.13.	 The	 scratch	 wounds	 were	 created	 when	 the	 cells	 became	100%	confluent,	 and	 images	of	wound	recovery	were	 captured	at	0,	4,	6	and	8	hours	after	creating	the	wounds.	
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Figure	 5.8:	 Migratory	 properties	 of	 C51R	 and	 R140W	 mutants.	 A,	 representative	
classical	scratch	wound	assays	in	NIH	3T3	cells	stably	transfected	with	VO,	WT-PBF,	C51R	
and	R140W	substitutions	at	0,	4,	6	and	8	hours	after	creating	the	wounds.	B,	Calculated	
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percentages	of	wound	recovery	at	4,	6	and	8	hours.	Graph	represents	mean	±	SEM	from	
three	 independent	experiments.	 SEM	=	 standard	error	of	mean.	 Inset	–	Western	blotting	
analysis	 of	 PBF	 expression	 levels	 relative	 to	 β-actin	 levels	 in	 response	 to	 transfection.	
*P<0.05.	N=3.	
Figure	 5.8A	 and	5.8B	 show	 that	wild-type	PBF	had	 a	 significant	 pro-migratory	capacity	 compared	 to	VO	controls	at	all	4,	6	and	8	hours	 (P<0.05)	post	 recovery	 (Fig.	5.8).	 In	contrast,	mutant	C51R	failed	to	significantly	induced	wound	healing	compared	to	stable	VO	cells	 (Fig.	5.8),	although	mutant	R140W	appeared	closer	 to	retaining	WT	function	 in	 inducing	wound	 recovery	 than	 C51R	 (Fig.	 5.8).	 Therefore,	 2	mutations	 of	PBF	discovered	in	colon	cancer,	one	N-terminal	and	the	other	C-terminal,	both	lost	the	ability	 to	 induce	 cell	 invasion	 and	 also	 reduced	 capability	 to	 increase	 cell	 migration	compared	to	WT-PBF.	
	Altogether	these	results	demonstrate	in	thyroid,	breast,	colorectal	and	fibroblast	cells	that	oncogenic	expression	of	PBF	exhibits	a	broad	and	consistent	role	in	promoting	cell	invasion	and	migration,	but	the	mutants	C51R	and	R140W	lose	this	ability.	
	
5.3.3.3	In	Vitro	Binding	between	C51R	and	Cortactin		 PBF	specifically	interacts	and	co-localises	with	CTTN	in	vitro	in	three	cancer	cell	lines	 through	 co-IP,	 PLA	 and	 immunofluorescence,	 resulting	 in	 significantly	 induced	cellular	 invasion	and	migration	 (Fig.	5.2-5.7).	Further,	C51R	and	R140W	substitutions	show	 significantly	 reduced	 cellular	 invasion	 in	 both	 thyroid	 and	 breast	 cancer	 cells	(Figure	5.7),	and	lower	migratory	potential	compared	to	WT-PBF	(Figure	5.8).	However,	the	effect	of	these	substitutions,	C51R	and	R140W,	on	the	ability	of	PBF	to	interact	with	
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cortactin	remains	ill-defined	and	was	therefore	investigated.	However,	R140W	can	only	be	detected	via	FLAG	 tagging,	which	caused	 technical	 issues	 in	 initial	 co-IPs	 (data	not	shown).	 Consequently,	 it	was	 only	 possible	 to	 examine	 the	 interaction	between	C51R	and	CTTN.		
	 HeLa	 cells	 were	 transfected	 with	 VO,	WT-HA,	 C51R-HA	 and	 CTTN-Myc	 for	 48	hours	as	described	in	section	2.1.3,	before	performing	co-IP	assays.		
	
	
	
	
	
	
	
Figure	5.9:	C51R	substitution	increases	protein	binding	with	cortactin	compared	to	
wild-type	PBF.	A,	representative	co-IP	assay	illustrating	specific	interactions	(red	square)	
at	~25	kDa	between	CTTN-Myc	and	PBF-HA.	B,	quantification	of	protein	interaction	levels	
through	scanning	densitometry	relative	to	β-actin	from	three	independent	experiments	in	
HeLa	cells.	Data	presented	as	PBF	levels	±	SEM.	*P<0.05.	N=3.		
The	 co-IP	 results	 revealed	 that	 arginine	 substitution	 at	 the	 C51	 residue,	 C51R,	was	associated	with	a	greatly	 increased	binding	affinity	with	CTTN	compared	to	wild-type	PBF	(Fig.	5.9;	>6-fold;	P<0.05).		
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5.3.3.4	Subcellular	Localisation	of	C51R-PBF	and	Cortactin	To	 investigate	whether	 the	C51R	mutation	 impacts	on	 subcellular	 location	and	co-localisation	with	CTTN	further	immunofluorescence	studies	were	carried	out.	Again,	R140W	was	 difficult	 to	 investigate	 in	 this	 context	 due	 to	 our	 validated	HA	 and	 FLAG	antibodies	both	being	murine	in	origin,	and	mutant	R140W	being	difficult	to	detect	via	HA-tagging.	We	 therefore	 determined	 only	 C51R-HA	 compared	 to	WT-PBF-HA	 in	 this	study.	
	After	HeLa	cervical	and	SW1736	thyroid	cancer	cells	were	transfected	with	VO,	WT-HA,	 C51R-HA	 and	 CTTN-Myc	 for	 48	 hours,	 immunofluorescence	 assays	 were	performed	as	described	in	section	2.6.		
	
	
	
	
	
	
	
	
CTTN_Myc	 VO	 MERGE	
CTTN_Myc	 WT-HA	 MERGE	
CTTN_Myc	 C51R-HA	 MERGE	
A	 HeLa	
Chapter	5	
142	
Figure	 5.10:	 WT-PBF	 and	 mutant	 C51R	 co-localise	 with	 cortactin	 through	
immunofluorescence	 assays.	 Representative	 immunofluorescence	 images	 showing	 co-
localisation	(merge,	yellow)	between	CTTN-Myc	(mouse	anti-Myc,	green)	and	either	WT-
PBF-HA	 (rabbit	 anti-HA,	 red)	 or	 C51R-PBF-HA	 (rabbit	 anti-HA,	 red)	 in	 HeLa	 (A)	 and	
SW1736	(B)	cells.	Blue	indicates	DAPI	nuclear	staining.	Magnification	=	100X.	Scale	bars	=	
20	μm.	
IF	experiments	in	HeLa	and	SW1736	cells	demonstrated	that	CTTN	and	WT-PBF	were	 located	 in	 both	 the	 cytoplasm	 and	 the	 plasma	membrane	 (Figure	 5.10),	 whilst	C51R-PBF	 was	 mainly	 apparent	 in	 the	 endoplasmic	 reticulum	 (ER)	 (Figure	 5.10)	 as	illustrated	previously	 in	Figure	4.10.	 Interestingly,	when	HeLa	and	SW1736	cells	were	co-transfected	with	 C51R-PBF	 and	 CTTN,	 the	 location	 of	 CTTN	 seemed	 to	 shift	 away	
CTTN_Myc	 VO	 MERGE	
CTTN_Myc	 WT-HA	 MERGE	
CTTN_Myc	 C51R-HA	 MERGE	
B	 SW1736	
Chapter	5	
143	
from	the	plasma	membrane	to	be	more	apparent	in	the	intracellular	compartment,	and	co-localised	with	mutant	C51R	at	the	endoplasmic	reticulum	(Figure	5.10).		
Together,	 co-IP	 results	 suggest	 that	 C51R	 binds	 more	 strongly	 with	 cortactin	compared	to	WT-PBF,	and	although	not	quantified,	IF	suggested	that	over-expression	of	C51R	was	associated	with	CTTN	being	localised	less	intensely	at	the	plasma	membrane,	where	 CTTN	 it	 is	 functional.	 This	 apparent	 shift	 in	 CTTN	 localisation	 might	 be	hypothesised	 to	 underlie	 the	 reduced	 ability	 of	 C51R	 to	 induce	 cell	 invasion	 and	migration.	
	
5.4	Discussion	
Differentiated	 thyroid	 cancer	has	 a	5-year	 survival	 rate	of	97.7%,	but	 this	 falls	dramatically	to	54%	in	patients	with	distant	metastases	(http://seer.cancer.gov/).	The	statistics	 are	 equally	 unpromising	 in	 metastatic	 breast	 and	 colorectal	 cancer,	 where	patients	 have	 a	 5-year	 survival	 rate	 of	 just	 26%	 and	 13%,	 respectively	(http://seer.cancer.gov/).	In	general,	as	it	is	the	metastasis	that	ultimately	proves	fatal,	the	metastatic	 pathway	 requires	 continued	 investigation	 to	 establish	new	 therapeutic	targets.	The	movement	of	cells	within	the	metastatic	pathway	is	contingent	upon	CTTN,	which	 enables	 individual	 actin	 filaments	 to	 be	 assembled	 into	 branched	 structures	predominantly	 at	 the	 periphery	 of	 cells.	 However,	 the	 cellular	 actions	 of	 CTTN	 are	diverse	and	incompletely	understood,	especially	as	CTTN	binds	signalling,	cytoskeletal,	membrane	 phospholipids	 and	 trafficking	 proteins	 thereby	 linking	 them	 to	 dynamic	actin	networks	(Mattila,	Batista	&	Treanor	2016,	Kirkbride	et	al.	2011).		
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Through	 extensive	 mass	 spectrometry	 a	 previous	 study	 in	 the	 McCabe	 lab	identified	 CTTN	 as	 a	 potential	 binding	 partner	 of	 the	 proto-oncogene	 PBF.	 In	 this	Chapter,	 a	 clear	 interaction	 between	 PBF	 and	 CTTN	was	 demonstrated	 by	 co-IP	 and	PLA.	 PBF	 phosphorylation	 at	 Y174	 was	 of	 importance	 to	 this	 interaction,	 which	occurred	 mainly	 within	 or	 close	 to	 the	 PM,	 as	 revealed	 by	 PLA	 analysis	 and	immunofluorescent	assays.	However,	the	specific	binding	site	between	PBF	and	CTTN	is	not	established	in	this	thesis	and	should	be	therefore	investigated	through	a	GST	pull-down	assay	to	characterise	the	actual	domain	where	PBF	and	CTTN	interact.	Critically,	functional	 CTTN	 expression	 was	 needed	 in	 order	 for	 PBF	 to	 induce	 invasion.	 The	oncogenic	action	of	PBF	would	therefore	appear	to	be	contingent	upon	CTTN	function.		
Expression	 of	 PBF	 has	 been	 circumstantially	 associated	 with	 metastasis	 in	patients	with	breast	(Xiang	et	al.	2012)	and	thyroid	cancer	(Hsueh	et	al.	2013),	and	we	recently	reported	that	colorectal	cancer	patients	who	demonstrate	extramural	vascular	invasion	 have	 significantly	 higher	 PBF	 expression	 (Read	 et	 al.	 2016).	 However,	 these	associations	 have	 not	 been	 appraised	 for	 causality,	 and	 the	 in	 vitro	 mechanisms	 by	which	 PBF	 induces	 tumour	 cell	 invasion	 are	 unclear.	 For	 this	 section	 of	 work	 in	 the	thesis,	 established	 thyroid,	 breast	 and	 colorectal	 models	 were	 used	 to	 address	 the	mechanism	by	which	PBF	induces	cellular	invasion	and	migration.	A	robust	finding	was	that	 PBF	 consistently	 induced	 pro-migratory	 and	 pro-invasive	 phenotypes	 across	 a	panel	of	different	cell	 types	and	across	each	of	the	assays	used	(Figure	5.5-5.7).	These	results	therefore	imply	that	PBF	may	represent	a	novel	marker	of	the	ability	of	cells	to	escape	tumours	and	invade,	which	provides	further	insight	for	the	recent	identification	of	 PBF	 as	 a	 central	 driver	 gene	 in	 human	 cancers	 across	 multiple	 tumour	 types	including	thyroid	(Melloni	et	al.	2014).		
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Immunofluorescence	 (IF)	 assays	 in	 cervical	 HeLa	 and	 thyroid	 SW1736	 cells	demonstrated	that	CTTN	is	predominantly	expressed	within	intracellular	vesicles	and	at	the	 PM	 (Figure	 5.5).	 WT-PBF	 has	 previously	 been	 shown	 to	 be	 enriched	 within	 late	endosomes	(Smith	et	al.	2009).	In	both	HeLa	and	SW1736	cells,	PBF-HA	expression	was	mainly	 vesicular,	 and	 partially	 overlapped	with	 CTTN-Myc,	 although	 not	 consistently	within	 the	 same	 vesicular	 structures.	 However,	 co-localisation	 was	 pronounced	 at	discrete	 PM	 regions	 where	 CTTN-Myc	 expression	 was	 concentrated	 (Figure	 5.5).	Together	 these	 results	 indicate	 that	CTTN,	 as	well	 as	binding	 to	PBF,	 colocalises	with	PBF	predominately	at	the	PM.		
As	described	in	Chapter	4,	C51R	and	R140W	substitutions	provided	a	significant	alteration	in	both	subcellular	localisation	of	PBF	itself	and	cellular	proliferation.	In	this	Chapter	 the	 impact	 of	 these	 two	 mutations	 on	 cell	 invasion	 and	 migration	 was	determined	 in	 vitro.	 Mutants	 C51R	 and	 R140W	 lost	 invasive	 and	 migratory	characteristics	in	thyroid	and	breast	cancer	cells.	Co-IP	and	immunofluorescence	assays	demonstrated	that	when	PBF	was	predominantly	located	in	the	endoplasmic	reticulum	by	C51R	mutation,	the	invasive	capacity	of	TPC1	and	MCF7	cells	in	vitro	was	lost,	which	was	 accompanied	 by	 significantly	 increased	 PBF:CTTN	 binding	 through	 co-IP	experiments	(Fig.	5.9),	and	enhanced	co-localisation	between	the	2	proteins	 in	 the	ER	via	 IF	 microscopy	 (Fig.	 5.10).	 A	 possible	 explanation	 is	 that	 C51R-PBF	 sequestered	CTTN	 activity	 by	 pulling	 it	 away	 from	 its	 canonical	 site	 of	 action	 at	 the	 PM	 or	 by	blocking	critical	interactions	with	one	or	more	recognised	CTTN	binding	partners	such	as	Src	(Sarcoma)	and	NCK1	(non-catalytic	region	of	tyrosine	kinase	adaptor	protein	1)	(Kirkbride	 et	 al.	 2011).	 Unfortunately,	 the	 precise	 mechanism	 of	 how	 the	 R140W	mutant	 abrogates	 cellular	 invasion	 and	migration	 compared	 to	WT-PBF	 could	 not	 be	
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investigated	 due	 to	 detection	 problems	 via	 HA-tagging	 of	 this	 plasmid.	 The	 Biacore	system	 represents	 another	 method	 to	 gain	 further	 insights	 into	 potential	 protein-protein	interactions	using	purified	recombinant	proteins,	including	WT-PBF,	C51R-PBF,	R140W-PBF	 and	 CTTN.	 In	 these	 experiments,	 a	 sensor	 chip	 surface	 would	 first	 be	labelled	 with	 CTTN	 and	 potential	 protein	 binding	 partners	 such	 as	WT-PBF	 injected	across	 the	 surface	based	on	 surface	plasmon	 resonance	 (SPR)	 technique.	This	 system	would	help	to	identify	specific	binding	between	two	proteins	by	determining	the	affinity	of	 their	 interaction	 (Kd/Ka	 values)	 in	 real	 time	 without	 the	 need	 for	 labelling.	Assessment	 of	 the	 affinity	 of	 interaction	 between	 CTTN	 and	 PBF,	 as	 well	 as	 PBF	mutants,	would	therefore	help	to	validate	the	results	of	co-IP	and	PLA	assays	performed	in	this	thesis.	
To	conclude,	the	proto-oncogene	PBF	is	a	novel	interacting	partner	of	the	F-actin	binding	protein	CTTN,	which	regulates	the	actin-nucleating	Arp2/3	complex	(Weaver	et	al.	2001).	PBF	potently	and	consistently	 induces	 cell	 invasion	and	migration,	which	 is	dependent	upon	the	presence	of	functional	CTTN.	As	PBF	and	CTTN	are	both	induced	in	multiple	 tumour	 types,	 it	 is	 possible	 that	 PBF	 specifically	 interacts	 with	 CTTN	 to	increase	 invasion	and	metastasis.	Hypothetically,	when	CTTN	 is	pulled	away	 from	the	PM	 via	 PBF	 mutation,	 cell	 motility,	 invasion	 and	 metastatic	 mechanisms	 may	 be	inhibited.	Hence,	therapeutic	strategies	to	manipulate	the	interaction	between	PBF	and	CTTN	 by	 direct	 or	 indirect	 routes	 might	 represent	 promising	 new	 avenues	 in	 the	treatment	of	tumour	metastasis.	
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6.1	Introduction	
PBF	 is	 a	 ubiquitously	 expressed	 glycoprotein	 that	 is	 induced	 in	 multiple	endocrine	 neoplasias	 including	 pituitary	 and	 thyroid	 (McCabe	 et	 al.	 2003,	 Smith,	Franklyn	&	McCabe	2011,	Smith,	Franklyn	&	McCabe	2010).	PBF	is	also	associated	with	decreased	specific	survival	and	increased	early	recurrence	and	distant	metastasis	at	the	time	 of	 diagnosis	 in	 papillary	 thyroid	 cancer	 (Hsueh	 et	 al.	 2013),	 while	 colon	 cancer	having	 extramural	 invasion	 has	 higher	 PBF	 expression	 (Read	 et	 al.	 2016).	 PBF	 is	associated	 with	 vesicular	 trafficking,	 and	 interacts	 with	 multiple	 transport	 proteins	such	 as	 MCT8	 (Monocarboxylate	 transporter	 8),	 modulating	 thyroid	 hormone	 action	(Smith	et	al.	2013),	NIS,	modulating	radioiodine	uptake	in	thyroid	cells	(Smith,	Franklyn	&	McCabe	2011,	Smith	et	al.	2009),	and	p53,	 impacting	 its	stability	and	ubiquitination	(Read	et	al.	2016,	Read	et	al.	2014).	Extensive	mass	spectrometry	from	our	group	also	showed	 that	 cortactin	was	 a	 potential	 binding	 partner	 of	 PBF.	Moreover,	 we	 already	revealed	in	the	previous	Chapter	5	that	overexpressed	PBF	significantly	induced	cellular	invasion	and	cell	migration	 in	a	panel	of	cell	 lines,	 including	thyroid,	colon	and	breast	cancer	cells,	via	a	mechanism	dependent	upon	the	presence	and	subcellular	localisation	of	cortactin.	The	C51R	substitution	increased	binding	affinity	with	CTTN	predominantly	within	 the	 endoplasmic	 reticulum,	 resulting	 in	 significantly	 reduced	 cellular	 invasion	and	cell	migration.	
Cortactin	 (CTTN)	 is	 a	 cytoskeleton	 protein	 that	 enhances	 actin	 polymerization	and	 prohibits	 debranching	 of	 actin	 networks	 (Weaver	 et	 al.	 2001),	 resulting	 in	 the	promotion	of	cell	motility	and	cellular	invasion	in	a	variety	of	cancer	cells	such	as	breast	and	head	and	neck	squamous	cell	carcinoma	(HNSCC)	(Spring	et	al.	2015,	Fantozzi	et	al.	2008).	CTTN	is	also	upregulated	in	a	panel	of	human	malignant	tumours	such	as	colon	
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cancer,	oral	squamous	cell	carcinoma	(SCC)	and	esophageal	cancer	(Cai	et	al.	2010,	Ni	et	al.	2015,	Yamada	et	al.	2010,	Lu	et	al.	2014).	For	example,	Ni	et	al.	reported	upregulation	of	CTTN	expression	in	colon	cancer	compared	to	normal	tissue,	and	that	overexpression	was	 associated	with	 tumour	 size,	 staging,	 lymphatic	 invasion	 and	prognosis	 (Ni	 et	 al.	2015).	 In	oral	SCC,	cortactin	overexpression	was	 found	more	commonly	 in	high	grade	and	aggressive	carcinomas	(Yamada	et	al.	2010).	Xu	et	al.	also	 found	that	 there	was	a	significant	 increase	 in	CTTN	expression	 levels	 in	melanoma	compared	to	normal	nevi,	with	higher	expression	levels	in	metastatic	compared	to	non-metastatic	cancers	(Xu	et	al.	 2010).	 They	 also	 revealed	 that	 high	 CTTN	 levels	 were	 associated	 with	 poorer	disease-specific	 survival	 compared	 to	 those	who	 had	 low	 CTTN	 expression	 (Xu	 et	 al.	2010).	Although	there	is	a	range	of	evidence	addressing	the	influence	of	CTTN	on	cancer	outcome,	 no	 studies	 to	 date	 have	 investigated	 CTTN	 expression	 in	well-differentiated	thyroid	cancer.		
In	 this	 Chapter,	we	 therefore	 determined	 PBF	 and	 CTTN	 expression,	 including	mRNA	 and	 protein	 levels,	 in	 differentiated	 thyroid	 cancer,	 and	 also	 investigated	 the	correlations	between	the	expression	levels	of	these	2	genes	in	ex	vivo	human	samples.		
	
6.2	Materials	and	Methods	6.2.1	Protein	Homogenisation	and	Quantification	
After	weighing	normal	and	tumourous	thyroid	cancer	samples	(obtained	via	local	ethical	approval;	LREC	05/Q2704/43),	protein	homogenisation,	protein	extraction	and	Bicinchoninic	Acid	(BCA)	assays	were	performed	as	described	in	section	2.2	and	section	2.3	to	quantify	and	prepare	the	samples	for	Western	blotting.		
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	 6.2.2	Western	Blotting	
Western	blotting	in	this	study	was	applied	to	quantify	protein	levels	of	cortactin	in	human	thyroid	samples.	The	procedure	was	carried	out	as	described	in	Section	2.5.	The	primary	antibodies	used	in	this	chapter	were	mouse	monoclonal	anti-CTTN	(1:500,	Merck	 and	 Millipore,	 Germany)	 and	 mouse	 monoclonal	 anti-β-actin	 AC-15	 (1:10000,	Sigma,	USA).	
	 6.2.3	Ribonucleic	Acid	(RNA)	Extraction	of	Formalin-fixed,	Paraffin-embedded	(FFPE)	Samples	
After	determining	areas	of	normal	and	cancerous	lesions	of	human	thyroid	FFPE	samples	under	the	microscope,	samples	were	scraped	using	a	sterile	scalpel,	transferred	to	a	1.5	ml	Eppendorf,	and	then	kept	on	 ice.	Changing	blades	and	leaving	a	small	area	between	normal	and	cancer	tissue	were	vital	 to	prevent	cross-contamination	between	the	 samples.	 RNA	was	 next	 extracted	 from	 the	 FFPE	 samples	 using	 RNeasy	 FFPE	 kit	(Qiagen,	USA)	 following	 the	manufacturer’s	 instructions.	Firstly,	paraffin	coated	 tissue	was	removed	by	adding	160	μl	Deparaffinization	Solution	(Qiagen,	USA)	to	each	sample,	vortexing	vigorously	for	10	seconds,	and	centrifuging	briefly	to	let	the	sample	fall	to	the	bottom	of	the	Eppendorf.		After	the	sample	was	incubated	at	56°C	for	3	minutes	and	left	to	 cool	 at	 room	 temperature,	 150	 μl	 Buffer	 PKD	 or	 proteinase	 K	 digestion	 buffer	(Qiagen,	 USA),	 an	 optimized	 lysis	 buffer	 containing	 proteinase	 K	 that	 was	 used	 to	release	RNA	from	the	sections,	were	added	and	mixed	by	vortex.	The	sample	was	then	centrifuged	at	10,000	rpm	for	1	min,	before	10	μl	proteinase	K	were	added	to	the	clear	
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lower	 phase	 of	 the	 tube	 and	 mixed	 by	 pipetting	 up	 and	 down.	 Next,	 the	 RNA	 was	incubated	 at	 56°C	 for	 15	 minutes,	 then	 at	 80°C	 for	 the	 next	 15	 minutes.	 The	 clear	content	was	transferred	to	a	new	Eppendorf	and	incubated	on	ice	for	3	minutes,	before	being	centrifuged	at	13,500	rpm	for	15	minutes.	The	supernatant	was	next	transferred	to	a	new	microcentrifuge	tube,	and	16	μl	of	DNase	Booster	Buffer	(Qiagen,	USA)	were	added,	before	being	mixed	gently	by	 inverting	 the	Eppendorf	and	centrifuging	briefly.	After	 the	RNA	was	 incubated	at	 room	 temperature	 for	15	min,	 320	μl	Red	Blood	Cell	lysis	solution	(Qiagen,	USA)	was	mixed	thoroughly	to	optimise	binding	conditions.	720	μl	100%	ethanol	were	applied	to	the	sample,	and	mixed	by	pipetting,	before	the	content	was	 transferred	 to	 an	 RNeasy	MinElute	 spin	 column	 placed	 in	 a	 2	ml	 collection	 tube	(supplied	 in	 the	kit).	The	 tube	was	centrifuged	at	10,000	rpm	for	15	seconds,	and	the	flow-through	was	 discarded.	 500	 μl	 Buffer	 RPE	were	 added	 to	 the	 spin	 column,	 and	centrifuged	at	10,000	rpm	for	15	seconds,	before	discarding	the	flow-through.	Another	500	μl	of	Buffer	RPE	were	placed	into	the	spin	column,	and	the	tube	was	centrifuged	at	10,000	rpm	for	2	minutes	to	wash	the	column	membrane.	The	old	collection	tube	and	the	flow-through	were	discarded,	and	the	spin	column	was	placed	into	a	new	collection	tube,	before	being	centrifuged	with	the	lid	open	at	full	speed	for	5	minutes	to	get	rid	of	all	 residual	 ethanol.	 After	 the	 RNeasy	MinElute	 spin	 column	was	 inserted	 into	 a	 new	sterile	 collection	 tube,	 14	 μl	RNase-free	water	were	 added	directly	 to	 the	membrane,	and	centrifuged	at	full	speed	for	1	minute	to	elute	the	RNA.	The	concentration	of	RNA	samples	were	quantified	using	the	NanoDrop	Spectrometer	(NanoDrop	Products,	USA)	and	the	extracted	RNA	products	were	stored	at	-80°C.		
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6.2.4	One	Step	Reverse	Transcription	and	Quantitative	Real-time	Polymerase	Chain	Reaction	(One	Step	RT-PCR)	
The	 one	 step	 RT-PCR	 assay	 is	 a	 technique	 allowing	 the	 process	 of	 reverse	transcription	 and	 polymerase	 chain	 reaction	 to	 occur	 sequentially	 in	 the	 same	 tube	using	 any	 RNA	 samples.	 The	 one	 step	 RT-PCR	 kit	 (Qiagen,	 UK)	 provides	 specific	enzymes,	 including	 Sensiscript	 and	 Omniscript	 reverse	 transcriptases,	 having	 high	affinity	 for	 RNA	 samples,	 and	 HotStarTaq	 DNA	 polymerase,	 yielding	 specific	 PCR	amplification	 by	 stopping	 extension	 of	 nonspecific	 annealed	 primers	when	 PCR	 cycle	starts.	
In	 this	 Chapter,	 the	mRNA	 expression	 of	 genes	 including	 PBF	 and	 cortactin	 in	matched	normal	and	thyroid	cancer	samples	was	determined	by	using	one	step	RT-PCR	(Qiagen,	UK)	following	the	manufacturer’s	instructions,	and	compared	with	the	internal	controls	 PPIA	 (peptidylprolyl	 isomerase	A	 (cyclophilin	A))	 and	HPRT1	 (hypoxanthine	gaunine	phosphoribosyltransferase	1).	The	TaqMan	probes	(Life	technologies,	UK)	were	oligonucleotides	 consisting	 of	 a	 5’fluorophore,	 VIC	 for	 HPRT1	 and	 FAM	 (6-carboxy-fluoresciein)	 for	 other	 genes,	 and	 a	 3’quencher,	 which	 was	 TAMRA	 (6-carboxy-tetramethyl-rhodamine).	Each	sample	consisted	of	20	ng	of	RNA	combined	with	1	µl	of	each	TaqMan	gene	set,	10	µl	of	2x	QuantiTect	Probe	RT-PCR	Master	Mix	(Qiagen,	UK),	0.2	µl	of	QuantiTect	RT	Mix	(Qiagen,	UK)	and	6.8	µl	of	nuclease	free	water	in	a	96-well	plate.	Polymerase	chain	reaction	(PCR)	was	performed	to	evaluate	the	cycle	threshold	(Ct)	 values	 using	 the	 ABI	 prism	 7500	 real-time	 PCR	 system.	 There	 were	 two	 steps	consisting	of	reverse	transcription	and	PCR	cycles	as	follows:	50°C	for	30	minutes;	95°C	for	15	minutes;	45	cycles	of	94°C	for	15	seconds	and	60°C	for	60	seconds.	Comparative	cycle	 threshold	 (ΔCt)	 values	were	 obtained	 from	 the	 Ct	 value	 of	 the	 gene	 of	 interest	
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deducted	from	the	Ct	value	of	internal	controls,	and	then	A	ΔΔCt	value	was	calculated,	and	 used	 to	 ascertain	 a	 fold	 change	 to	 determine	 relative	mRNA	 expression	with	 an	equation:	2-(ΔCt	of	an	experimental	group	–	ΔCT	of	a	control	group)	or	2-ΔΔCt.	
	 6.2.5	Statistical	Analysis	
In	 this	 Chapter,	 Spearman's	 rank	 correlation	 coefficient	was	 used	 to	 study	 the	significance	of	 the	association	between	PBF	and	cortactin	gene	expression	datasets.	 If	two	variables	show	the	same	tend,	the	coefficient	or	rho	(r)	is	positive.	However,	if	two	variables	 have	 an	 inverse	 trend,	 the	 rho	 is	 negative.	When	 two	 parameters	 correlate	perfectly,	 the	rho	is	closer	to	1	or	-1.	A	correlation	of	zero	(0)	 implies	that	there	 is	no	association	 between	 them	 (http://www.biostathandbook.com/spearman.html).	 The	non-parametric	 Kruskal-Wallis	 test	 was	 also	 used	 to	 compare	 statistical	 differences	between	median	values	in	non-matched	samples.	
		
6.3	Results	6.3.1	mRNA	Expression	Levels	of	Pituitary	Tumor	Transforming	Gene	1	-	Binding	Factor	(PBF)	and	Cortactin	in	Normal	and	Matched	Human	Thyroid	Cancer	Samples		
	 PBF	 expression	 has	 been	 documented	 in	 multiple	 tumours	 such	 as	 pituitary,	breast,	 colon	 and	 thyroid	 (McCabe	 et	 al.	 2003,	Watkins	 et	 al.	 2010,	 Read	 et	 al.	 2016,	Smith,	Franklyn	&	McCabe	2010,	Smith,	Franklyn	&	McCabe	2011).	Cortactin	expression	has	also	been	investigated	in	a	variety	of	human	cancers,	but	has	not	been	addressed	in	
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well-differentiated	thyroid	cancer	(DTC).	In	this	study,	we	determined	the	mRNA	levels	of	 PBF	 and	 CTTN	 expression	 in	 a	 series	 of	 N=43	 matched	 tumour	 and	 normal	 DTC	formalin-fixed,	paraffin-embedded	(FFPE)	specimens	through	one	step	RT-PCR.			
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Figure	 6.1:	 CTTN	 is	 over-expressed	 in	 thyroid	 cancer,	 especially	 in	 metastatic	
disease.	A,	quantification	of	fold	change	of	CTTN	and	PBF	expressions	in	thyroid	tumours	
relative	 to	 matched	 normal	 tissue	 (N=43).	 Red	 dashed	 line	 represents	 a	 relative	 fold	
change	=	1.0.	The	value	above	the	red	dashed	line	(1)	illustrates	overexpression	of	CTTN	or	
PBF	 in	 a	 thyroid	 cancer	 compared	 to	matched	normal	 tissue.	B	and	C,	 quantification	of	
fold	change	of	RNA	expressions	of	CTTN	(B)	and	PBF	(C)	comparing	between	cancers	and	
matched	normal	thyroid	samples	(N=43).	Black	lines	show	mean	fold	change	of	CTTN	(B)	
and	PBF	(C)	RNA	expressions	in	each	group.	D,	quantification	of	fold	change	of	CTTN	and	
PBF	 RNA	 expressions	 in	 thyroid	 cancers	 relative	 to	 matched	 normal	 tissue	 in	 non	
metastatic	group	(AnyT,	N0,	M0),	N=23.	E,	quantification	of	fold	change	of	CTTN	and	PBF	
RNA	 expressions	 in	 thyroid	 cancers	 relative	 to	matched	 normal	 tissue	 in	 the	metastatic	
group	 (AnyT,	 N1,	 AnyM),	 N=20.	 Results	 are	 mean	 ±	 SEM	 for	 B,	 C,	 D	 and	 E.	 *P<0.05	
(Student’s	t-test).		
The	 results	 revealed	 CTTN	 RNA	 expression	 was	 variable,	 but	 showed	 a	significant	 approximately	 1.5-fold	 induction	 overall	 in	 N=43	 tumours	 compared	with	matched	 normal	 thyroid	 tissue	 (Fig.	 6.1A	 and	 6.1B).	 In	 contrast	 to	 previous	 studies	(Stratford	et	al.	2005)	PBF	RNA	expression	did	not	differ	between	tumours	compared	to	
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matched	 normal	 thyroid	 tissue	 (Fig	 6.1A	 and	 6.1C).	 Indeed,	 in	 Stratford	 et	 al.	 2005,	there	was	 a	 3-fold	 increase	 in	 PBF	 expression	 in	 thyroid	 cancer	 compared	 to	 normal	tissue,	 and	 they	 used	 the	 tissue	 of	 contralateral	 lobe	 of	 thyroid	 glands	 to	 be	 normal	samples	(Stratford	et	al.	2005).	 In	contrast,	 the	matched	normal	tissue	 in	this	Chapter	came	 from	 the	 normal	 area	 within	 the	 same	 FFPE	 slides	 having	 tumour,	 probably	having	higher	tendency	to	contain	non	cancerous	abnormality	such	as	hyperplasia	and	resulting	in	more	similar	levels	of	PBF	expression	in	both	tumour	and	normal	samples.	A	further	consideration	is	that	PBF	expression	is	reported	to	be	highly	elevated	in	more	aggressive	and	recurrent	thyroid	disease.	In	this	study,	a	broad	range	of	thyroid	cancers	with	different	TNM	staging	was	used	from	T1	to	T3,	and	the	majority	of	samples	were	non-metastatic	(N0).	In	contrast,	the	majority	of	samples	used	in	the	study	by	Stratford	et	al	2005	were	from	more	aggressive	cancers	(i.e	TNM	staging	of	T3	and	N1).	Hence,	differences	 in	 the	 size	 and	 aggressiveness	 of	 thyroid	 tumours	 examined	 in	my	 study	may	have	accounted	for	the	disparate	result.	
When	we	classified	patients	into	2	groups,	non-metastatic	and	nodal	metastatic	disease	 (Fig	 6.1D	 and	 6.1E),	 only	 the	 metastatic	 group	 had	 significant	 CTTN	overexpression	 in	 tumours	 compared	 to	 normal	 tissue	 (Fig.	 6.1E;	 P<0.05).	 However,	PBF	expression	did	not	differ	in	either	classification	(Fig	6.1D	and	6.1E).	
	6.3.2	Correlation	of	Genes	of	Interest		
We	 first	 next	 determined	 the	 association	 between	 CTTN	 and	 PBF	 gene	expression	in	human	well-differentiated	thyroid	cancer	(N=43).		
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Figure	 6.2:	 CTTN	 is	 correlated	 with	 PBF	 in	 thyroid	 cancer.	 Scatterplot	 showing	
relationship	between	CTTN	and	PBF	gene	expression	 in	normal	thyroid	tissue	(A)	and	 in	
human	well-differentiated	thyroid	cancer	(B).	Data	represented	as	ΔCt	values	of	CTTN	and	
PBF	 expressions,	 and	 a	 correlation	 was	 determined	 via	 Spearman’s	 rank	 correlation.	
N=43.		
The	 result	using	 the	Spearman's	 rank	correlation	 coefficient	 analysis	 showed	a	positive	and	significant	correlation	expression	between	CTTN	and	PBF	genes	in	human	DTC	 (P=0.014;	 rs=0.373;	 N=43)	 (Figure	 6.2B),	 while	 there	 was	 no	 any	 association	between	two	genes	in	normal	thyroid	tissue	(P=0.0546;	rs=-0.295;	N=43)	(Figure	6.2A).	
	6.3.3	Protein	Expression	Levels	of	Cortactin	in	Normal	and	Human	Thyroid	Cancer	Samples	
	 We	next	determined	the	protein	expression	levels	of	cortactin	comparing	human	thyroid	 cancer	 and	 normal	 thyroid	 samples	 through	 Western	 blotting	 analysis.	 The	protein	samples	were	extracted	from	fresh	thyroid	tissues	of	a	further	9	patients	which	did	not	belong	to	the	43	FFPE	samples	used	in	section	6.3.1	and	6.3.2.	
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Figure	6.3:	CTTN	protein	 is	over-expressed	 in	 thyroid	 cancer,	determined	 through	
Western	blotting.	A,	detection	of	CTTN	expression	by	Western	blotting	in	thyroid	tumours	
(C1-9)	and	normal	tissue	(N1-3),	with	quantification	of	relative	protein	levels	shown	in	B.	
*P<0.05	(Student’s	t-test).		
CTTN	 expression	 was	 also	 increased	 in	 a	 small	 additional	 series	 of	 DTC	specimens	 by	Western	 blotting	 (Figure	 6.3A).	 Again,	 CTTN	 expression	 was	 relatively	variable,	but	scanning	densitometry	revealed	a	statistically	significant	~3-fold	induction	in	CTTN	protein	level	in	tumours	compared	to	normal	thyroid	(Figure	6.3B).	
	6.3.4	Correlation	between	PBF	and	CTTN	in	Human	Thyroid	Cancers	from	the	TCGA	Database	
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We	 further	 evaluated	 mRNA	 levels	 of	 CTTN	 and	 PBF	 expression	 and	 their	correlation	in	well-differentiated	thyroid	cancer	as	detected	by	RNA-seq,	from	the	TCGA	database,	 in	 which	 gene	 expression	 data	 for	 a	 large	 number	 of	 thyroid	 tumours	(N=326),	with	complete	clinical	annotation,	are	available.		
For	 TCGA	 database,	 the	 normalized	 gene	 expression	 data	 generated	 using	 the	Illuminia	 RNA-seq	 platform	 and	 the	 clinical	 information	 from	 the	 cBioPortal	 were	downloaded.	Gene	expression	values	based	on	RNA-seq	data	were	transformed	as	X	=	log2(X+1)	 where	 X	 represents	 the	 normalized	 fragments	 per	 kilobase	 transcript	 per	million	 mapped	 reads	 (FPKM)	 values	 retrieved	 from	 the	 TCGA	 dataset.	 For	 matched	normal	(N)	and	tumour	(C)	pairs	relative	fold-changes	(FC)	were	transformed	as	log2FC	=	log2(C)	–	log2(N)	where	C	and	N	represent	normalized	FPKM	values.	
The	error	bars	for	the	RNAseq	data	based	on	log2	FPKM	values	would	be	wide	as	they	 were	 plotted	 on	 a	 box-whisper	 plot	 in	 which	 the	 error	 bars	 show	 the	 full	distribution	 of	 the	 data	 (i.e.	 from	 the	 third	 quartile	 to	 the	maximum	 value),	 and	 the	median	value	is	shown	instead	on	the	mean	value	in	the	qPCR	data.	The	non-parametric	Kruskal-Wallis	 test	 however	 clearly	 showed	 a	 significant	 difference	 between	 datasets	which	is	indicative	of	a	difference	in	median	values	as	well	as	in	the	overall	distribution	of	the	data.	
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Figure	6.4:	CTTN	is	upregulated	in	thyroid	cancer	and	associated	with	PBF	via	the	
TCGA	data.	A,	CTTN	and	PBF	gene	expression	levels	are	increased	in	non-metastatic	(N0;	
N=121)	and	metastatic	 (N1,	N=205)	 thyroid	 cancer	 versus	normal	 thyroid	 (N=59).	Data	
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represented	 in	 box	 plots.	 ***P<0.001	 (Kruskal-Wallis	 test).	 B,	 scatterplots	 showing	
correlation	between	CTTN	and	PBF	gene	expression	in	normal	and	DTC	samples.	P=0.014;	
rs=0.317;	N=59	for	normal	tissue	and	P=4.7	x	10-8;	rs=0.299;	N=326	for	thyroid	cancer.	C,	
scatterplot	illustrating	correlation	in	the	fold-change	in	relative	gene	expression	between	
CTTN	and	PBF	in	matched	cancer	and	normal	pairs	(shown	as	log2	values).	P=2.74	x	10-6;	
rs=0.564;	N=59.	Data	analysed	by	Spearman’s	rank	correlation	in	B	and	C.	Consistent	with	our	initial	observations	in	section	6.3.1,	6.3.2	and	6.3.3,	we	also	found	 a	 significant	 increase	 in	 CTTN	 mRNA	 expression	 (Fig.	 6.4A)	 in	 both	 non-metastatic	 (N0;	 P=5.6	 x	 10-17;	 N=121)	 and	 nodal	 metastatic	 DTC	 (N1;	 P=7.5	 x	 10-27;	N=205)	compared	to	normal	thyroid	tissue	(N=59).	Moreover,	PBF	expression	from	the	TCGA	 database	 (Fig.	 6.4A)	 was	 induced	 in	 both	 non-metastatic	 (N0;	 P=1.0	 x	 10-7;	N=121)	and	nodal	metastatic	DTC	(N1;	P=8.5	x	10-13;	N=205),	in	contrast	to	PBF	mRNA	expression	 being	 similar	 in	 our	 own	 samples	 of	 normal	 and	 tumourous	 tissue.	Importantly,	 we	 again	 found	 a	 strong	 correlation	 between	 CTTN	 and	 PBF	 gene	expression	 in	both	normal	and	DTC	(Figure	6.4B;	P=0.014;	rs=0.317;	N=59	 for	normal	thyroid	 and	 P=4.7	 x	 10-8;	 rs=0.299;	 N=326	 for	 cancer).	 Examination	 of	 relative	 fold-changes	in	CTTN	and	PBF	expression	using	matched	tumour	and	normal	samples	(N	=	59)	 in	 the	 TCGA	 dataset	 also	 showed	 a	 strong	 correlation	 (Fig.	 6.4C;	 P=2.74	 x	 10-6,	
rs=0.564).	
Together	 our	 results	 demonstrated	 that	 even	 being	 quite	 variable,	 CTTN	 was	noticeably	 over-expressed	 in	well-differentiated	 thyroid	 cancer,	 especially	 in	 patients	carrying	metastasis,	and	also	significantly	correlated	with	PBF	expression.	Of	particular	significance,	 CTTN	 gene	 expression	 (Figure	 6.4A)	 was	 higher	 in	 invasive	 nodal	metastatic	DTC	(N1;	P=3.6	x	10-5)	than	in	non-metastatic	DTC	(N0).	 In	addition,	 in	the	
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larger	TCGA	dataset	PBF	was	up-regulated	in	thyroid	cancer	compared	to	normal	tissue,	although	 there	 was	 no	 PBF	 induction	 when	 comparing	 nodal	 metastatic	 and	 non-metastatic	thyroid	cancer	(Figure	6.4A).	
	
6.4	Discussion	
CTTN	expression	has	not	been	determined	before	in	human	thyroid	tumours.	In	this	 study	 analysis	 of	 human	 DTC	 specimens	 revealed	 that	 CTTN	 expression,	 whilst	variable,	 was	 elevated	 in	 approximately	 two	 thirds	 of	 tumours,	 with	 an	 overall	induction	 of	 around	 1.5-fold	 at	 the	 mRNA	 level	 and	 2.5-fold	 at	 the	 protein	 level.	Importantly,	analysis	of	a	much	larger	clinically	annotated	genomic	dataset	(TCGA)	for	DTC	confirmed	that	CTTN	was	significantly	increased	in	DTC,	especially	in	cases	where	regional	 lymph	 node	 metastasis	 (N1)	 was	 present.	 A	 significant	 positive	 association	between	PBF	and	CTTN	mRNA	expression	was	also	evident	in	DTC	specimens	from	our	group,	 as	 well	 as	 in	 the	 TCGA	 dataset.	 This	 would	 not	 likely	 result	 from	 direct	transcriptional	 regulation	via	 either	binding	partner	 as	 recent	 in	 vitro	 experiments	 in	our	laboratory	have	shown	that	neither	CTTN	nor	PBF	were	capable	of	upregulating	the	other	(Watkins	et	al.	2016,	Manuscript	under	revision).	Previously,	amplification	of	the	gene	 that	 encodes	 CTTN	 has	 been	 reported	 in	 ~15%	 of	 primary	 metastatic	 breast	carcinomas	and	~30%	of	head	and	neck	squamous	cell	carcinomas	(Buday,	Downward	2007).	Thus	the	apparent	 induction	of	CTTN	in	DTC	may	be	via	gene	amplification,	or	other	 gene	 regulatory	 mechanisms.	 Notwithstanding	 this,	 CTTN	 over-expression	 has	been	 extensively	 linked	 to	 invasive	 cancers,	 including	 glioblastoma,	 melanoma	 and	colorectal	cancer	(Kirkbride	et	al.	2011,	Xu	et	al.	2010,	Hirakawa,	Shibata	&	Nakayama	2009).		
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PBF	 is	 upregulated	 in	 multiple	 types	 of	 human	 cancer,	 especially	 endocrine	neoplasias,	and	has	been	associated	with	poor	prognosis	(McCabe	et	al.	2003,	Watkins	et	al.	2010,	Read	et	al.	2016,	Smith,	Franklyn	&	McCabe	2010,	Smith,	Franklyn	&	McCabe	2011).	In	this	Chapter,	the	analysis	of	differentiated	thyroid	cancer	in	the	TCGA	dataset	illustrated	 DTC	 harboured	 a	 significant	 increase	 in	 PBF	 mRNA	 expression	 levels	compared	 to	 normal	 samples,	 although	 the	 mean	 levels	 were	 similar	 in	 both	 non-metastatic	 and	 nodal	 metastatic	 groups.	 In	 our	 smaller	 series	 (N=43)	 there	 was	 no	difference	 in	 PBF	 mRNA	 expression	 comparing	 cancer	 and	 matched	 normal	 thyroid	tissue.	This	may	in	part	reflect	the	problem	of	how	to	define	normal	thyroid	tissue	on	FFPE	 slides.	 Our	 samples	 for	 the	 normal	 category	 included	 either	 an	 area	 with	 no	grossly	 abnormal	 histopathology,	 or	 an	 area	 having	 hyperplastic	 or	 macrofollicular	structure.	 Importantly,	Read	et	 al.	 showed	 that	human	multinodular	 goitre	or	 thyroid	tissue	 demonstrating	 hyperplastic	 or	 macrofollicular	 structure	 had	 higher	 PBF	expression	 compared	 to	 normal	 thyroid	 (Read	 et	 al.	 2011).	 Thus	 the	 constraints	 of	estimating	that	a	histopathological	region	is	‘normal’	may	underlie	the	reason	that	PBF	expression	in	our	group	of	43	samples	was	similar	in	normal	and	cancer	specimens.	
In	this	study	RNA	was	extracted	from	FFPE-fixed	thyroid	tissue	which	is	known	to	 be	 highly	 degraded.	 Instead	 I	 focused	my	 efforts	 in	 developing	 techniques	 such	 as	one-step	 RT-PCR	 that	 can	 be	 used	 to	 determine	 expression	 levels	 in	 degraded	 RNA	samples.	 This	 was	 achieved	 by	 using	 specific	 targeted	 primers	 of	 PBF	 or	 CTTN	 to	perform	both	reverse	transcription	and	qPCR	in	a	single	step.	In	addition,	the	primers	were	chosen	to	produce	only	short	amplicons	in	the	PCR	reaction	(<100	bases)	which	helps	the	detection	of	gene	expression	in	degraded	RNA	samples.	
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In	 conclusion,	 this	 is	 the	 first	 study	 to	 determine	 CTTN	 expression	 in	 well-differentiated	 thyroid	 cancer,	 and	 reveals	 a	 significant	 correlation	between	CTTN	and	PBF	mRNA	expression.	As	both	genes	promote	cell	migration,	cell	invasion	and	tumour	metastasis,	both	cortactin	and	PBF	might	be	specific	targets	in	the	treatment	of	thyroid	cancer	metastasis.	However,	further	experiments	are	needed	to	address	this	hypothesis.	
CHAPTER	7		- EFFECT	OF	PBF	MUTATIONS	
C51R	AND	R140W	ON	RADIOIODINE	UPTAKE	
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7.1	Introduction	
In	the	previous	Chapters,	it	was	apparent	that	whilst	wild-type	PBF	significantly	induces	cellular	proliferation,	cell	 invasion	and	cell	migration,	 some	PBF	substitutions	retain	 these	 properties	 whereas	 others	 do	 not.	 In	 addition,	 PBF	 is	 significantly	upregulated	 in	 thyroid	 cancer,	 and	 patients	 diagnosed	 with	 papillary	 thyroid	 cancer	who	demonstrate	overexpressed	PBF	are	also	more	likely	to	have	distant	metastases	at	the	 time	 of	 diagnosis,	 and	 poorer	 disease	 specific	 survival	 compared	 to	 patients	who	have	low	PBF	expression	levels	(Hsueh	et	al.	2013).		
Successful	 radioactive	 iodine	 (RAI)	 treatment	 is	 a	 necessary	 step	 to	 destroy	remaining	 thyroid	 cancer	 cells	 after	 surgery,	 and	 influences	 the	 prognosis	 of	 this	particular	cancer,	by	virtue	of	significantly	reduced	locoregional	recurrence	and	distant	metastasis	 (Sawka	 et	 al.	 2004).	 RAI	 therapy	 also	 facilitates	 long	 term	 follow	 up	 and	early	 detection	 of	 tumour	 recurrence	 or	 metastasis	 in	 patients	 who	 undergo	 total	thyroidectomy	 by	 scheduled	measurement	 of	 serum	 thyroglobulin	 (Tg)	 levels	 or	 RAI	scanning.	 However,	 thyroid	 tumour	 tissues	 are	 able	 to	 take	 up	 only	 a	 small	 amount	(around	0.1-27%)	of	administered	131I,	while	the	remaining	131I	 is	excreted	via	kidney	(Maxon	et	al.	1983).		
The	 data	 from	 our	 group	 previously	 demonstrated	 that	 overexpressed	 PBF	significantly	reduced	radioiodine	uptake	by	two	mechanisms.	Firstly,	PBF	upregulation	significantly	 represses	 activity	 of	 the	 gene	 promoter	 of	NIS,	 leading	 to	 decreased	NIS	expression	 (Boelaert	 et	 al.	 2007).	 Secondly,	 PBF	 interacts	 with	 and	 modulates	 the	subcellular	 localisation	 of	 NIS	 from	 the	 plasma	 membrane	 to	 intracellular	 late	endosomes,	 where	 NIS	 co-localises	 with	 PBF	 and	 is	 non-functional,	 contributing	 to	decreased	functional	activity	of	NIS	in	vitro,	and	resulting	in	reduced	radioiodine	uptake	
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(Smith	et	al.	2009).	Transgenic	mice	with	targeted	thyroid	specific	PBF	overexpression	also	 showed	 reduced	 NIS	 expression	 and	 impaired	 radioiodine	 uptake	 (Read	 et	 al.	2011).		
NIS,	or	solute	carrier	family	5	membrane	5	(SLC5A5),	is	encoded	by	the	SLC5A5	gene.	 It	 is	 a	 transmembrane	 glycoprotein	 with	 13	 transmembrane	 domains	 and	 a	molecular	weight	of	around	90	kDa.	NIS	delivers	two	sodium	cations	for	an	iodide	anion	into	 thyroid	 cells	 and	 regulates	 iodine	 uptake	 into	 follicular	 cells.	 This	 process	 is	positively	 influenced	 by	 thyroid-stimulating	 hormone	 (TSH)	 in	 thyroid	 cells	 via	 both	transcriptional	 and	 posttranslational	 mechanisms	 (Kogai,	 Brent	 2012,	 Kogai,	 Taki	 &	Brent	2006).	In	contrast,	transforming	growth	factor	beta	or	TGFβ,	which	is	induced	by	several	 factors	 including	 the	 BRAFV600E	mutation,	 negatively	 regulates	NIS	 expression	and	also	 inhibits	NIS	 localising	 at	 the	plasma	membrane	 (Kogai,	Brent	2012).	 Indeed,	overexpression	of	TGFβ1	significantly	repressed	TSH-stimulated	NIS	mRNA	and	protein	expression	levels,	reflecting	reduced	ability	to	uptake	radioiodine	in	FRTL-5	rat	thyroid	cells	 (Kawaguchi	 et	 al.	 1997).	 Importantly,	 a	 low	 level	 of	 NIS	 mRNA	 expression	 is	associated	with	aggressive	papillary	thyroid	carcinomas	(Ward	et	al.	2003).		
In	 this	 Chapter,	 the	 impact	 of	 the	 substitutions	 C51R	 and	R140W	 identified	 in	
vivo	on	the	well-described	ability	of	PBF	to	repress	the	central	thyroid	cancer	treatment	of	radioiodine	uptake	was	appraised.	The	hypothesis	was	that	alteration	of	subcellular	localisation	of	PBF	mutants	might	affect	co-localisation	with	NIS,	resulting	in	an	altered	ability	to	uptake	radioiodine,	which	is	critical	for	treatment	of	thyroid	cancer.		
	
7.2	Materials	and	Methods	
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7.2.1	Cell	Culture	and	Transfection	
TPC1	and	MCF7	cells	were	maintained	in	RPMI	containing	10%	FCS	as	described	in	section	2.1.1.1.	The	cells	were	transfected	with	VO,	WT-PBF,	C51R-PBF,	R140W-PBF	and	NIS-Myc	as	described	in	section	2.1.3.	
	7.2.2	Radioiodine	Uptake	Assays	
Radioiodine	uptake	assays	were	performed	in	cells	co-transfected	with	VO,	wild-type	 PBF,	 mutated	 PBF	 and	 the	 sodium	 iodide	 symporter	 (NIS).	 After	 48	 hours	 of	transfection,	sodium	perchlorate	was	added	to	block	 iodine	uptake	 in	control	samples	for	1	hour,	before	administration	of	10-4M	sodium	iodide	(NaI)	and	0.05	μl	125I	solution	and	incubation	at	37°C	for	an	hour.	Next,	Hank’s	balanced	salt	solution	(HBSS)	was	used	to	wash	 away	any	 excess	 radioiodine,	 ensuring	 that	 only	 iodine	 that	was	 internalised	into	 the	 cells	was	measured.	 Finally,	 cells	were	 lysed	 twice	with	 2%	 sodium	 dodecyl	sulfate	(SDS)	and	the	radioactivity	was	count	using	a	LKB	Wallac	1260	Multi	gamma	II	gamma	 counter.	 All	 results	 of	 radioiodine	 uptake	 assays	 were	 normalized	 to	 control	samples	 with	 sodium	 perchlorate.	 The	 control	 data	 demonstrated	 background	radioiodine	 levels	and	all	other	data	 represent	NIS-specific	uptake	of	 radioiodine	 into	the	cells.		
	
7.2.3	Protein	Quantification	for	Actual	Radioiodine	Counts	(Bicinchoninic	Acid	Assay	or	BCA)	
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After	measuring	 the	 radioiodine	 activity,	 protein	 concentration	 was	measured	using	the	bicinchoninic	acid	(BCA)	assay	kit	as	described	in	section	2.2,	with	cell	lysates	compared	to	bovine	serum	albumin	(BSA)	standards	of	0,	0.125,	0.25,	0.5,	0.75,	1	and	2	mg/ml	 in	 2%	 SDS	 solution.	 The	 standard	 curve	 produced	 from	 the	 BSA	 standard	concentrations	 was	 then	 used	 to	 determine	 the	 protein	 concentration.	 Finally,	 the	sample	 concentration	 and	 the	 relative	 radioiodine	 count	 measured	 with	 the	 Wallac	gamma	counter	were	used	to	calculate	the	actual	radioiodine	counts.		
	
7.2.4	Western	Blotting	
	 Western	 Blotting	 was	 performed	 as	 described	 in	 Section	 2.5.	 The	 primary	antibodies	used	in	this	Chapter	were	mouse	anti-Myc	(1:1000,	Cell	Signaling,	UK),	rabbit	anti-PBF	(1:500,	In-house)	and	mouse	anti-β-actin	AC-15	(1:10000,	Sigma,	USA).	
	 7.2.5	Immunofluorescence	Microscopy	
	 HeLa,	 MCF7	 and	 SW1736	 cells	 were	 plated	 on	 coverslips	 and	 were	 then	transfected	 with	 VO,	 FLAG-tagged	 WT-PBF,	 C51R-PBF,	 R140W-PBF	 and	 NIS-Myc	 as	described	 in	 section	 2.1.3.	 The	 cells	were	 then	 processed	 as	 described	 in	 section	 2.6.	Primary	 antibodies	were	mouse	monoclonal	 anti-FLAG	 (1:200,	 Sigma,	UK)	 and	 rabbit	polyclonal	anti-NIS	(1:500,	Abcam,	UK).		
	
7.3	Results	
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7.3.1	Radioiodine	Uptake	Assays	
125I	 radioiodine	uptake	 assays	 in	TPC1	 and	MCF7	 cells	 co-transfected	with	VO,	WT-PBF,	C51R-PBF,	R140W-PBF	and	NIS-Myc	confirmed	that	transient	NIS	transfection	induced	 125I	 uptake	 compared	 to	 VO	 alone	 (Figure	 7.1A	 and	 7.1B)	 as	 previously	described	by	our	group	(Smith	et	al.	2009).	Western	blotting	demonstrated	successful	transfection	of	both	PBF	and	NIS	(Figure	7.1A	and	7.1B).	Co-transfection	with	WT-PBF	resulted	in	significantly	reduced	uptake	in	TPC1	and	MCF7	cells	(Figure	7.1A	and	7.1B).	Interestingly,	both	PBF	mutations	retained	the	ability	to	repress	radioiodine	uptake	in	both	cell	lines	(Figure	7.1A	and	7.1B).	
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Figure	 7.1:	 PBF	mutations	 retain	 the	 capability	 to	 repress	 radioiodine	 uptake	 in	
vitro.	Representative	graphical	data	of	 radioiodine	uptake	experiments	 in	TPC1	(A)	and	
MCF7	(B)	cells	transfected	with	VO,	WT-PBF,	C51R-PBF,	R140W-PBF	or	NIS-Myc.	Graphs	
represent	 mean	 ±	 SEM	 from	 three	 independent	 experiments.	 SEM	 =	 standard	 error	 of	
mean.	 Inset	 –	 Western	 blotting	 of	 PBF	 and	 NIS	 levels	 relative	 to	 β-actin	 levels	 for	
confirmation	 of	 transfection.	 PBF	 bands	 were	 detected	 with	 a	 polyclonal	 anti-PBF	
antibody	 (1:500),	 while	 NIS	 bands	 were	 demonstrated	 with	 a	 monoclonal	 anti-Myc	
antibody	(1:1000).	**P<0.01;	***P<0.001.	N=3.	
	7.3.2	Co-localisation	between	PBF	and	NIS	
To	determine	the	consequence	of	mutated	PBF	on	the	subcellular	localisation	of	NIS,	immunofluorescence	microscopy	was	carried	out	in	HeLa,	MCF7	and	SW1736	cells	either	transfected	with	VO	alone	or	co-transfected	with	VO,	WT	PBF-FLAG,	C51R-FLAG,	
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R140W-FLAG	and	NIS-Myc.	Figure	7.2A	shows	that	endogenous	NIS	(in	red)	 in	MCF-7	cells	transfected	with	VO	alone	was	located	ubiquitously	throughout	the	cells,	with	little	evidence	of	plasma	membrane	staining.	These	findings	explained	the	result	of	 the	 low	radioiodine	uptake	of	 transfected	VO	 in	MCF7	 cells	 in	 Figure	7.1B.	However,	 cells	 co-transfected	 with	 VO	 and	 NIS-Myc	 revealed	 distinct	 NIS	 staining	 at	 the	 plasma	membrane,	 resulting	 in	 a	 definite	 outline	 of	 the	 cells	 (Figure	 7.2B	 and	 7.2C).	Nevertheless,	 when	 the	 cells	 were	 co-transfected	 with	WT	 or	 mutated	 PBF,	 NIS	 was	increasingly	 intracellular	 (Figure	7.2B	and	7.2C)	 compared	 to	VO	and	NIS-Myc	 as	our	group	has	shown	before	(Smith	et	al.	2009).	In	addition,	there	was	visible	co-localisation	(in	yellow)	between	WT	PBF	and	NIS-Myc	 in	definite	vesicles	within	 the	 cells	 (Figure	7.2B	and	7.2C),	while	the	co-localisation	of	mutant	C51R	with	NIS-Myc	was	apparent	in	the	 endoplasmic	 reticulum	 (Figure	 7.2B	 and	 7.2C),	 and	 the	 Golgi	 apparatus	 was	 the	main	structure	where	R140W	mutant	and	NIS-Myc	co-localised	(Figure	7.2B	and	7.2C).	
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Figure	 7.2:	 PBF	 mutations	 co-localise	 with	 NIS	 in	 vitro.	 A,	 representative	
immunofluorescent	microscopy	of	endogenous	NIS	(rabbit,	anti-NIS,	red)	and	DAPI	(blue)	
in	 untransfected	MCF7	 cells.	 B	 and	 C,	 representative	 immunofluorescent	 images	 of	 NIS-
Myc	 (rabbit,	 anti-NIS,	 red)	 and	 PBF-FLAG	 (mouse,	 anti-FLAG,	 green)	 co-localisation	
(yellow)	 in	 HeLa	 (B)	 and	 MCF7	 (C)	 cells	 co-transfected	 with	 VO,	 WT-PBF-FLAG,	 C51R-
FLAG,	R140W-FLAG	and	NIS-Myc.	Zoomed	image	shows	NIS	and	WT-PBF	co-localisation	in	
specific	 vesicles	 within	 the	 cells.	 Arrows	 highlight	 regions	 of	 co-localisation	 (yellow).	
Magnification	=	100x.	Scale	bars	=	20	μm.	
	 Thus,	 mutants	 C51R	 and	 R140W	 retained	 the	 ability	 to	 repress	 radioiodine	uptake	 in	 vitro,	 despite	 being	 mislocalised	 to	 the	 ER	 and	 the	 Golgi	 apparatus,	respectively.	This	would	 imply	 for	 the	 first	 time	 that	 the	well-documented	 interaction	between	PBF	and	NIS	is	able	to	occur	in	multiple	compartments	of	the	cell.		
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7.4	Discussion	
PBF	 is	 significantly	 upregulated	 in	 thyroid	 cancer	 (Stratford	 et	 al.	 2005),	 and	radioiodine	 treatment	 is	 the	 necessary	 step	 for	 destroying	 residual	 cancer	 cells	 and	improving	 oncological	 outcome.	 The	 best-characterised	 function	 of	 PBF	 lies	 in	 its	repression	 of	 radioiodine	 uptake	 via	 the	 cellular	 redistribution	 of	 the	 sodium	 iodide	symporter,	NIS	 (Smith	 et	 al.	 2013,	 Smith,	 Franklyn	&	McCabe	2011,	Read	 et	 al.	 2011,	Smith	et	al.	2010,	Smith	et	al.	2009).	According	to	previous	data	from	the	McCabe	group,	the	 tyrosine	 phosphorylated	 residue	 Y174	 is	 the	 critical	 amino	 acid	 regulating	 PBF	trafficking	(Smith	et	al.	2013).	Artificial	mutation	of	Y174	to	Y174A	resulted	in	PBF	not	internalising	 and	 being	 retained	 at	 the	 plasma	 membrane	 (Smith	 et	 al.	 2013).	 This	substitution	significantly	alters	interaction	between	PBF	and	NIS,	and	then	modifies	the	ability	to	uptake	radioiodine	in	vitro	(Smith	et	al.	2013).	To	further	examine	the	impact	of	PBF	mutations	C51R	and	R140W,	125I	radioiodine	uptake	assays	were	conducted	 in	thyroid	and	breast	cancer	cells.	Interestingly,	both	PBF	mutations	retained	the	ability	to	repress	radioiodine	uptake	even	though	they	lost	invasive	and	transforming	properties	in	 other	 studies	 within	 this	 thesis.	 To	 examine	 this	 more	 closely	 through	immunofluorescent	microscopy,	 PBF	WT	 co-localised	 with	 NIS	 predominantly	 in	 late	endosomes	as	we	have	reported	previously	(Smith	et	al.	2013).	As	IF	results	in	Chapter	4	demonstrated	that	the	C51R	mutant	was	mainly	located	in	the	endoplasmic	reticulum,	shown	 by	 co-localisation	with	 the	 ER	marker	 (anti-PDI	 antibody),	 while	 R140W	was	mostly	 noticed	 in	 the	 Golgi	 apparatus,	 with	 co-localisation	 between	 the	 mutant	 and	Golgi	marker	 (anti-golgin-97	 antibody)	 (Figure	 4.10),	 and	 the	 use	 of	 three	 antibodies	simultaneously	 in	 an	 immunofluorescence	 study	 is	 impractical	 and	 technically	extremely	 difficult,	 in	 this	 Chapter	 IF	 microscopy	 therefore	 illustrated	 only	 co-
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localisation	between	the	C51R	or	R140W	mutants	and	NIS.	The	results	showed	that	co-localisation	between	C51R	or	R140W	 substitutions	with	NIS	 presumably	 appeared	 to	occur	 in	 the	 endoplasmic	 reticulum,	 where	 C51R	 is	 observed,	 and	 in	 the	 Golgi	apparatus,	 where	 R140W	 was	 detected,	 respectively	 (Figure	 7.2).	 Hence	 although	mutations	 C51R	 and	 R140W	 show	 significantly	 altered	 subcellular	 localisation,	 they	retain	NIS	 co-localisation,	 and	 preserve	 the	 ability	 to	 repress	 radioiodine	 uptake.	We	hypothesise	therefore	that	PBF	binds	to	NIS	in	multiple	cellular	compartments,	and	not	solely	in	late	endosomes	as	previously	described	(Smith	et	al.	2009).		
The	 sodium	 iodide	 symporter	NIS	 is	 known	 to	 be	 an	 intrinsic	 transmembrane	glycoprotein	that	usually	originates	in	the	endoplasmic	reticulum	(ER),	traffics	through	the	 Golgi	 apparatus,	 and	 then	moves	 to	 cell	 surface	membrane	where	 it	 is	 functional	(Beyer	 et	 al.	 2011).	 NIS	 is	 also	 generally	 processed,	 phosphorylated	 and	 glycosylated	during	its	cellular	journey.	Therefore,	we	hypothesise	that	while	travelling	through	the	ER	 and	 the	 Golgi	 apparatus,	 NIS	 interacts	 with	 mutants	 C51R-PBF	 and	 R140W-PBF,	respectively,	 resulting	 in	reduced	NIS	 localisation	at	 the	plasma	membrane	and	hence	then	repressed	iodine	uptake.	This	process	is	in	contrast	to	the	effects	of	overexpressed	PBF	 on	 cellular	 invasion,	 migration,	 colony	 formation	 ability	 and	 anchorage	independent	growth,	where	appropriate	subcellular	localisation	of	PBF	would	appear	to	be	 critical	 given	 that	 mutants	 C51R	 and	 R140W	 lost	 wild-type	 function.	 Regarding	cellular	invasion	and	migration	investigated	in	Chapter	5,	WT-PBF	interacted	with	CTTN	predominantly	at	 the	PM	where	CTTN	 is	 functional,	 resulting	 in	 induced	cell	 invasion	and	migration	in	vitro.	However,	mutant	C51R	altered	the	subcellular	localisation	of	PBF	from	the	 late	endosomes	and	 the	PM	to	 the	endoplasmic	reticulum.	The	C51R	mutant	was	able	to	bind	and	interact	with	cortactin	more	tightly	than	WT-PBF,	leading	to	a	shift	
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of	 CTTN	 from	 the	 PM,	 and	 reducing	 cellular	 invasion	 and	migration.	 In	 contrast,	 the	C51R	and	R140W	mutants	reduced	NIS	localisation	to	the	plasma	membrane,	retaining	the	 ability	 of	 WT-PBF	 to	 interfere	 with	 NIS	 trafficking,	 albeit	 by	 a	 different	 route,	through	 preventing	 NIS	moving	 to	 the	 plasma	membrane	 from	 the	 ER	 and	 the	 Golgi	compartments,	respectively.	Thus	these	2	PBF	mutants	were	able	to	function	to	reduce	RAI	 in	 vitro	 to	 a	 similar	 degree	 as	 wild-type	 PBF.	 Accordingly,	 if	 C51R	 and	 R140W	substitutions	were	 discovered	 in	 thyroid	 cancer,	 they	would	 be	 predicted	 to	 provide	reduced	 radioiodine	 uptake	 and	 repressed	 131I	 treatment,	 in	 common	 with	 over-expressed	wild-type	PBF.	
	
CHAPTER	8		- EFFECT	OF	PBF	MUTATIONS	
C51R	AND	R140W	ON	CELL	
TRANSFORMATION	ABILITY	
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8.1	Introduction	
	 The	critical	hallmark	of	oncogenic	mutation	is	the	ability	to	render	normal	cells	malignant,	 through	 the	 process	 of	 cell	 transformation.	 Driver	mutation	 status	 can	 be	confirmed	 by	 switching	 on	 or	 off	 expression	 or	 function	 of	 the	 oncogene	 in	 vitro	 to	examine	 its	 contribution	 to	 the	 process	 of	 cell	 transformation.	 For	 instance,	 NRAS	(neuroblastoma	 rat	 sarcoma	 viral	 oncogene	 homolog)	 overexpression	 transformed	murine	NIH	3T3	cells,	resulting	in	a	significant	increase	in	anchorage	independent	cell	growth	in	soft	agar	assays	(Eisfeld	et	al.	2014).	Alternatively,	inhibition	of	BRAF	(v-Raf	murine	sarcoma	viral	oncogene	homolog	B)	 levels	 in	papillary	 thyroid	cell	 lines	using	siRNA	knockdown	 significantly	 reduced	 colony	numbers	 in	 colony	 formation	and	 soft	agar	assays,	demonstrating	that	the	BRAF	gene	is	vital	for	transformation	capability	of	these	 cells	 (Liu	 et	 al.	 2007).	 Cells	 carrying	 stable	 BRAF	 knockdown	 also	 showed	decreased	 tumourigenic	 ability	 in	 nude	mice	 compared	 to	 controls	 (Liu	 et	 al.	 2007).	Thus,	 manipulating	 the	 expression	 and	 function	 of	 putative	 oncogenes	 in	 vitro	 and	examining	anchorage-independent	growth	remains	a	useful	initial	tool	in	assessing	the	potential	oncogenic	impact	of	a	mutational	change.	PBF	has	previously	been	reported	to	be	transforming	 in	vitro	and	tumourigenic	
in	vivo.	Stratford	et	al.	demonstrated	that	thyroid	cancer	had	significantly	increased	PBF	mRNA	expression	 compared	 to	normal	 thyroid,	 and	PBF	mRNA	expression	 in	 thyroid	tumours	 which	 subsequently	 recurred	 was	 higher	 than	 those	 for	 cancers	 without	recurrence	(Stratford	et	al.	2005).	In	Chapter	6,	PBF	expression	from	the	TCGA	dataset	was	also	significantly	upregulated	in	thyroid	tumour	compared	to	normal	tissue	(Figure	6.4A).	 In	 addition,	 stably	 overexpressed	 PBF	 in	 murine	 NIH	 3T3	 fibroblast	 cells	significantly	induced	colony	formation	in	soft	agar	assays	(Stratford	et	al.	2005).		
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In	 Chapter	 4,	 the	 effect	 of	 C51R	 and	 R140W	 substitutions	 on	 cellular	proliferation	 was	 investigated.	 Mutant	 C51R	 demonstrated	 increased	 proliferative	function,	 while	 R140W	 had	 an	 anti-proliferative	 consequence.	 In	 this	 Chapter,	 we	therefore	performed	colony	formation	and	soft	agar	assays	to	 investigate	whether	the	mutants	 C51R	 and	 R140W	 retained	 colony	 formation	 capability	 and	 anchorage	independent	transforming	ability.		
8.2	Materials	and	Methods	8.2.1	Cell	Culture	and	Transfection	
	 Early	passage	TPC1	and	NIH3T3	fibroblast	cell	lines	were	used	to	produce	stable	cell	 lines,	 and	were	 stably	 transfected	with	 VO,	WT-PBF,	 C51R-PBF	 and	 R140W-PBF.	These	cell	lines	were	selected	and	subcultured	as	described	in	section	2.13.	
	 8.2.2	Western	Blotting	
Protein	 samples	 from	 stable	 clones	 were	 extracted	 and	 used	 to	 run	 Western	blotting	as	described	in	section	2.5.	The	experiments	were	performed	to	determine	PBF	protein	expression	levels	between	PBF	stable	cells	and	VO	control	group.	The	primary	antibodies	 were	 rabbit	 anti-PBF	 (1:500,	 In-house)	 and	 mouse	 anti-β-actin	 AC-15	(1:10000,	Sigma,	USA). 	8.2.3	Stable	Cell	Line	Generation	
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TPC1	 and	 NIH	 3T3	 cell	 lines	 were	 selected	 to	 produce	 stable	 cell	 lines	 as	described	in	section	2.13.	These	cells	were	transfected	with	VO,	WT-PBF,	C51R-PBF	and	R140W-PBF	plasmids,	with	pcDNA3.1(+)	vectors	for	TPC1	cells	and	pCI-neo	vectors	for	NIH	3T3	cells	as	described	in	section	2.1.3.	1	mg/ml	G418	was	applied	to	both	TPC1	and	NIH	 3T3	 cells	 after	 24	 hours	 of	 transfection	 to	 select	 cells	 containing	 plasmids.	 Cells	were	 supplemented	with	new	 fresh	media	with	 suitable	 antibiotics	 twice	 a	week	 and	cultured	until	they	formed	colonies	as	described	in	section	2.13.	The	expression	levels	of	each	clone	were	then	determined	before	the	cells	were	used	in	subsequent	assays.	
	8.2.4	Colony	Formation	Assays	
	 TPC1	 stable	 cell	 lines	 overexpressing	 VO,	WT-PBF,	 C51R	 and	 R140W	mutants	were	 used	 in	 colony	 formation	 assays.	 After	 validating	 PBF	 overexpression,	 the	experiments	were	established	in	6-well	plates,	and	cells	were	seeded	at	400	cells/well.	The	cells	were	supplemented	with	RPMI	containing	10%	FCS	and	G418	(1mg/ml)	twice	weekly.	After	14	days	of	 incubation,	 colonies	were	 stained	with	0.005%	crystal	 violet	and	the	numbers	of	colonies	were	counted.	The	assays	were	carried	out	in	3	individual	experiments.	
	 8.2.5	Soft	Agar	Assays	
	 Stable	NIH	3T3	colonies	with	elevated	PBF	expression	compared	to	VO	controls	were	selected	to	determine	transforming	capability	through	soft	agar	assays.	Cells	were	resuspended	in	media,	counted	and	seeded	into	6-well	plates,	with	two	layers	of	agar:	The	 bottom	 layer	 was	 made	 from	 0.8%	 sterile	 agar,	 aliquoted	 into	 each	 well	 and	
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allowed	 to	 set	 at	 room	 temperature,	 whilst	 the	 upper	 layer	was	 created	 from	 sterile	0.35%	 agarose	 and	 mixed	 with	 the	 single-cell	 suspension.	 Both	 layers	 were	 set	 and	equilibrated	 at	 40°C.	 The	 cells	 were	 fed	 with	 DMEM	 containing	 10%	 calf	 serum	 and	G418	(1mg/ml)	 twice	a	week.	After	14	days	of	 incubation,	 the	colonies	were	counted.	The	assays	were	performed	in	3	separate	experiments.	
	
8.3	Results	8.3.1	Confirmation	of	Stable	Cell	Line	Expression	
For	 each	 PBF	 genotype	 (wild-type,	 C51R	 and	 R140W),	 3	 stable	 clones	 were	selected	 for	 determination	 of	 PBF	 expression	 compared	 to	 VO	 stable	 control	 cells,	before	using	these	cells	in	further	assays.			
	Protein	expression	 levels	of	PBF	 in	selected	TPC1	 thyroid	cancer	and	NIH	3T3	fibroblast	 clones	 were	 determined	 through	 Western	 blotting	 as	 described	 in	 section	8.2.2.	
	
	 	
Figure	8.1:	Overexpression	of	PBF	 in	 selected	TPC1	and	NIH	3T3	 stable	 clones	 via	
Western	blotting.	Western	blots	of	PBF	protein	expression	levels	relative	to	β-actin	levels	
in	TPC1	(A)	and	NIH	3T3	(B)	clones	stably	transfected	with	VO,	WT-PBF,	C51R	and	R140W	
mutants.		
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	 Initial	screening	(data	not	shown)	identified	one	clone	from	each	stable	cell	line	with	 similar	 levels	 of	 PBF	 protein	 over-expression	 from	 the	 3	 clones.	 Subsequent	Western	blotting	confirmed	that	selected	TPC1	and	NIH	3T3	clones	stably	 transfected	with	 WT-PBF,	 C51R-PBF	 and	 R140W-PBF	 carried	 similarly	 induced	 PBF	 protein	expression	 compared	 to	 VO	 controls	 (Figure	 8.1).	 These	 cell	 lines	were	 subsequently	utilised	in	colony	formation	and	soft	agar	assays.		
	 It	 is	 difficult	 to	 determine	 the	 relative	 proportion	 of	 endogenous	WT-PBF	 and	exogenous	 PBF	 within	 each	 stable	 cell	 line	 through	 Western	 blotting,	 although	significant	levels	of	overexpression	of	both	WT	and	mutants	PBF	are	clearly	seen.	Some	effects	 of	 the	 mutants	 may	 be	 under-	 or	 over-estimated	 due	 to	 the	 presence	 of	endogenous	WT	 protein.	 However,	 the	 level	 of	 endogenous	 protein	 is	 likely	 to	 have	been	comparable	across	each	cell	line,	including	the	WT	line	to	which	each	mutant	was	compared.	
	 8.3.2	Effect	of	PBF	Mutations	C51R	and	R140W	on	Cell	Transformation	Ability	
8.3.2.1	Colony	Formation	Assays	Previous	 data	 from	 our	 group	 revealed	 that	 up-regulation	 of	 PBF	 significantly	induces	cell	 transformation	 in	vitro	 (Stratford	et	al.	2005).	To	determine	whether	PBF	mutations	C51R	and	R140W	retain	this	capability,	colony	formation	assays	were	firstly	utilised	in	TPC1	cells	stably	transfected	with	VO,	WT-PBF	and	both	PBF	mutants	(Figure	8.2).		
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Figure	8.2:	C51R	and	R140W	substitutions	lose	colony	formation	ability	compared	
to	WT-PBF.	Colony	formation	assays	in	TPC1	cells	stably	transfected	with	VO,	WT-PBF	and	
2	mutants;	representative	photomicrographs	shown	above.	Data	showed	as	mean	±	SEM.	
SEM	=	standard	error	of	mean.	N=3	experiments,	each	with	3	replicates.	*P<0.05.			
Wild-type	PBF	significantly	enhanced	the	ability	of	TPC1	cells	 to	 form	colonies,	whereas	both	C51R	and	R140W	mutants	failed	to	induce	colony	formation	compared	to	WT	in	stably	transfected	TPC1	cells	(Figure	8.2).		
	
8.3.3.2	Soft	Agar	Assays	To	further	assess	whether	the	mutants	C51R	and	R140W	preserved	an	ability	to	transform	cells	in	vitro	compared	to	WT-PBF,	soft	agar	experiments	were	conducted	in	NIH	 3T3	 cells	 stably	 transfected	 with	 VO,	 WT-PBF,	 C51R	 and	 R140W	 mutants	 to	examine	anchorage-independent	growth.		
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Figure	8.3:	C51R	and	R140W	substitutions	show	reduced	cell	transformation	ability	
in	vitro	compared	to	WT-PBF.	Soft	agar	assays	in	NIH	3T3	cells	stably	transfected	with	
VO,	WT-PBF,	C51R	and	R140W	mutants.	Colonies	of	over	~50	cells	in	size	were	counted.	N	
=	3	experiments,	each	with	3	replicates.	Microscopic	figures	illustrate	relative	numbers	of	
colonies	as	demonstrated	above.	Graph	represents	mean	±	SEM.	SEM	=	standard	error	of	
mean.	*P<0.05.			
Figure	8.3	illustrates	that	all	3	genotypes	of	PBF,	including	WT,	C51R	and	R140W	mutants,	 showed	 a	 variably	 significant	 increase	 in	 transforming	 ability	 compared	 to	stable	VO	controls	(Figure	8.3).	However,	mutants	C51R	and	R140W	markedly	lost	the	ability	 to	 elicit	 anchorage-independent	 growth	 in	 soft	 agar	 assays	 compared	 to	wild-type	PBF	(Figure	8.3).		
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Taken	 together,	 even	 though	 the	 PBF	mutations	 C51R	 and	R140W	 still	 had	 an	ability	 to	 transform	the	cells	 in	soft	agar	assays,	a	critical	hallmark	of	malignant	cells,	both	substitutions	significantly	reduced	transforming	capability	compared	to	WT-PBF.	Therefore,	 although	 some	 canonical	 PBF	 functionality	 is	 retained,	 these	 two	 PBF	mutants	are	unlikely	to	be	driver	mutations.	
	
8.4	Discussion	
Soft	 agar	 assays	 in	 this	 Chapter	 were	 applied	 to	 assess	 whether	 C51R	 and	R140W	substitutions	carried	an	ability	to	transform	cells	compared	to	VO	and	wild-type	PBF.	 Generally,	 normal	 cells	 have	 an	 anchorage-dependent	 cell	 growth,	 and	 require	solid	 surfaces	 such	 as	 a	 plate	 or	 a	 flask	 to	 grow	 and	 divide.	 They	 usually	 grow	 in	 a	monolayer	pattern	and	when	reaching	confluency,	the	cells	stop	dividing	and	enter	into	G0	 phase,	 via	 contact	 inhibition.	 By	 contrast,	 when	 normal	 cells	 transform	 into	malignant	cells,	 they	gain	 the	ability	 to	grow	 in	semi-solid	agar,	named	an	anchorage-independent	 ability.	 This	 characteristic	 is	 associated	with	 tumourigenicity	 in	 vivo	 and	invasiveness	of	cancer	(Carney,	Gazdar	&	Minna	1980).		A	soft	agar	assay	remains	the	best	in	vitro	method	to	identify	an	ability	of	cells	to	grow	 independently	without	 solid	 surface,	 suggesting	 transforming	 ability	 in	 vitro.	 In	comparison,	 colony	 formation	 assays,	 whilst	 easily	 performed	 and	 a	 good	 screening	tool,	do	not	directly	evaluate	malignant	characteristics,	because	the	cells	still	grow	and	form	colonies	on	solid	surfaces	such	as	culture	plates.	Although	the	results	of	the	colony	formation	assays	were	consistent	 in	3	experiments,	 the	TPC1	papillary	 thyroid	cancer	cell	 line	 is	not	 ideal	 to	demonstrate	 transforming	ability	 in	vitro	because	 these	cancer	cells	 are	 already	 transformed.	 Therefore,	 the	 stably	 overexpressed	NIH	3T3	 cell	 lines	
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were	constructed	and	applied	 in	 this	Chapter.	As	 fibroblast	cell	 lines	such	as	NIH	3T3	cells	are	essentially	untransformed,	these	cells	are	suitable	for	estimating	the	capability	of	genes	or	mutations	to	transform	normal	to	malignant	cells	in	soft	agar	assays.		In	this	Chapter,	we	found	that	WT-PBF	had	a	significant	increase	in	the	ability	to	transform	cells	compared	to	VO	stable	clones,	as	assessed	through	colony	formation	and	soft	agar	assays.	However,	mutants	C51R	and	R140W	almost	entirely	lost	this	property	compared	 to	 WT-PBF	 as	 shown	 in	 both	 experiments.	 Should	 these	 mutants	 have	demonstrated	 strong	 in	 vitro	 oncogenic	 activity,	 in	 vivo	 studies	 would	 be	 needed	 to	confirm	 that	 these	 mutations	 drive	 tumourigenesis.	 The	 stable	 cell	 lines	 could	 have	been	 employed	 in	 a	 xenograft	 model.	 However,	 as	 C51R	 and	 R140W	 demonstrated	reduced	cell	 invasion,	migration	and	transforming	ability	compared	with	WT-PBF,	and	in	 line	with	the	3Rs	(replacement,	reduction	and	refinement)	principle	used	 in	animal	research	to	minimise	animal	numbers	and	suffering,	such	studies	are	not	warranted.		We	therefore	conclude	that,	in	contrast	to	bioinformative	prediction	(Melloni	et	al.	 2014),	 rare	 mutations	 in	 PBF	 are	 unlikely	 to	 be	 driver	 events	 in	 human	 cancer.	Although	 some	 canonical	 PBF	 functionality	 is	 retained,	 we	 propose	 that	 PBF	 over-expression	 in	human	tumours,	 rather	 than	sequence	alteration,	 is	 the	more	 important	cellular	 mechanism.	 Over-expression	 of	 the	 wild	 type	 protein,	 which	 has	 been	associated	 with	 tumour	 induction	 in	 xenograft	 models	 (Stratford	 et	 al.	 2005),	hyperplasia	and	follicular	lesions	in	thyroid	glands	of	transgenic	mice	(Read	et	al.	2011),	extramural	 vascular	 invasion	 in	 human	 colorectal	 tumours	 (Read	 et	 al.	 2016)	 and	reduced	disease-specific	survival	in	patients	with	papillary	thyroid	cancer	(Hsueh	et	al.	2013),	is	a	more	pertinent	driver	event.	However,	why	PBF	is	upregulated	in	tumours,	and	exactly	how	this	induction	drives	hyperplastic	and	neoplastic	progression,	remains	ill-defined.				
CHAPTER	9		- FINAL	CONCLUSIONS	AND	
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	 	Recently,	there	has	been	a	dramatic	increase	in	the	number	of	genetic	mutations	reported	 in	 human	 cancer,	 which	 has	 come	 as	 a	 result	 of	 improvements	 in	 next	generation	sequencing,	and	have	been	collated	via	the	COSMIC	and	the	TCGA	initiatives.	Nevertheless,	 cell	 biology	 has	 not	 kept	 pace	 with	 sequencing	 technology:	 quick	 and	effective	 methods	 to	 discern	 those	 genes	 eliciting	 a	 tumour	 growth	 benefit	 (driver	mutations)	 from	 the	 majority	 of	 gene	 changes	 which	 do	 not	 drive	 clonal	 expansion	(passenger	mutations)	still	remain	elusive.	Computational	statistical	approaches	based	on	protein	function,	frequency	of	mutation,	pathway	and	pattern	are	widely	used	for	the	prediction	 of	 rare	 driver	 gene	 changes.	 However,	 the	 results	 are	 not	 guaranteed.	 For	instance,	 BRAFV600E	 is	 prominent	 in	 a	 variety	 of	 human	 tumours	 such	 as	 melanoma,	breast,	 thyroid	 and	 colon	 cancer	 through	 the	 COSMIC	 and	 the	 TCGA	 databases	(http://cancer.sanger.ac.uk/,	 http://www.cbioportal.org/),	 and	 is	 the	 most	 common	mutation	found	in	BRAF	gene.	Mutation	of	BRAFV600E	also	retains	transforming	ability	in	
vitro	 (Liu	et	al.	2007)	and	 tumourigenicity	 in	 vivo	 (Knauf	et	 al.	2005),	 suggesting	 that	BRAFV600E	is	a	driver	mutation.	However,	BRAFV600E	is	predicted	to	be	a	non-functional	mutation	through	the	Mutation	Assessor	server,	which	 is	a	computational	programme	based	 on	 conservation	 of	 the	 mutated	 amino	 acid	 residue	 in	 protein	 homologs	(http://mutationassessor.org/).	 Therefore,	 a	 range	 of	 standard	 assays	 applied	 to	determine	 the	 impact	 of	 discovered	 mutations	 on	 cell	 biology	 is	 still	 needed	 to	 the	confirm	status	of	these	genes.		
The	 studies	 in	 this	 thesis	 were	 established	 to	 investigate	 whether	 PBF	 amino	acid	 substitutions	 discovered	 in	 the	 COSMIC	 database	 influenced	 important	 PBF	functions	 and	 impacted	 on	 routine	 cellular	 measures	 of	 cell	 behaviour,	 to	 estimate	whether	these	PBF	mutations	might	be	driver	mutations.	This	notion	was	supported	by	
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recent	 bioinformatic	 data	 which	 predicted	 that	 PBF	may	 be	 a	 driver	 gene	 in	 thyroid	cancer	(Melloni	et	al.	2014).	
	 PBF	is	a	ubiquitously	expressed	glycoprotein	upregulated	in	a	variety	of	human	tumours,	especially	endocrine	neoplasias	such	as	pituitary,	breast	and	thyroid	(McCabe	et	 al.	 2003,	 Xiang	 et	 al.	 2012,	 Watkins	 et	 al.	 2010,	 Smith,	 Franklyn	 &	 McCabe	 2010,	Stratford	et	al.	2005).	PBF	overexpression	also	correlates	with	poorer	clinical	outcome	in	various	human	cancers.	To	 illustrate	 this,	 colorectal	 samples	containing	extramural	vascular	invasion	showed	significantly	higher	PBF	expression	levels	(Read	et	al.	2016),	while	high	PBF	mRNA	expression	 in	patients	diagnosed	with	papillary	 thyroid	 cancer	was	 also	 associated	with	 early	 local	 recurrence	 and	 tumour	metastasis	 at	 the	 time	of	diagnosis	 and	 significantly	 reduced	 disease-specific	 survival	 (Hsueh	 et	 al.	 2013).	Additionally,	 high	 PBF	 promoter	 activity	 influences	 metastatic	 incidence	 in	 breast	cancer	(Xiang	et	al.	2012).	PBF	expression	is	higher	in	human	multinodular	goiter	and	inversely	 correlates	 with	 NIS	 expression,	 resulting	 in	 decreased	 radioiodine	 uptake	(Read	et	al.	2011).	
PBF	modulates	the	intracellular	signaling	and	trafficking	of	a	variety	of	proteins,	resulting	in	an	alteration	of	their	functions.	For	instance,	when	binding	and	interacting	with	 monocarboxylate	 transporter	 8	 (MCT8),	 PBF	 alters	 the	 subcellular	 location	 of	MCT8	 from	 the	 plasma	 membrane	 to	 intracellular	 vesicles,	 resulting	 in	 a	 significant	increase	in	thyroid	hormone	accumulation	in	the	thyroid	gland,	and	a	marked	reduction	in	 thyroid	 hormone	 secretion	 in	 a	 murine	 model	 with	 thyroid	 specific	 PBF	overexpression	 (Smith	 et	 al.	 2012,	 Smith	 et	 al.	 2010).	 Upregulated	 PBF	 also	 reduces	activity	 of	 the	basal	 promoter	 and	hNUE	 (human	NIS	upstream	enhancer	 element)	 of	the	sodium	iodide	symporter	(NIS)	promoter,	leading	to	repression	of	ability	to	uptake	
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radioiodine	(Boelaert	et	al.	2007).	Furthermore,	PBF	binds	NIS,	and	pulls	NIS	away	from	the	plasma	membrane	(PM)	where	NIS	 is	 functional,	 leading	 to	decreased	radioiodine	uptake	 (Read	 et	 al.	 2011,	 Smith	 et	 al.	 2010,	 Smith	 et	 al.	 2009),	 which	 is	 critical	 for	radioiodine	treatment	and	prognosis	in	thyroid	cancer.	Src	kinase	also	interacts	and	co-localises	 with	 PBF,	 and	 phosphorylates	 PBF	 at	 tyrosine	 174	 residue,	 regulating	 its	influence	on	radioiodine	uptake	activity	(Smith	et	al.	2013).	Additionally,	PBF	reduces	p53	 stability	 and	 induces	 p53	 ubiquitination,	 dysregulating	 p53	 function	 (Read	 et	 al.	2016,	Read	et	al.	2014).	PBF	has	a	moderate	pro-proliferative	property	 in	various	cell	lines	such	as	breast,	colon	and	thyroid	(Watkins	et	al.	2010,	Read	et	al.	2016,	Read	et	al.	2011),	 and	 is	 transforming	 in	 vitro	 and	 tumourigenic	 in	 vivo	 (Stratford	 et	 al.	 2005).	Taken	together,	therefore,	there	was	a	broad	rationale	to	predict	that	patient	mutations	in	PBF	might	relate	to	tumour	behaviour	or	outcome.	The	work	presented	in	this	thesis	sought	to	examine	whether,	rather	than	simple	overexpression	of	PBF,	these	sequence	changes	might	alter	tumour	cell	behaviour.	
	 Currently,	 the	 incidence	 of	 discovered	 PBF	mutations	 continues	 to	 increase	 in	the	COSMIC	and	the	TCGA	databases	as	more	tumours	are	sequenced.	However,	when	this	 thesis	 started	 in	 2013,	 the	COSMIC	database	 reported	 the	 first	 ten	missense	PBF	substitutions	found	in	multiple	types	of	cancer	such	as	colon,	prostate	and	ovary.	Seven	out	of	10	PBF	mutations	were	found	in	colon	cancer.	At	the	beginning	of	this	study,	the	I-TASSER	(Iterative	Threading	Assembly	Refinement)	and	the	SIFT	(Sorting	 Intolerant	From	 Tolerant)	 databases	 were	 used	 to	 predict	 3D	 protein	 structures	 and	 risk	 of	alteration	in	protein	function	for	all	10	mutations,	respectively.	The	results	in	Chapter	3	revealed	 that	 most	 missense	 amino	 acid	 substitutions	 were	 likely	 to	 elicit	 protein	damage,	and	be	potentially	oncogenic.		
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	 The	 effects	 of	 all	 10	 PBF	 substitutions	 were	 first	 characterised	 through	immunofluorescence	 microscopy	 to	 determine	 potential	 alterations	 in	 subcellular	localisation	compared	to	WT-PBF.	Wild-type	PBF	localised	to	late	endosomes	and	at	the	plasma	 membrane	 as	 previously	 shown	 (Smith	 et	 al.	 2009).	 Interestingly,	 most	mutations	retained	this	WT	subcellular	localisation	pattern,	with	only	C51R,	G106R	and	R140W	mutants	showing	noticeably	different	 localisations.	 Indeed,	mutants	C51R	and	G106R	 were	 mainly	 noticed	 in	 the	 endoplasmic	 reticulum,	 and	 R140W	 was	predominantly	 observed	 in	 the	 Golgi	 apparatus.	 As	 the	 precise	 status	 of	 cellular	 PBF	glycosylation,	 dimerisation	 and	 stability	 have	 not	 been	 definitively	 established	 in	previous	 studies,	 they	were	 investigated	 through	Western	blotting	 in	Chapter	4.	Most	amino	 acid	 substitutions	 showed	 both	 glycosylated	 (~25-37	 kDa)	 and	 dimeric	 (~50	kDa)	forms	in	keeping	WT-PBF.	Interestingly,	reductions	in	apparent	glycosylation	and	oligomerisation	patterns	were	most	obvious	 in	C51R	and	G106R	mutants,	which	were	located	 in	 the	 ER.	 Regarding	 PBF	 stability,	 the	 results	 showed	 for	 the	 first	 time	 that	wild-type	PBF	has	a	half-life	around	24	hours,	which	was	preserved	 for	 the	C51R	and	V55I	mutations	 in	 the	 PSI	 domain,	 and	 R140W	 close	 to	 C-terminal	 end.	 However,	 all	remaining	mutations	had	considerably	less	protein	stability	than	WT,	with	G106R	most	unstable.		
	 WT-PBF	 significantly	 increased	 cell	 turnover	 in	 breast	 and	 colon	 (Read	 et	 al.	2016,	Watkins	et	al.	2010).	In	Chapter	4,	the	impact	of	these	PBF	mutations	identified	in	
vivo	 on	 cellular	 proliferation	 was	 determined	 using	 BrdU	 and	 MTS	 assays.	 Whilst	substitutions	 at	 the	 G106	 residue	 (G106R/V/W)	 failed	 to	 alter	 this	 proliferative	characteristic,	mutants	C51R	and	V55I	in	the	PSI	domain	increased	cellular	proliferation	compared	 to	 WT-PBF.	 In	 contrast,	 R140W	 and	 R146W	 mutations	 proximal	 to	 C-
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terminus	 provided	 broadly	 anti-proliferative	 phenotypes.	 Together,	 these	 data	 reveal	no	consistent	effect	of	amino	acid	substitutions	on	glycosylation,	dimerisation,	stability,	subcellular	 localisation	 and	 cellular	 proliferation.	 However,	 as	 PBF	 generally	 traffics	through	the	ER	and	the	Golgi	to	be	processed	and	some	glycosylation	and	dimerisation	processes	occur	in	the	ER	(Lodish	et	al.	2000),	protein	synthesised	from	mutants	C51R	and	G106R,	located	in	the	ER,	might	not	be	correctly	processed,	resulting	in	decreased	glycosylation	 and	 oligomerisation.	 Nevertheless,	 even	 though	 C51R	 had	 the	 same	stability	as	WT-PBF	and	induced	cellular	proliferation,	the	G106R	mutant,	observed	in	the	same	subcellular	 location	as	C51R,	harboured	the	 least	stability	and	failed	to	alter	proliferation	 compared	 to	 wild-type	 PBF.	 Therefore,	 it	 is	 difficult	 to	 correlate	 ER	localisation	of	both	substitutions	with	PBF	stability	and	proliferation	ability.		
Following	 the	 investigations	 of	 Chapters	 3	 and	 4,	 we	 narrowed	 further	experiments	 from	10	mutations	down	to	2	potentially	 functional	mutations,	C51R	and	R140W.	However,	 curtailing	 our	 subsequent	 approaches	was	 a	 potential	 drawback	 in	this	study	because	oncogenic	functions	of	the	remaining	8	PBF	substitutions	may	have	been	missed.	Nevertheless,	this	approach	provided	the	advantage	of	focusing	in	depth	in	complicated	 assays	 such	 as	 2D	 cell	 invasion	 assays	 and	 proximity	 ligation	 assays,	improving	accuracy	of	those	approaches	unsuited	to	large	scale	studies.	
Other	cellular	mechanisms	 involved	 in	cancer	progression	 include	cell	 invasion	and	 migration	 as	 precursors	 to	 tumour	 metastasis.	 Generally,	 distant	 metastasis	 in	human	cancers	such	as	breast,	colon	and	thyroid	is	associated	with	a	marked	reduction	in	 overall	 survival	 rate	 (http://seer.cancer.gov/),	 and	 may	 eventually	 become	 fatal.	Understanding	 of	 the	 metastatic	 pathway	 is	 therefore	 needed	 to	 appraise	 targeted	treatments.	Previous	mass	spectrometry	in	our	group	demonstrated	cortactin	to	be	one	
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of	 the	 top	 potential	 protein	 binding	 partners	 of	 PBF	 (Sharma	 2014).	 While	 PBF	significantly	 increases	cell	 invasion	and	migration	 in	a	panel	of	 cancer	cells,	 including	breast	and	colon	(Watkins	et	al.	2010,	Read	et	al.	2016),	CTTN	also	induces	assembly	of	actin	 filaments	 mainly	 at	 the	 cell	 periphery,	 and	 inhibits	 debranching	 of	 actin	 fibres	(Weaver	 et	 al.	 2001)	 leading	 cell	 to	 migrate	 and	 invade	 (MacGrath,	 Koleske	 2012,	Kirkbride	 et	 al.	 2011,	 Pollard,	 Borisy	 2003).	However,	 the	precise	mechanism	of	 how	PBF	and	CTTN	promote	cell	invasion	and	migration	still	remains	ill-defined.		
In	 Chapter	 5,	 the	 specific	 interaction	 between	 PBF	 and	 CTTN	 was	 confirmed	through	co-IP,	PLA	and	immunofluorescence,	especially	at	the	plasma	membrane	(PM).	The	ability	of	PBF	to	induce	cell	invasion	was	also	entirely	dependent	on	the	presence	of	cortactin	 function.	 IF	 assays	 showed	 endogenous	 CTTN	 co-localised	 with	 PBF	 within	intracellular	vesicles	and	at	the	PM.	However,	the	specific	in-house	antibody,	PBF8,	used	in	 the	 detection	 of	 PBF	 was	 not	 able	 to	 detect	 all	 forms	 of	 PBF,	 especially	phosphorylated	PBF	at	the	PM	(Smith	et	al.	2009).	HA-tagged	PBF	and	Myc-tagged	CTTN	plasmids	were	 applied	 in	 subsequent	 co-IP	 and	 IF	microscopy	 assays	 to	 appraise	 the	interaction	between	2	proteins.	Additionally,	co-IP	experiments	in	cells	transfected	with	WT-PBF-HA	 and	 CTTN-Myc	 confirmed	 exogenous	 wild-type	 PBF	 and	 CTTN	 had	 a	specific	 interaction	 in	 keeping	 with	 the	 untransfected	 conditions.	 The	immunofluorescence	 results	 affirmed	 that	WT-PBF-HA	co-localised	with	CTTN-Myc	 in	definite	vesicles	within	the	cells	and	at	the	PM.	In	addition,	wild-type	PBF	demonstrated	pro-invasive	 and	 pro-migratory	 characteristics	 in	 different	 cell	 lines	 such	 as	 thyroid,	colon,	breast	and	fibroblast	cells.	However,	mutants	C51R	and	R140W	had	entirely	lost	invasive	and	migratory	phenotypes	in	thyroid	and	breast	cancer	cells	compared	to	WT-PBF.	 The	 results	 of	 IF	 experiments	 illustrated	 that	 the	 C51R-HA	 mutant	 of	 PBF	 was	
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mainly	located,	and	co-localised	with,	CTTN-Myc	in	the	endoplasmic	reticulum	(ER).	Co-IP	 assays	demonstrated	 that	C51R-PBF	bound	CTTN	more	 avidly	 than	WT-PBF.	 C51R	specifically	interacted	with	CTTN	and	appeared	to	‘lock’	it	in	the	ER,	pulling	CTTN	away	from	the	plasma	membrane	where	it	binds	proteins	such	as	Src	kinase,	Arp2/3	complex	and	NCK1	(Kirkbride	et	al.	2011,	Weaver	et	al.	2001),	resulting	in	significantly	reduced	cell	 invasion	 compared	 to	 VO	 and	 WT-PBF.	 However,	 mutant	 R140W	 was	 not	investigated	 in	 Chapter	 5	 because	 of	 detection	 problems	 of	 HA-tagged	 R140W.	Therefore,	C51R	showed	altered	subcellular	 localisation,	 from	late	endosomes	and	the	plasma	 membrane	 to	 the	 ER,	 but	 was	 still	 able	 to	 bind	 CTTN,	 albeit	 in	 a	 different	subcellular	 location.	One	hypothesis	 is	 thus	 that	 by	holding	CTTN	away	 from	 the	PM,	C51R	 prevented	 its	 interaction	with	 proteins	 involved	 in	 actin	 polymerisation,	 hence	abrogating	cell	invasion.		
Although	CTTN	is	up-regulated	in	various	cancers	such	as	colon,	melanoma	and	esophagus,	and	influences	their	prognosis	(Ni	et	al.	2015,	Cai	et	al.	2010,	Xu	et	al.	2010,	Lu	et	al.	2014),	it	has	not	been	investigated	in	thyroid	tumours.	The	studies	in	Chapter	6	revealed	 a	 significant	 upregulation	 of	 cortactin	mRNA	 and	 protein	 expression	 in	 our	small	series	of	43	human	well-differentiated	thyroid	cancers	(DTC)	compared	to	normal	thyroid	tissue	as	demonstrated	through	PCR	and	Western	blotting.	The	data	from	326	thyroid	 cancers	 and	 59	 normal	 thyroid	 samples	 in	 the	 TCGA	 database	 importantly	confirmed	 that	 CTTN	 and	 PBF	 were	 significantly	 over-expressed	 in	 thyroid	 tumours	compared	to	normal	tissue,	and	CTTN	expression	in	tumours	with	nodal	metastasis	had	a	 significantly	 higher	 level	 compared	 to	 those	 which	 had	 no	 nodal	 metastasis.	Interestingly,	the	results	in	both	sample	groups	demonstrated	a	significant	correlation	between	PBF	and	CTTN	mRNA	expression	 in	human	DTC.	Taken	 together,	 the	data	of	
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Chapters	5	and	6	imply	that	PBF	and	CTTN	may	play	important	roles	in	thyroid	tumour	development	 and	 progression,	 and	 may	 represent	 future	 prognostic	 markers	 and	therapeutic	targets	in	the	treatment	of	thyroid	cancer	metastasis.		
As	PBF	is	vital	 for	modulating	radioiodine	uptake	 in	thyroid	cells,	 the	assays	 in	Chapter	 7	 investigated	 the	 outcome	 of	 the	 C51R	 and	 R140W	 substitutions	 on	radioiodine	 uptake,	 which	 is	 critical	 for	 thyroid	 cancer	 treatment.	 Co-expressed	WT-PBF	 and	 NIS	 again	 significantly	 reduced	 radioiodine	 activity	 compared	 to	 NIS	transfection	alone	as	previously	shown	(Smith	et	al.	2013,	Smith	et	al.	2009).	Moreover,	both	mutants	C51R	and	R140W	still	maintained	a	 significant	 reduction	 in	 radioiodine	activity.	IF	results	showed	that	WT-PBF	co-localised	with	NIS	in	late	endosomes	(Smith	et	al.	2009),	while	co-localisation	between	NIS	and	C51R	and	R140W	took	place	in	the	ER	and	the	Golgi	apparatus,	respectively.	This	implies	that	even	though	the	subcellular	locations	 of	 the	 two	 PBF	 mutants	 were	 significantly	 altered,	 C51R	 and	 R140W	 still	interacted	with	NIS	and	pulled	it	away	from	the	plasma	membrane	where	is	functional,	leading	to	repressed	radioiodine	uptake	similarly	to	WT-PBF.	Further	evidence	for	this	proposed	 mechanism	 could	 come	 from	 performing	 co-IP	 assays	 on	 ER	 and	 Golgi	extracts	from	transfected	cells,	although	this	would	be	technically	challenging.	However,	given	the	effects	of	the	C51R	and	R140W	substitutions	on	cell	 invasion,	migration	and	radioiodine	 uptake	 ability,	 it	 is	 interesting	 to	 note	 that	 despite	 marked	 changes	 in	subcellular	 localisation,	 these	 mutations	 retain	 the	 ability	 to	 interact	 with	 critical	proteins	 such	 as	 CTTN	 and	NIS,	 suggesting	 that	 the	 avidity	 of	 binding	 is	 presumably	high.		
Although	both	C51R	and	R140W	mutations	altered	proliferative	characteristics	and	retained	radioiodine	uptake	repression,	the	ability	of	these	2	mutants	to	transform	
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normal	 cells	 to	 malignant	 was	 needed	 to	 determine	 whether	 the	 changes	 might	 be	aetiological.	 This	 was	 evaluated	 through	 colony	 formation	 and	 soft	 agar	 assays	 in	Chapter	 8.	 Soft	 agar	 assays	 are	 used	 for	 evaluating	 the	 capability	 of	 anchorage-independent	cell	growth,	reflecting	transformation	ability	in	vitro,	and	tumourigenicity	and	tumour	cell	aggressiveness	in	vivo	(Mori	et	al.	2009,	Carney,	Gazdar	&	Minna	1980,	Shin	et	 al.	 1975,	Freedman,	 Shin	1974).	Unfortunately,	 although	WT-PBF	retained	 the	anchorage-independent	growth	pattern,	with	significantly	increased	colony	numbers	in	both	 assays,	 C51R	 and	 R140W	 stably	 transfected	 cells	 lost	 transforming	 ability	compared	 to	WT-PBF	 suggesting	 that	 these	2	 substitutions	are	unlikely	 to	be	directly	oncogenic.		
Given	 that	 PBF	 impacts	 on	 the	 progression	 of	 several	 cancers,	 interacts	 with	multiple	important	proteins	and	has	multiple	point	mutations,	the	studies	in	this	thesis	aimed	 to	 determine	 the	 functional	 characteristics,	 including	 the	 stability,	 cellular	proliferation,	 cellular	 invasion,	 cell	migration	 and	 radioiodine	 uptake,	 of	 the	 first	 ten	non-synonymous	 substitutions,	 and	 to	 shed	 new	 light	 onto	 the	 precise	 molecular	mechanisms	of	PBF	biology	in	tumourigenesis.	Extensive	data	delineated	in	this	thesis	indicate	that	even	though	the	mutations	still	preserve	some	canonical	PBF	functions,	its	up-regulation	 in	 cancer	 may	 be	 more	 critical	 in	 terms	 of	 tumour	 development	 and	progression	than	sequence	changes	per	se.		
Moreover,	 although	 there	 are	 a	 lot	 of	 novel	 genetic	 substitutions	 discovered	through	 next	 generation	 sequencing	 in	 the	 COSMIC	 and	 the	 TCGA	 databases,	 cell	biological	 experiments	 to	 investigate	 exactly	 how	 the	mutations	 function	 are	 still	 the	most	important	steps	to	identify	driver	genes	that	may	further	influence	specific	targets	for	treatment	in	human	cancer.	
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Regarding	future	directions,	there	are	currently	27	PBF	mutations	discovered	in	the	 COSMIC	 database,	 the	 vast	 majority	 (18/27)	 being	 single	 amino	 acid	 missense	substitutions.	 Some	 of	 these	mutations	 are	 found	 in	 both	 the	 COSMIC	 and	 the	 TCGA	databases,	 including	 Q42E,	 C121del,	 E153K,	 R140Q	 and	 R144Q	 in	 different	 human	tumour	 types.	 Several	 of	 them	 are	 highly	 predicted	 to	 cause	 protein	 damage	 using	Mutation	 assessor	 or	 PolyPhen	 score.	 Future	 work	 may	 therefore	 use	 further	 cell	biological	 assays	 to	 determine	 whether	 these	 new	 PBF	 mutations	 are	 driver	 events.	Furthermore,	 even	 though	 CTTN	 and	 PBF	 are	 up-regulated	 in	 differentiated	 thyroid	cancer,	and	significantly	induce	cellular	invasion	and	migration	as	shown	in	Chapters	5	and	6,	the	precise	mechanism	of	how	PBF	and	CTTN	interact	still	remains	elusive.	Other	future	 directions	 could	 focus	 on	 treatments	 to	 specifically	 abolish	 CTTN	 or	 PBF	expression,	or	drug	targets	to	increase	binding	between	PBF	and	CTTN	and	to	prevent	CTTN	 trafficking	 to	 the	 plasma	 membrane	 and	 interacting	 with	 other	 important	proteins	related	to	cell	motility,	resulting	in	decreased	cell	invasion	and	metastasis.	
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